DEI_Document
DEI Document | 9 Months Ended | ||
Sep. 30, 2013 | Nov. 04, 2013 | Nov. 04, 2013 | |
Common Class B (Authorized 12,000 shares; 1,085 and 1,086, issued and outstanding in 2013 and 2012, respectively - no par | Common Class A [Member] | ||
Document Information [Line Items] | ' | ' | ' |
Entity Registrant Name | 'INVACARE CORPORATION | ' | ' |
Entity Central Index Key | '0000742112 | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Filer Category | 'Accelerated Filer | ' | ' |
Document Type | '10-Q | ' | ' |
Document Period End Date | 30-Sep-13 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'Q3 | ' | ' |
Amendment Flag | 'false | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 1,084,747 | 30,921,729 |
Consolidated_Statement_Of_Comp
Consolidated Statement Of Comprehensive Income (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Net sales | $341,176 | $361,518 | $1,017,373 | $1,077,767 |
Cost of Goods Sold | 244,352 | 252,106 | 733,408 | 746,369 |
Gross Profit | 96,824 | 109,412 | 283,965 | 331,398 |
Selling, general and administrative expense | 98,719 | 103,281 | 306,042 | 306,755 |
Charge related to restructuring activities | 1,884 | 1,175 | 6,998 | 3,742 |
Loss on debt extinguishment including debt finance charges and associated fees | 0 | 0 | 0 | 312 |
Asset Impairment Charges | 167 | 0 | 167 | 0 |
Interest expense | 745 | 2,114 | 2,677 | 6,339 |
Interest income | -58 | -166 | -239 | -610 |
Earnings before Income Taxes | -4,633 | 3,008 | -31,680 | 14,860 |
Income Tax Expense (Benefit) | 750 | 2,445 | 3,900 | 14,486 |
Income (Loss) from Continuing Operations Attributable to Parent | -5,383 | 563 | -35,580 | 374 |
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax amounts of $227, $2,629; $237 and $5,264, respectively | 307 | 2,301 | 3,321 | 8,746 |
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax amounts of $1,583 and $11,083 | 21,178 | 0 | 71,080 | 0 |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | 21,485 | 2,301 | 74,401 | 8,746 |
Net Earnings (loss) | 16,102 | 2,864 | 38,821 | 9,120 |
Common Stock, Dividends, Per Share, Declared | $0.01 | $0.01 | $0.04 | $0.04 |
Income (Loss) from Continuing Operations, Per Basic Share | ($0.17) | $0.02 | ($1.12) | $0.01 |
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share | $0.67 | $0.07 | $2.33 | $0.27 |
Net Earnings (loss) per Share - Basic | $0.50 | $0.09 | $1.21 | $0.28 |
Weighted Average Shares Outstanding - Basic | 31,902 | 31,877 | 31,902 | 31,838 |
Income (Loss) from Continuing Operations, Per Diluted Share | ($0.17) | $0.02 | ($1.12) | $0.01 |
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share | $0.67 | $0.07 | $2.32 | $0.27 |
Net Earnings (loss) per Share - Assuming Dilution | $0.50 | $0.09 | $1.20 | $0.28 |
Weighted Average Shares Outstanding - Assuming Dilution | 32,066 | 31,901 | 32,009 | 31,847 |
Other Comprehensive Income (Loss), Net of Tax | ' | ' | ' | ' |
Foreign currency translation adjustments | 9,790 | 15,764 | 554 | -24,288 |
Defined Benefit Plans | ' | ' | ' | ' |
Amortization of prior service costs and unrecognized gains (losses) | 359 | 38 | 895 | 136 |
Amounts arising during the year, primarily due to the addition of new participants | -154 | 0 | -320 | -168 |
Deferred tax adjustment resulting from defined benefit plan activity | -71 | -13 | -199 | 13 |
Valuation reserve (reversal) associated with defined benefit plan activity | 69 | 13 | 193 | -17 |
Current period unrealized gain (loss) on cash flow hedges | -104 | -1,322 | 779 | -276 |
Deferred tax benefit (loss) related to unrealized gain (loss) on cash flow hedges | -15 | 38 | -57 | -73 |
Other Comprehensive Income (Loss), Net of Tax | 9,874 | 14,518 | 1,845 | -24,673 |
Comprehensive Income | $25,976 | $17,382 | $40,666 | ($15,553) |
Consolidated_Statement_Of_Comp1
Consolidated Statement Of Comprehensive Income (Parentheticals) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Discontinued Operation, Tax Effect of Discontinued Operation | $227 | $2,629 | $237 | $5,264 |
Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation | $1,583 | $0 | $11,083 | $0 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current Assets | ' | ' |
Cash and cash equivalents | $32,625 | $38,791 |
Trade receivables, net | 191,464 | 198,791 |
Installment receivables, net | 1,560 | 2,188 |
Inventories, net | 167,368 | 183,246 |
Other current assets | 33,830 | 41,776 |
Assets Held-for-sale, Current | 0 | 103,157 |
Total Current Assets | 426,847 | 567,949 |
Other Assets | 40,327 | 42,262 |
Other Intangibles | 65,105 | 71,652 |
Property and Equipment, net | 108,391 | 118,231 |
Goodwill | 450,727 | 462,200 |
Total Assets | 1,091,397 | 1,262,294 |
Current Liabilities | ' | ' |
Accounts payable | 117,684 | 133,048 |
Accrued expenses | 130,479 | 135,189 |
Accrued income taxes | 7,201 | 2,713 |
Short-term debt and current maturities of long-term obligations | 1,294 | 5,427 |
Liabilities of Assets Held-for-sale | 0 | 23,358 |
Total Current Liabilities | 256,658 | 299,735 |
Long-Term Debt | 54,775 | 229,375 |
Other Long-Term Obligations | 114,773 | 112,195 |
Shareholders' Equity | ' | ' |
Preferred Shares (Authorized 300 shares; none outstanding) | 0 | 0 |
Additional paid-in-capital | 232,881 | 228,187 |
Retained earnings | 402,181 | 364,546 |
Accumulated other comprehensive earnings | 114,588 | 112,743 |
Treasury shares | -93,262 | -93,262 |
Total Shareholders' Equity | 665,191 | 620,989 |
Total Liabilities and Shareholders' Equity | 1,091,397 | 1,262,294 |
Common Class A [Member] | ' | ' |
Common Stock, Shares, Issued | 34,053 | 33,952 |
Common Shares (Authorized 100,000 shares; 34,053 and 33,952 issued in 2013 and 2012, respectively) - no par | ' | ' |
Shareholders' Equity | ' | ' |
Common Shares | 8,531 | 8,503 |
Common Class B (Authorized 12,000 shares; 1,085 and 1,086, issued and outstanding in 2013 and 2012, respectively - no par | ' | ' |
Common Stock, Shares, Issued | 1,085 | 1,086 |
Shareholders' Equity | ' | ' |
Common Shares | $272 | $272 |
Balance_Sheet_Parentheticals
Balance Sheet Parentheticals (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Preferred Stock, Shares Authorized | 300 | 300 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Treasury Stock, Shares | 3,135 | 3,135 |
Common Class A [Member] | ' | ' |
Common Stock, Shares Authorized | 100,000 | 100,000 |
Common Stock, Shares, Issued | 34,053 | 33,952 |
Common Stock, Par or Stated Value Per Share | 0 | 0 |
Common Class B [Member] | ' | ' |
Common Stock, Shares Authorized | 12,000 | 12,000 |
Common Stock, Shares, Issued | 1,085 | 1,086 |
Common Stock, Par or Stated Value Per Share | 0 | 0 |
Consolidated_Statement_Of_Cash
Consolidated Statement Of Cash Flows (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Operating Activities | ' | ' |
Net Earnings (loss) | $38,821 | $9,120 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | ' | ' |
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal | -82,163 | 0 |
Depreciation and amortization | 28,236 | 29,065 |
Provision for losses on trade and installment receivables | 3,160 | 4,252 |
(Benefit) provision for deferred income taxes | 2,698 | 628 |
Provision for other deferred liabilities | 140 | 821 |
Provision for stock-based compensation | 4,721 | 5,198 |
Loss on disposals of property and equipment | 565 | 108 |
Loss on debt extinguishment including debt finance charges and associated fees | 0 | 312 |
Amortization of convertible debt discount | 468 | 430 |
Changes in operating assets and liabilities: | ' | ' |
Trade receivables | 3,049 | -8,149 |
Installment sales contracts, net | -633 | 4,353 |
Inventories | 10,599 | -30,936 |
Other current assets | 7,539 | -90 |
Accounts payable | -16,848 | -329 |
Accrued expenses | -390 | 251 |
Other long-term liabilities | -1,374 | 11,788 |
Net Cash Provided (Used) by Operating Activities | -1,245 | 26,822 |
Investing Activities | ' | ' |
Purchases of property and equipment | -11,086 | -14,775 |
Proceeds from sale of property and equipment | 856 | 97 |
Proceeds from Divestiture of Business, net | 187,552 | 0 |
(Increase) Decrease in other long-term assets | 949 | 409 |
Other | -147 | -219 |
Net Cash Used for Investing Activities | 178,124 | -14,488 |
Financing Activities | ' | ' |
Proceeds from revolving lines of credit and long-term borrowings | 250,124 | 255,703 |
Payments on revolving lines of credit and long-term borrowings | -432,185 | -266,721 |
Payment of Financing Costs | 0 | -1 |
Payment of dividends | -1,187 | -1,183 |
Net Cash Provided (Used) by Financing Activities | -183,248 | -12,202 |
Effect of exchange rate changes on cash | 203 | 226 |
Increase (decrease) in cash and cash equivalents | -6,166 | 358 |
Cash and cash equivalents at beginning of year | 38,791 | 34,924 |
Cash and cash equivalents at end of year | $32,625 | $35,282 |
Accounting_Policies
Accounting Policies | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Accounting Policies [Abstract] | ' | |||||||||||||||
Accounting Policies | ' | |||||||||||||||
Accounting Policies | ||||||||||||||||
Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home based upon the company’s distribution channels, breadth of product line and net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets. | ||||||||||||||||
Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of September 30, 2013, the results of its operations for the three and nine months ended September 30, 2013 and changes in its cash flow for the nine months ended September 30, 2013 and 2012, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using an August 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year. | ||||||||||||||||
Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. | ||||||||||||||||
Stock-Based Compensation Plans: The company accounts for share-based compensation under the provisions of Compensation-Stock Compensation, ASC 718. The company has not made any modifications to the terms of any previously granted options and no significant changes have been made regarding the valuation methodologies used to determine the fair value of options granted. The company continues to use a Black-Scholes valuation model. | ||||||||||||||||
Stock options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods. The amounts of stock-based compensation expense recognized were as follows (in thousands): | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Stock-based compensation expense recognized as part of selling, general and administrative expense | $ | 2,147 | $ | 2,208 | $ | 4,721 | $ | 5,198 | ||||||||
The amounts above reflect compensation expense related to restricted stock awards and nonqualified stock options awarded under the 2003 Performance Plan and the 2013 Equity Compensation Plan. Stock-based compensation is not allocated to the business segments, but is reported as part of All Other as shown in the company's Business Segment Note to the Consolidated Financial Statements. | ||||||||||||||||
Recent Accounting Pronouncements: In February, 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (ASU 2013-02 or the ASU). ASU 2013-02 requires companies to report, in one place, changes in and reclassifications out of accumulated other comprehensive income (OCI). The ASU does not change what is required to be reported in OCI. The company adopted ASU 2013-02 in the first quarter of 2013 with no impact on the company's Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows. See Accumulated Other Comprehensive Income (Loss) in the Notes to these Consolidated Financial Statements. | ||||||||||||||||
In February 2013, the FASB issued ASU No. 2013-04, Liabilities (Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. This update requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, as the sum of a) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and b) any additional amount the reporting entity expects to pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. The requirements of ASU No. 2013-04 are effective on a retrospective basis for interim and annual periods beginning after December 15, 2013. The company is in the process of determining the effects, if any, that the adoption of ASU No. 2013-04 will have on the company’s financial position, results of operations or cash flows. | ||||||||||||||||
In December, 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, and in January, 2013, issued ASU 2013-01, Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities (ASU 2013-01). ASU 2013-01 is intended to help investors and other financial statement users to better assess the effect or potential effect of offsetting arrangements on an entity's financial position and requires companies to disclose both gross and net information about both instruments and transactions eligible for offset in the financial position; and to disclose instruments and transactions subject to an agreement similar to a master netting agreement. The company adopted ASU 2013-01 in the first quarter of 2013 with no impact on the company's Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows. See Derivatives in the Notes to these Consolidated Financial Statements. See Accumulated Other Comprehensive Income (Loss) in the Notes to these Consolidated Financial Statements. |
Discontinued_Operations_Notes
Discontinued Operations (Notes) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Discontinued Operations [Abstract] | ' | ||||||||
Discontinuted Operations | ' | ||||||||
Discontinued Operations | |||||||||
On December 21, 2012, as part of the company's globalization strategy, and to allow it to focus on its core equipment product lines, the company entered into an agreement to sell Invacare Supply Group (ISG) and accordingly the company determined on that date that the "held for sale" criteria of ASC 360-10-45-9 were met. Accordingly, the assets and liabilities of ISG (long-lived asset disposal group) are shown at their carrying amounts, which are lower than the fair values less cost to sale as of December 31, 2012. | |||||||||
On January 18, 2013, the company completed the sale of the ISG medical supplies business for a purchase price of $150,800,000 in cash, which remains subject to final post-closing adjustments. ISG had been operated on a stand-alone basis and reported as a reportable segment of the company. The company recorded a gain of $59,402,000 pre-tax in the first quarter of 2013 which represents the excess of the net sales price over the book value of the assets and liabilities of ISG. The sale of this business is dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the first quarter of 2013. The company recorded expenses related to the sale of $5,350,000, of which $3,392,000 were paid as of September 30, 2013. The gain recorded by the company reflects the company's estimated final purchase adjustments. | |||||||||
The assets and liabilities of ISG that were sold are shown as held for sale in the company's Consolidated Balance Sheets and are comprised of the following (in thousands): | |||||||||
December 31, | |||||||||
2012 | |||||||||
Trade receivables, net | $ | 44,196 | |||||||
Inventories, net | 25,165 | ||||||||
Other current assets | 9,355 | ||||||||
Property and Equipment, net | 1,368 | ||||||||
Goodwill | 23,073 | ||||||||
Assets held for sale - current | $ | 103,157 | |||||||
Accounts payable | $ | 17,692 | |||||||
Accrued expenses | 4,602 | ||||||||
Accrued income taxes | 1,064 | ||||||||
Liabilities held for sale - current | $ | 23,358 | |||||||
The net sales of the discontinued operation were $0 and $18,498,000 for the three and nine months ended September 30, 2013 and $85,763,000 and $246,433,000 for the three and nine months ended September 30, 2012, respectively. Earnings before income taxes for the discontinued operation were $0 and $402,000 for the three and nine months ended September 30, 2013 and $3,894,000 and $10,703,000 for the three and nine months ended September 30, 2012, respectively. | |||||||||
The company will continue to sell products to the acquirer of ISG and provide certain transitional services to the acquirer over a period of less than one year from the date of sale. The net cash flows expected to be paid and received related to such product sales and transitional services are not expected to be significant. | |||||||||
On August 6, 2013, the company sold Champion Manufacturing, Inc. (Champion), its domestic medical recliner business for dialysis clinics, to Champion Equity Holdings, LLC for $45,000,000 in cash, which is subject to final post-closing adjustments. Champion had been operated on a stand-alone basis and reported as part of the IPG segment of the company. The company recorded a gain of $22,761,000 pre-tax in the third quarter of 2013, which represents the excess of the net sales price over the book value of the assets and liabilities of Champion. The sale of this business is dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the third quarter of 2013. The company recorded expenses related to the sale of $2,130,000, of which $1,367,000 were paid as of September 30, 2013. The gain recorded by the company reflects the company's estimated final purchase adjustments. | |||||||||
The assets and liabilities of Champion were the following as of the date of the sale, August 6, 2013, and as of December 31, 2012 (in thousands): | |||||||||
August 6, | December 31, | ||||||||
2013 | 2012 | ||||||||
Trade receivables, net | $ | 3,030 | $ | 2,375 | |||||
Inventories, net | 1,689 | 1,617 | |||||||
Other current assets | 92 | 21 | |||||||
Property and Equipment, net | 309 | 237 | |||||||
Goodwill | 16,277 | 16,277 | |||||||
Assets sold | $ | 21,397 | $ | 20,527 | |||||
Accounts payable | $ | 936 | $ | 475 | |||||
Accrued expenses | 352 | 318 | |||||||
Accrued income taxes | — | 200 | |||||||
Liabilities sold | $ | 1,288 | $ | 993 | |||||
The net sales of the discontinued operation were $2,643,000 and $15,857,000 for the three and nine months ended September 30, 2013 and $5,700,000 and $17,271,000 for the three and nine months ended September 30, 2012, respectively. Earnings before income taxes for the discontinued operation were $484,000 and $3,156,000 for the three and nine months ended September 30, 2013 and $1,037,000 and $3,307,000 for the three and nine months ended September 30, 2012, respectively. Results for Champion include an interest expense allocation from continuing operations to discontinued operations of $78,000 and $449,000 for the three and nine months ended September 30, 2013 and $198,000 and $594,000 for the three and nine months ended September 30, 2012, respectively, as proceeds from the sale were required to be utilized to pay down debt. The interest allocation was based on the net proceeds assumed to pay down debt applying the company's average interest rates for the periods presented. | |||||||||
In addition, in accordance with ASC 350, when a portion of a reporting entity that constitutes a business is disposed of, goodwill associated with that business should be included in the carrying amount of the net assets of the business sold in determining the gain or loss on the disposal. As such, the company allocated additional goodwill of $16,205,000 to Champion from the continuing operations of the IPG segment based on the relative fair value of Champion as compared to the remaining IPG reporting unit. | |||||||||
The company will continue to purchase an immaterial amount of products from the acquirer of Champion until the company transitions manufacturing of the product, which is expected to occur before the end of the year. | |||||||||
The company recorded an incremental intra-period tax allocation expense to discontinued operations in the quarter representing the cumulative intra-period allocation expense to discontinued operations based on the company's current estimate of the projected domestic taxable loss related to continuing operations for 2013. The amount recorded through September 30, 2013 is less than the federal statutory rate as the expected taxable loss in continuing operations is less than the taxable gain from discontinued operations. | |||||||||
The company has classified ISG and Champion as discontinued operations for all periods presented. |
Receivables
Receivables | 9 Months Ended | |||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||
Receivables [Abstract] | ' | |||||||||||||||||||||||
Receivables | ' | |||||||||||||||||||||||
Receivables | ||||||||||||||||||||||||
Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts ($20,836,000 at September 30, 2013 and $22,213,000 at December 31, 2012) is based primarily on management’s evaluation of the financial condition of specific customers. In addition, as a result of the company's third party financing arrangement with De Lage Landen, Inc. ("DLL"), a third party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet. | ||||||||||||||||||||||||
The company’s U.S. customers electing to finance their purchases can do so using DLL. In addition, the company often provides financing directly for its Canadian customers for which DLL is not an option. The installment receivables recorded on the books of the company represent a single portfolio segment of finance receivables to the independent provider channel. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by 3 payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by the company because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for 12 months and historically have had a very low risk of default. | ||||||||||||||||||||||||
The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. The company is closely monitoring the roll-out of the second round of NCB, which became effective in 91 additional metropolitan statistical areas on July 1, 2013. At this early stage of the program, it is difficult to characterize the impact from NCB on its domestic home medical equipment business, as there continues to be uncertainty as the industry realigns and adjusts itself to the small number of bid contracts awarded. | ||||||||||||||||||||||||
For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for customers desiring credit greater than $250,000 which generally includes a detailed review of the customer’s financials as well as consideration of other factors such as exposure to changing reimbursement laws. | ||||||||||||||||||||||||
Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process of adjudication which typically approximates 18 months. Any write-offs are made after the legal process has been completed. The company has not made any changes to either its accounting policies or methodology to estimation allowances for doubtful accounts in the last twelve months. | ||||||||||||||||||||||||
Installment receivables consist of the following (in thousands): | ||||||||||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||||||||||
Current | Long- | Total | Current | Long- | Total | |||||||||||||||||||
Term | Term | |||||||||||||||||||||||
Installment receivables | $ | 3,554 | $ | 2,394 | $ | 5,948 | $ | 4,982 | $ | 1,506 | $ | 6,488 | ||||||||||||
Less: Unearned interest | (70 | ) | — | (70 | ) | (71 | ) | — | (71 | ) | ||||||||||||||
3,484 | 2,394 | 5,878 | 4,911 | 1,506 | 6,417 | |||||||||||||||||||
Allowance for doubtful accounts | (1,924 | ) | (1,718 | ) | (3,642 | ) | (2,723 | ) | (1,100 | ) | (3,823 | ) | ||||||||||||
$ | 1,560 | $ | 676 | $ | 2,236 | $ | 2,188 | $ | 406 | $ | 2,594 | |||||||||||||
Installment receivables purchased from DLL during the nine months ended September 30, 2013 increased the gross installment receivables balance by $2,415,000. No sales of installment receivables were made by the company during the quarter. | ||||||||||||||||||||||||
The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): | ||||||||||||||||||||||||
Nine Months Ended June 30, 2013 | Year Ended December 31, 2012 | |||||||||||||||||||||||
Balance as of beginning of period | $ | 3,823 | $ | 4,273 | ||||||||||||||||||||
Current period provision | 943 | 458 | ||||||||||||||||||||||
Direct write-offs charged against the allowance | (1,124 | ) | (908 | ) | ||||||||||||||||||||
Balance as of end of period | $ | 3,642 | $ | 3,823 | ||||||||||||||||||||
Installment receivables by class as of September 30, 2013 consist of the following (in thousands): | ||||||||||||||||||||||||
Total | Unpaid | Related | Interest | |||||||||||||||||||||
Installment | Principal | Allowance | Income | |||||||||||||||||||||
Receivables | Balance | for | Recognized | |||||||||||||||||||||
Doubtful | ||||||||||||||||||||||||
Accounts | ||||||||||||||||||||||||
U.S. | ||||||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | $ | 4,510 | $ | 4,510 | $ | 3,477 | $ | — | ||||||||||||||||
Canada | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,273 | 1,203 | — | 76 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 165 | 165 | 165 | — | ||||||||||||||||||||
Total Canadian Installment Receivables | $ | 1,438 | $ | 1,368 | $ | 165 | $ | 76 | ||||||||||||||||
Total | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,273 | 1,203 | — | 76 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 4,675 | 4,675 | 3,642 | — | ||||||||||||||||||||
Total Installment Receivables | $ | 5,948 | $ | 5,878 | $ | 3,642 | $ | 76 | ||||||||||||||||
Installment receivables by class as of December 31, 2012 consist of the following (in thousands): | ||||||||||||||||||||||||
Total | Unpaid | Related | Interest | |||||||||||||||||||||
Installment | Principal | Allowance | Income | |||||||||||||||||||||
Receivables | Balance | for | Recognized | |||||||||||||||||||||
Doubtful | ||||||||||||||||||||||||
Accounts | ||||||||||||||||||||||||
U.S. | ||||||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | $ | 4,508 | $ | 4,508 | $ | 3,365 | $ | — | ||||||||||||||||
Canada | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,522 | 1,451 | — | 120 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 458 | 458 | 458 | — | ||||||||||||||||||||
Total Canadian Installment Receivables | $ | 1,980 | $ | 1,909 | $ | 458 | $ | 120 | ||||||||||||||||
Total | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,522 | 1,451 | — | 120 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 4,966 | 4,966 | 3,823 | — | ||||||||||||||||||||
Total Installment Receivables | $ | 6,488 | $ | 6,417 | $ | 3,823 | $ | 120 | ||||||||||||||||
Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of September 30, 2013, the company had no U.S. installment receivables past due of 90 days or more for which the company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. However, while the full balance may be deemed to be impaired, the company has historically collected a large percentage of the principal of its U.S. installment receivables. | ||||||||||||||||||||||||
The company had an immaterial amount of Canadian installment receivables which were past due of 90 days or more as of September 30, 2013 and December 31, 2012 for which the company is still accruing interest. The aging of the company’s installment receivables was as follows (in thousands): | ||||||||||||||||||||||||
September 30, 2013 | 31-Dec-12 | |||||||||||||||||||||||
Total | U.S. | Canada | Total | U.S. | Canada | |||||||||||||||||||
Current | $ | 1,218 | $ | — | $ | 1,218 | $ | 1,467 | $ | — | $ | 1,467 | ||||||||||||
0-30 Days Past Due | 9 | — | 9 | 43 | — | 43 | ||||||||||||||||||
31-60 Days Past Due | 6 | — | 6 | 2 | — | 2 | ||||||||||||||||||
61-90 Days Past Due | — | — | — | — | — | — | ||||||||||||||||||
90+ Days Past Due | 4,715 | 4,510 | 205 | 4,976 | 4,508 | 468 | ||||||||||||||||||
$ | 5,948 | $ | 4,510 | $ | 1,438 | $ | 6,488 | $ | 4,508 | $ | 1,980 | |||||||||||||
Inventories
Inventories | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Inventory, Net [Abstract] | ' | |||||||
Inventories | ' | |||||||
Inventories | ||||||||
Inventories consist of the following (in thousands): | ||||||||
30-Sep-13 | 31-Dec-12 | |||||||
Finished goods | $ | 90,422 | $ | 94,675 | ||||
Raw materials | 61,642 | 71,596 | ||||||
Work in process | 15,304 | 16,975 | ||||||
$ | 167,368 | $ | 183,246 | |||||
Other_Current_Assets_Notes
Other Current Assets (Notes) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Other Current Assets [Abstract] | ' | |||||||
Other Assets Disclosure [Text Block] | ' | |||||||
Other Current Assets | ||||||||
Other current assets consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Value added tax receivables | $ | 15,004 | $ | 18,002 | ||||
Recoverable income taxes | 3,457 | 6,192 | ||||||
Derivatives (foreign currency forward contracts) | 1,311 | 1,062 | ||||||
Prepaid insurance | 300 | 2,241 | ||||||
Prepaids and other current assets | 13,758 | 14,279 | ||||||
$ | 33,830 | $ | 41,776 | |||||
Other_LongTerm_Assets_Notes
Other Long-Term Assets (Notes) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Text Block [Abstract] | ' | |||||||
Investments and Other Noncurrent Assets [Text Block] | ' | |||||||
Other Long-Term Assets | ||||||||
Other long-term assets consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Cash surrender value of life insurance policies | $ | 35,772 | $ | 36,375 | ||||
Deferred Financing Fees | 1,356 | 2,728 | ||||||
Investments | 1,190 | 1,171 | ||||||
Long-term installment receivables | 676 | 406 | ||||||
Other | 1,333 | 1,582 | ||||||
$ | 40,327 | $ | 42,262 | |||||
Property_And_Equipment
Property And Equipment | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property And Equipment | ' | |||||||
Property and Equipment | ||||||||
Property and equipment consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Machinery and equipment | $ | 356,935 | $ | 356,512 | ||||
Land, buildings and improvements | 90,234 | 95,047 | ||||||
Furniture and fixtures | 12,998 | 13,397 | ||||||
Leasehold improvements | 14,886 | 14,975 | ||||||
475,053 | 479,931 | |||||||
Less allowance for depreciation | (366,662 | ) | (361,700 | ) | ||||
$ | 108,391 | $ | 118,231 | |||||
Goodwill_And_Other_Intangibles
Goodwill And Other Intangibles | 9 Months Ended |
Sep. 30, 2013 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ' |
Goodwill Disclosure [Text Block] | ' |
Goodwill | |
The goodwill decrease reflected on the balance sheet from December 31, 2012 to September 30, 2013 was due to the sale of Champion which decreased goodwill by $16,277,000, partially offset by an increase in goodwill due to foreign currency translation. |
Other_Intangibles
Other Intangibles | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||
Intangible Assets Disclosure [Text Block] | ' | |||||||||||||||
Other Intangibles | ||||||||||||||||
All of the company’s other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $31,299,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2012 to September 30, 2013 were the result of foreign currency translation, amortization and an intangible impairment write-down charge of $167,000 for a customer list in the NA/HME segment. The after-tax and pre-tax impairment amounts were the same for the impairment. The company's intangibles consist of the following (in thousands): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Historical | Accumulated | Historical | Accumulated | |||||||||||||
Cost | Amortization | Cost | Amortization | |||||||||||||
Customer Lists | $ | 91,344 | $ | 61,888 | $ | 93,572 | $ | 58,447 | ||||||||
Trademarks | 31,299 | — | 31,280 | — | ||||||||||||
License Agreements | 1,428 | 1,428 | 3,212 | 3,212 | ||||||||||||
Developed Technology | 9,712 | 6,098 | 9,650 | 5,588 | ||||||||||||
Patents | 6,115 | 5,472 | 6,060 | 5,234 | ||||||||||||
Other | 7,481 | 7,388 | 7,571 | 7,212 | ||||||||||||
$ | 147,379 | $ | 82,274 | $ | 151,345 | $ | 79,693 | |||||||||
Amortization expense related to other intangibles was $6,937,000 in the first nine months of 2013 and is estimated to be $9,182,000 in 2013, $8,670,000 in 2014, $7,174,000 in 2015, $5,796,000 in 2016, $2,290,000 in 2017 and $2,290,000 in 2018. Amortized intangibles are being amortized on a straight-line basis for periods from 3 to 17 years with the majority of the intangibles being amortized over a life of between 10 and 13 years. |
Current_Liabilities_Notes
Current Liabilities (Notes) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Payables and Accruals [Abstract] | ' | |||||||
Current Liabilities Disclosure [Text Block] | ' | |||||||
Current Liabilities | ||||||||
Accrued expenses consist of accruals for the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Salaries and wages | $ | 37,480 | $ | 41,813 | ||||
Taxes other than income taxes, primarily Value Added Taxes | 23,225 | 24,600 | ||||||
Warranty cost | 25,020 | 21,451 | ||||||
Freight | 7,806 | 7,853 | ||||||
Professional | 7,355 | 7,595 | ||||||
Product liability, current portion | 3,572 | 3,323 | ||||||
Rebates | 2,136 | 3,635 | ||||||
Insurance | 2,726 | 2,674 | ||||||
Interest | 921 | 1,268 | ||||||
Derivative liabilities | 771 | 1,373 | ||||||
Severance | 3,481 | 5,211 | ||||||
Other items, principally trade accruals | 15,986 | 14,393 | ||||||
$ | 130,479 | $ | 135,189 | |||||
Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold in accordance with the guidance in ASC 605-50, Customer Payments and Incentives. |
Warrany_Costs
Warrany Costs | 9 Months Ended | |||
Sep. 30, 2013 | ||||
Accrued Liabilities, Current [Abstract] | ' | |||
Current Liabilities | ' | |||
Generally, the company's products are covered from the date of sale to the customer by warranties against defects in material and workmanship for various periods depending on the product. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. The increase in the liability for pre-existing warranties in 2013 is primarily the result of product recalls. The warranty accrual as of September 30, 2013 includes anticipated warranty expense related to the power wheelchair joystick recall of $3,800,000, provided for during the second quarter of 2013, which primarily impacted the Asia/Pacific segment. No change was made in the warranty accrual related to the power wheelchair joystick recall during the quarter ended September 30, 2013. | ||||
The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): | ||||
Balance as of January 1, 2013 | $ | 21,451 | ||
Warranties provided during the period | 7,843 | |||
Settlements made during the period | (8,741 | ) | ||
Changes in liability for pre-existing warranties during the period, including expirations | 4,467 | |||
Balance as of September 30, 2013 | $ | 25,020 | ||
LongTerm_Debt
Long-Term Debt | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Long-Term Debt | ' | |||||||
Long-Term Debt | ||||||||
Debt consists of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Senior secured revolving credit facility, due in October 2015 | $ | 38,968 | $ | 217,494 | ||||
Convertible senior subordinated debentures at 4.125%, due in February 2027 | 10,476 | 10,009 | ||||||
Other notes and lease obligations | 6,625 | 7,299 | ||||||
56,069 | 234,802 | |||||||
Less current maturities of long-term debt | (1,294 | ) | (5,427 | ) | ||||
$ | 54,775 | $ | 229,375 | |||||
The reduction in debt during the year was principally the result of utilizing the proceeds from the sale of the discontinued operations of ISG and Champion to reduce borrowing under the company's revolving credit agreement. On May 30, 2013, the company entered into a Fourth Amendment ("the Amendment") to its Credit Agreement (the “Credit Agreement”). Pursuant to the Amendment, the Credit Agreement was amended to: (i) decrease the aggregate principal amount of the revolving credit facility to $250,000,000 from $400,000,000, and limit the company's borrowings under the revolving credit facility to an amount not to exceed $200,000,000 aggregate principal amount through December 31, 2013; (ii) increase the maximum leverage ratio (consolidated funded indebtedness to consolidated EBITDA, each as defined in the Credit Agreement, as amended) to 4.00 to 1.00 from 3.50 to 1.00 until January 1, 2014, when the maximum leverage ratio will revert back to 3.50 to 1.00; (iii) decrease the minimum interest coverage ratio (consolidated EBITDA to consolidated interest charges, each as defined in the Credit Agreement, as amended) to 3.00 to 1.00 from 3.50 to 1.00 until January 1, 2014, when the minimum interest coverage ratio will revert back to 3.50 to 1.00; (iv) in calculating consolidated EBITDA for purposes of determining the ratios, provide for the add back to consolidated EBITDA of up to an additional $15,000,000 for future one-time cash restructuring charges and (v) provide for an increase of (A) 25 basis points in the margin applicable to determining the interest rate on borrowings under the revolving credit facility and letter of credit fees and (B) 10 basis points in the commitment fee, all during periods when the leverage ratio exceeds 3.50 to 1.00. Compliance with the ratios is tested at the end of the quarter in accordance with the credit agreement. As a result of the amendment, the company incurred $436,000 in fees in the second quarter of 2013 which were capitalized and are being amortized through October, 2015. In addition, as a result of reducing the capacity of the facility from $400,000,000 to $250,000,000, the company wrote-off $1,216,000 in fees previously capitalized in the second quarter of 2013, which is reflected in the expense of the North America / HME segment. | ||||||||
In 2007, the company issued $135,000,000 principal amount of Convertible Senior Subordinated Debentures due 2027. The debentures are unsecured senior subordinated obligations of the company guaranteed by substantially all of the company’s domestic subsidiaries, pay interest at 4.125% per annum on each February 1 and August 1, and are convertible upon satisfaction of certain conditions into cash, common shares of the company, or a combination of cash and common shares of the company, subject to certain conditions. The debentures allow the company to satisfy the conversion using any combination of cash or stock, and at the company’s discretion. The company intends to satisfy the accreted value of the debentures using cash. Assuming adequate cash on hand at the time of conversion, the company also intends to satisfy the conversion spread using cash, as opposed to stock. | ||||||||
The company may from time to time seek to retire or purchase its 4.125% Convertible Senior Subordinated Debentures due 2027, in open market purchases, privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the company's liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material. | ||||||||
The liability components of the company’s convertible debt consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Principal amount of liability component | $ | 13,350 | $ | 13,350 | ||||
Unamortized discount | (2,874 | ) | (3,341 | ) | ||||
Net carrying amount of liability component | $ | 10,476 | $ | 10,009 | ||||
The company is a party to an interest rate swap agreement to effectively convert a portion of floating rate revolving credit facility debt to fixed rate debt to avoid the risk of changes in market interest rates. Specifically, an interest rate swap agreement for a notional amount of $12,000,000 through April 2014 was entered into that fixes the LIBOR component of the interest rate on that portion of the revolving credit facility debt at a rate of 0.54% for an effective aggregate rate 3.04%. As of September 30, 2013, the weighted average floating interest rate on revolving credit borrowings was 2.45% compared to 2.21% as of December 31, 2012. | ||||||||
Shareholders_Equity_Transactio
Shareholders' Equity Transactions | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||||
Shareholders' Equity Transactions | ' | |||||||||||||||
Shareholders’ Equity Transactions | ||||||||||||||||
On May 16, 2013 shareholders approved the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”), which was adopted on March 27, 2013 by the company's Board of Directors (the “Board”). The Board adopted the 2013 Plan because the ten-year term of the company's prior equity plan, the Invacare Corporation Amended and Restated 2003 Performance Plan (the “2003 Plan”), expired on May 21, 2013. No new awards will be granted under the 2003 Plan following its expiration, but awards granted prior to its expiration will remain in effect under their original terms. | ||||||||||||||||
The 2013 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or SARs will count against the number of total shares available under the 2013 Plan as one share; and each common share underlying any award other than a stock option or a stock appreciation rights (“SAR”) will count against the number of total shares available under the 2013 Plan as two shares. Any common shares that are added back to the 2013 Plan as the result of the cancellation or forfeiture of an award granted under the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2013 Plan. Each common share that is added back to the 2013 Plan due to a cancellation or forfeiture of an award granted under the 2003 Plan will be added back as one common share. | ||||||||||||||||
The Compensation and Management Development Committee of the Board (the “Committee”), in its discretion, may grant an award under the 2013 Plan to any director or employee of the company or an affiliate. The 2013 Plan initially allows the Committee to grant up to 4,460,337 Common Shares in connection with the following types of awards with respect to shares of the company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock, and performance shares. The Committee also may grant performance units that are payable in cash. The Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards. | ||||||||||||||||
During the nine months ended September 30, 2013, the Committee granted 756,700 non-qualified stock options, each having a term of ten years and generally granted at the fair market value of the company’s Common Shares on the date of grant. In addition, restricted stock awards for 114,700 shares were granted without cost to the recipients which vest ratably over the four years after the award date. Compensation expense of $1,568,000 was recognized during the nine months ended September 30, 2013 related to restricted stock awards and there were outstanding restricted stock awards totaling 362,323 shares that were not vested. | ||||||||||||||||
As of September 30, 2013, there was $13,264,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the plan, which is related to non-vested options and shares, and includes $4,169,000 related to restricted stock awards. The company expects the compensation expense to be recognized over a weighted-average period of approximately two years. | ||||||||||||||||
The following table summarizes information about stock option activity for the nine months ended September 30, 2013: | ||||||||||||||||
September 30, 2013 | Weighted | |||||||||||||||
Average | ||||||||||||||||
Exercise | ||||||||||||||||
Price | ||||||||||||||||
Options outstanding at January 1, 2013 | 4,664,634 | $ | 26.21 | |||||||||||||
Granted | 756,700 | 14.47 | ||||||||||||||
Exercised | — | — | ||||||||||||||
Canceled | (792,584 | ) | 28.74 | |||||||||||||
Options outstanding at September 30, 2013 | 4,628,750 | $ | 23.86 | |||||||||||||
Options exercise price range at September 30, 2013 | $ 12.42 to | |||||||||||||||
$ | 47.8 | |||||||||||||||
Options exercisable at September 30, 2013 | 3,070,364 | |||||||||||||||
Options available for grant at September 30, 2013* | 4,460,337 | |||||||||||||||
________________________ | ||||||||||||||||
* | Options available for grant as of September 30, 2013 reduced by net restricted stock award activity of 793,351. | |||||||||||||||
The following table summarizes information about stock options outstanding at September 30, 2013: | ||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||
Exercise Prices | Number | Weighted Average | Weighted Average | Number | Weighted Average | |||||||||||
Outstanding | Remaining | Exercise Price | Exercisable | Exercise Price | ||||||||||||
At 9/30/13 | Contractual Life (Years) | At 9/30/13 | ||||||||||||||
$ 12.42 – $15.00 | 1,354,435 | 9.2 | $ | 13.95 | 166,045 | $ | 13.38 | |||||||||
$ 15.01 – $25.00 | 1,613,291 | 5.6 | 22.51 | 1,364,559 | 22.21 | |||||||||||
$ 25.01 – $35.00 | 950,109 | 5.7 | 25.81 | 828,846 | 25.85 | |||||||||||
$ 35.01 – $47.80 | 710,915 | 1.4 | 43.21 | 710,914 | 43.21 | |||||||||||
Total | 4,628,750 | 6 | $ | 23.86 | 3,070,364 | $ | 27.57 | |||||||||
When stock options are awarded, they generally become exercisable over a four-year vesting period whereby options vest in equal installments each year. Options granted with graded vesting are accounted for as single options. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected dividend yield, expected stock price volatility, risk-free interest rate and expected life. The assumed expected life is based on the company's historical analysis of option history. The expected stock price volatility is also based on actual historical volatility, and expected dividend yield is based on historical dividends as the company has no current intention of changing its dividend policy. | ||||||||||||||||
The 2013 Plan provides that shares granted come from the company's authorized but unissued Common Shares or treasury shares. In addition, the company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the company acquiring treasury shares. |
Accumulated_Other_Comprehensiv
Accumulated Other Comprehensive Income (Notes) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Abstract] | ' | |||||||||||||||
Comprehensive Income (Loss) Note [Text Block] | ' | |||||||||||||||
Accumulated Other Comprehensive Income (Loss) by Component | ||||||||||||||||
Changes in accumulated other comprehensive income (Loss) ("OCI") during the quarter ended September 30, 2013 were as follows (in thousands): | ||||||||||||||||
Foreign Currency | Long-Term Notes | Defined Benefit Plans | Derivatives | Total | ||||||||||||
June 30, 2013 | 117,817 | (6,743 | ) | (6,419 | ) | 59 | 104,714 | |||||||||
OCI before reclassifications | 17,852 | (8,062 | ) | 265 | (197 | ) | 9,858 | |||||||||
Amount reclassified from accumulated OCI | — | — | (62 | ) | 78 | 16 | ||||||||||
Net current-period OCI | 17,852 | (8,062 | ) | 203 | (119 | ) | 9,874 | |||||||||
30-Sep-13 | 135,669 | (14,805 | ) | (6,216 | ) | (60 | ) | 114,588 | ||||||||
Changes in OCI during the nine months ended September 30, 2013 were as follows (in thousands): | ||||||||||||||||
Foreign Currency | Long-Term Notes | Defined Benefit Plans | Derivatives | Total | ||||||||||||
December 31, 2012 | 117,465 | 2,845 | (6,785 | ) | (782 | ) | 112,743 | |||||||||
OCI before reclassifications | 18,204 | (17,650 | ) | 750 | 650 | 1,954 | ||||||||||
Amount reclassified from accumulated OCI | — | — | (181 | ) | 72 | (109 | ) | |||||||||
Net current-period OCI | 18,204 | (17,650 | ) | 569 | 722 | 1,845 | ||||||||||
30-Sep-13 | 135,669 | (14,805 | ) | (6,216 | ) | (60 | ) | 114,588 | ||||||||
Reclassifications out of accumulated OCI for the three and nine months ended September 30, 2013 were as follows (in thousands): | ||||||||||||||||
Amount reclassified from OCI | Affected line item in the Statement of Comprehensive Income (Loss) | |||||||||||||||
Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 | |||||||||||||||
Defined Benefit Plans | ||||||||||||||||
Service and interest costs | (64 | ) | (187 | ) | Selling, General and Administrative | |||||||||||
Tax | 2 | 6 | Income Taxes | |||||||||||||
Total after tax | (62 | ) | (181 | ) | ||||||||||||
Derivatives | ||||||||||||||||
Foreign currency forward contracts hedging sales | (54 | ) | (496 | ) | Net Sales | |||||||||||
Foreign currency forward contracts hedging purchases | 128 | 453 | Cost of Products Sold | |||||||||||||
Interest rate swaps | 13 | 139 | Interest Expense | |||||||||||||
Total before tax | 87 | 96 | ||||||||||||||
Tax | (9 | ) | (24 | ) | Income Taxes | |||||||||||
Total after tax | 78 | 72 | ||||||||||||||
Charges_Related_To_Restructuri
Charges Related To Restructuring Activities | 9 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||||||||||
Charges Related To Restructuring Activities | ' | |||||||||||||||||||
Charges Related to Restructuring Activities | ||||||||||||||||||||
Historically, the company's restructuring charges were necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affect the company's customers (e.g. home health care providers) and continued pricing pressures faced by the company as a result of outsourcing by competitors to lower cost locations. In addition, restructuring actions principally in the North America/HME segment have been precipitated by the negative impact on the business related to the FDA consent decree which has resulted in a sales decline in custom power wheelchairs, which is one of the company's higher margin product lines. While the company's restructuring efforts have been executed on a timely basis resulting in operating cost savings, the savings have been more than offset by continued margin decline, principally as a result of volume declines, unfavorable product mix, and higher regulatory and compliance costs related to quality system improvements. The company expects any near-term cost savings from restructuring will be offset by higher regulatory and compliance costs related to quality system improvements at least until the company has completed its quality systems remediation efforts. | ||||||||||||||||||||
The company's restructuring commenced in the second quarter of 2011 with the company's decision to close the Hong, Denmark assembly facility as part of the company's ongoing globalization initiative to reduce complexity in the company's supply chain which is intended to reduce expenses to help offset pricing pressures. In the third quarter of 2011, the company continued to execute on the closure of the Hong, Denmark assembly facility and initiated the closure of a smaller facility in the U.S. Charges for the quarter ended December 31, 2011 were primarily incurred at the company's corporate headquarters for severance, with additional costs incurred as a result of the closure of the Hong, Denmark facility. The facility closures were completed in 2012 in addition to the elimination of various positions principally in the North America/Home Medical Equipment (HME) and Asia/Pacific segments. | ||||||||||||||||||||
Charges for the year ended December 31, 2011 totaled $10,534,000 including charges for severance ($8,352,000), contract exit costs primarily related to the closure of the Hong, Denmark assembly facility ($1,788,000) and inventory write-offs ($277,000) recorded in cost of products sold and other miscellaneous costs ($117,000). The majority of the 2011 North America/HME charges were incurred for severance, primarily at the corporate headquarters as the result of the elimination of various positions principally in sales and administration in Elyria, Ohio. These eliminations were permanent reductions in workforce which primarily resulted in reduced selling, general and administrative expenses. In Europe, the charges were the result of the closure of the company's Hong, Denmark facility. The assembly activities were transferred to other company facilities or outsourced to third parties. This closure enabled the company to reduce fixed operating costs related to the facility and reduce headcount with the transfer of a portion of the production to other company facilities. The 2011 charges have now been paid out and were funded with operating cash flows. | ||||||||||||||||||||
Charges for the year ended December 31, 2012 totaled $11,395,000 including charges for severance ($6,775,000), lease termination costs ($1,725,000), building and asset write-downs, primarily related to the closure of the Hong, Denmark assembly facility, other miscellaneous charges, primarily building and asset write-downs, in Europe and Asia/Pacific ($2,404,000) and inventory write-offs ($491,000) in Asia/Pacific recorded in cost of products sold. Severance charges were primarily incurred in the North America/HME segment ($4,242,000), Asia/Pacific segment ($1,681,000) and Europe segment ($817,000). The charges were incurred as a result of the elimination of various positions as part of the company's globalization initiatives. In addition, a portion of the North America/HME segment severance was related to positions eliminated, principally in sales and marketing as well as manufacturing, at the company's Taylor Street facility as a result of the FDA consent decree. The savings from these charges are reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the company. In Europe, positions were eliminated as a result of finalizing the exit from the manufacturing facility in Denmark and an elimination of a senior management position in Switzerland. In Asia/Pacific, the company's management approved in the fourth quarter of 2012 a plan to restructure the company's operations in this segment. In Australia, the company consolidated offices / warehouses, decreased staffing and exited various activities while returning to a focus on distribution. At the company's subsidiary, which produces microprocessor controllers, the company decided to cease the contract manufacturing business for companies outside of the healthcare industry. Payments for the year ended December 31, 2012 were $9,381,000 and were funded with operating cash flows. The majority of the 2012 charges are expected to be paid out during 2013. | ||||||||||||||||||||
Restructuring continued during 2013 resulting in restructuring charges of $6,998,000 in the first nine months of 2013 principally for severance in NA/HME and Asia/Pacific and to a lesser extent Europe and IPG as a result of the permanent elimination of certain positions. Payments for the nine months ended September 30, 2013 were $9,830,000 and were funded with the company's credit facility. The majority of the outstanding charge accruals at September 30, 2013 are expected to be paid out within the next twelve months. | ||||||||||||||||||||
There have been no material changes in accrued balances related to the charges, either as a result of revisions in the plan or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting selling, general and administrative expenses, and to a lesser extent, costs of products sold. However, these savings have been more than offset by continued margin decline, principally as a result of volume declines, unfavorable product mix, and higher regulatory and compliance costs related to quality system improvements. To date, the company's liquidity has not been materially impacted by the company's restructuring charges. | ||||||||||||||||||||
A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands): | ||||||||||||||||||||
Severance | Product Line | Contract | Other | Total | ||||||||||||||||
Discontinuance | Terminations | |||||||||||||||||||
December 31, 2010 Balance | ||||||||||||||||||||
Total | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||
Charges | ||||||||||||||||||||
NA/HME | 4,755 | — | — | 4 | 4,759 | |||||||||||||||
IPG | 123 | — | — | — | 123 | |||||||||||||||
Europe | 3,288 | 277 | 1,788 | 113 | 5,466 | |||||||||||||||
Asia/Pacific | 186 | — | — | — | 186 | |||||||||||||||
Total | 8,352 | 277 | 1,788 | 117 | 10,534 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (1,663 | ) | — | — | (4 | ) | (1,667 | ) | ||||||||||||
IPG | (52 | ) | — | — | — | (52 | ) | |||||||||||||
Europe | (1,546 | ) | (277 | ) | (1,714 | ) | (113 | ) | (3,650 | ) | ||||||||||
Asia/Pacific | (186 | ) | — | — | — | (186 | ) | |||||||||||||
Total | (3,447 | ) | (277 | ) | (1,714 | ) | (117 | ) | (5,555 | ) | ||||||||||
December 31, 2011 Balance | ||||||||||||||||||||
NA/HME | 3,092 | — | — | — | 3,092 | |||||||||||||||
IPG | 71 | — | — | — | 71 | |||||||||||||||
Europe | 1,742 | — | 74 | — | 1,816 | |||||||||||||||
Asia/Pacific | — | — | — | — | — | |||||||||||||||
Total | 4,905 | — | 74 | — | 4,979 | |||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | 4,242 | — | 5 | — | 4,247 | |||||||||||||||
IPG | 35 | — | — | — | 35 | |||||||||||||||
Europe | 817 | — | 53 | 1,223 | 2,093 | |||||||||||||||
Asia/Pacific | 1,681 | 491 | 1,667 | 1,181 | 5,020 | |||||||||||||||
Total | 6,775 | 491 | 1,725 | 2,404 | 11,395 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (3,587 | ) | — | (5 | ) | — | (3,592 | ) | ||||||||||||
IPG | (106 | ) | — | — | — | (106 | ) | |||||||||||||
Europe | (1,964 | ) | — | (127 | ) | (1,223 | ) | (3,314 | ) | |||||||||||
Asia/Pacific | (812 | ) | (340 | ) | (42 | ) | (1,175 | ) | (2,369 | ) | ||||||||||
Total | $ | (6,469 | ) | $ | (340 | ) | $ | (174 | ) | $ | (2,398 | ) | $ | (9,381 | ) | |||||
Severance | Product Line | Contract | Other | Total | ||||||||||||||||
Discontinuance | Terminations | |||||||||||||||||||
December 31, 2012 Balance | ||||||||||||||||||||
NA/HME | $ | 3,747 | $ | — | $ | — | $ | — | $ | 3,747 | ||||||||||
IPG | — | — | — | — | — | |||||||||||||||
Europe | 595 | — | — | — | 595 | |||||||||||||||
Asia/Pacific | 869 | 151 | 1,625 | 6 | 2,651 | |||||||||||||||
Total | 5,211 | 151 | 1,625 | 6 | 6,993 | |||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | 1,679 | — | — | — | 1,679 | |||||||||||||||
IPG | 189 | — | — | — | 189 | |||||||||||||||
Europe | 115 | — | — | — | 115 | |||||||||||||||
Asia/Pacific | 453 | — | 86 | — | 539 | |||||||||||||||
Total | 2,436 | — | 86 | — | 2,522 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (2,005 | ) | — | — | — | (2,005 | ) | |||||||||||||
IPG | (17 | ) | — | — | — | (17 | ) | |||||||||||||
Europe | (461 | ) | — | — | — | (461 | ) | |||||||||||||
Asia/Pacific | (618 | ) | (151 | ) | (766 | ) | (4 | ) | (1,539 | ) | ||||||||||
Total | (3,101 | ) | (151 | ) | (766 | ) | (4 | ) | (4,022 | ) | ||||||||||
March 31, 2013 Balance | ||||||||||||||||||||
NA/HME | 3,421 | — | — | — | 3,421 | |||||||||||||||
IPG | 172 | — | — | — | 172 | |||||||||||||||
Europe | 249 | — | — | — | 249 | |||||||||||||||
Asia/Pacific | 704 | — | 945 | 2 | 1,651 | |||||||||||||||
4,546 | — | 945 | 2 | 5,493 | ||||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | 1,948 | — | — | — | 1,948 | |||||||||||||||
IPG | 13 | — | — | — | 13 | |||||||||||||||
Europe | 65 | — | — | — | 65 | |||||||||||||||
Asia/Pacific | 480 | — | 86 | — | 566 | |||||||||||||||
Total | 2,506 | — | 86 | — | 2,592 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (1,795 | ) | — | — | — | (1,795 | ) | |||||||||||||
IPG | (26 | ) | — | — | — | (26 | ) | |||||||||||||
Europe | (182 | ) | — | — | — | (182 | ) | |||||||||||||
Asia/Pacific | (129 | ) | — | (49 | ) | (2 | ) | (180 | ) | |||||||||||
Total | (2,132 | ) | — | (49 | ) | (2 | ) | (2,183 | ) | |||||||||||
June 30, 2013 Balance | ||||||||||||||||||||
NA/HME | 3,574 | — | — | — | 3,574 | |||||||||||||||
IPG | 159 | — | — | — | 159 | |||||||||||||||
Europe | 132 | — | — | — | 132 | |||||||||||||||
Asia/Pacific | 1,055 | — | 982 | — | 2,037 | |||||||||||||||
$ | 4,920 | $ | — | $ | 982 | $ | — | $ | 5,902 | |||||||||||
Severance | Product Line | Contract | Other | Total | ||||||||||||||||
Discontinuance | Terminations | |||||||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | $ | 644 | $ | — | $ | 213 | $ | 353 | $ | 1,210 | ||||||||||
IPG | 36 | — | — | — | 36 | |||||||||||||||
Europe | 739 | — | — | (198 | ) | 541 | ||||||||||||||
Asia/Pacific | 15 | — | 79 | 3 | 97 | |||||||||||||||
Total | 1,434 | — | 292 | 158 | 1,884 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (1,624 | ) | — | (85 | ) | (305 | ) | (2,014 | ) | |||||||||||
IPG | (52 | ) | — | — | — | (52 | ) | |||||||||||||
Europe | (157 | ) | — | — | 198 | 41 | ||||||||||||||
Asia/Pacific | (1,040 | ) | — | (557 | ) | (3 | ) | (1,600 | ) | |||||||||||
Total | (2,873 | ) | — | (642 | ) | (110 | ) | (3,625 | ) | |||||||||||
September 30, 2013 Balance | ||||||||||||||||||||
NA/HME | 2,594 | — | 128 | 48 | 2,770 | |||||||||||||||
IPG | 143 | — | — | — | 143 | |||||||||||||||
Europe | 714 | — | — | — | 714 | |||||||||||||||
Asia/Pacific | 30 | — | 504 | — | 534 | |||||||||||||||
$ | 3,481 | $ | — | $ | 632 | $ | 48 | $ | 4,161 | |||||||||||
Income_Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2013 | |
Income Tax Disclosure [Abstract] | ' |
Income Taxes | ' |
Income Taxes | |
The company had an effective tax rate of 16.2% and 12.3% on losses before tax from continuing operations for the three and nine month periods ended September 30, 2013, respectively, compared to an expected benefit at the U.S. statutory rate of 35%. The company's effective tax rate for the three and nine months ended September 30, 2013 was greater than the U.S. federal statutory rate, principally due to losses overseas without tax benefit due to valuation allowances, foreign dividends which reduced the domestic intra-period allocation benefit in continuing operations, and the recording of a discreet adjustment of $3,143,000 related to a federal domestic valuation allowance adjustment. The rate was benefited by taxes outside the United States, excluding countries with valuation allowances that are in losses in 2013, recorded at a lower effective rate than the U.S. statutory rate. | |
The company had an effective tax rate of 81.3% and 97.5% on earnings before tax from continuing operations for the three and nine month period ended September 30, 2012, respectively, compared to an expected rate at the U.S. statutory rate of 35%. The company's effective tax rate for the three and nine months ended September 30, 2012 was greater than the U.S. federal statutory rate, principally due to a discrete foreign tax adjustment of $9,173,000 ($0.29 per share), recorded in the first nine months 2012, of which $3,178,000 was interest, related to prior year periods under audit, which is being contested by the company. This adjustment was partially offset by foreign earnings taxed at an effective rate lower than the U.S. statutory rate principally due to foreign taxes recognized at rates below the U.S. statutory rate. |
Net_Earnings_Loss_Per_Common_S
Net Earnings (Loss) Per Common Share | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Earnings Per Share [Abstract] | ' | |||||||||||||||
Net Earnings (Loss) Per Common Share | ' | |||||||||||||||
Net Earnings (Loss) Per Common Share | ||||||||||||||||
The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated. | ||||||||||||||||
(In thousands except per share data) | For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Basic | ||||||||||||||||
Average common shares outstanding | 31,902 | 31,877 | 31,902 | 31,838 | ||||||||||||
Net earnings (loss) from continuing operations | $ | (5,383 | ) | $ | 563 | $ | (35,580 | ) | $ | 374 | ||||||
Net earnings from discontinued operations | $ | 21,485 | $ | 2,301 | $ | 74,401 | $ | 8,746 | ||||||||
Net earnings | $ | 16,102 | $ | 2,864 | $ | 38,821 | $ | 9,120 | ||||||||
Net earnings (loss) per common share from continuing operations | $ | (0.17 | ) | $ | 0.02 | $ | (1.12 | ) | $ | 0.01 | ||||||
Net earnings per common share from discontinued operations | $ | 0.67 | $ | 0.07 | $ | 2.33 | $ | 0.27 | ||||||||
Net earnings per common share | $ | 0.5 | $ | 0.09 | $ | 1.21 | $ | 0.28 | ||||||||
Diluted | ||||||||||||||||
Average common shares outstanding | 31,902 | 31,877 | 31,902 | 31,838 | ||||||||||||
Shares related to convertible debt | — | — | — | — | ||||||||||||
Stock options and awards | 164 | 24 | 107 | 9 | ||||||||||||
Average common shares assuming dilution | 32,066 | 31,901 | 32,009 | 31,847 | ||||||||||||
Net earnings (loss) from continuing operations | $ | (5,383 | ) | $ | 563 | $ | (35,580 | ) | $ | 374 | ||||||
Net earnings from discontinued operations | $ | 21,485 | $ | 2,301 | $ | 74,401 | $ | 8,746 | ||||||||
Net earnings | $ | 16,102 | $ | 2,864 | $ | 38,821 | $ | 9,120 | ||||||||
Net earnings (loss) per common share from continuing operations * | $ | (0.17 | ) | $ | 0.02 | $ | (1.12 | ) | $ | 0.01 | ||||||
Net earnings per common share from discontinued operations | $ | 0.67 | $ | 0.07 | $ | 2.32 | $ | 0.27 | ||||||||
Net earnings per common share * | $ | 0.5 | $ | 0.09 | $ | 1.2 | $ | 0.28 | ||||||||
* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the period in which there was a net loss. | ||||||||||||||||
At September 30, 2013, 4,375,829 and 4,406,045 shares associated with stock options were excluded from the average common shares assuming dilution for the three and nine months ended September 30, 2013 as they were anti-dilutive. At September 30, 2013, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $15.88 and $15.04 for the three and nine months ended September 30, 2013. At September 30, 2012, 4,639,809 and 4,679,093 shares associated with stock options were excluded from the average common shares assuming dilution for the three and nine months ended September 30, 2012 as they were anti-dilutive. At September 30, 2012, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $14.74 and $15.55 for the three and nine months ended September 30, 2012. For both the three and nine months ended September 30, 2013 and September 30, 2012, there were no shares necessary to settle a conversion spread on the convertible notes to be included in the common shares assuming dilution as the average market price of the company stock for these periods did not exceed the conversion price. |
Concentration_Of_Credit_Risk
Concentration Of Credit Risk | 9 Months Ended |
Sep. 30, 2013 | |
Risks and Uncertainties [Abstract] | ' |
Concentration Of Credit Risk | ' |
Concentration of Credit Risk | |
The company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The company performs credit evaluations of its customers’ financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to the company’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation which was $7,074,000 at September 30, 2013 to DLL for events of default under the leasing contracts, which total $50,570,000 at September 30, 2013. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4. Credit losses are provided for in the financial statements. | |
Substantially all of the company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. The company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company’s customers. | |
In addition, the company is closely monitoring the roll-out of the second round of NCB, which became effective in 91 additional metropolitan statistical areas on July 1, 2013. At this early stage of the program, it is difficult to characterize the impact from NCB on the company's domestic home medical equipment business, as there continues to be uncertainty as the industry realigns and adjusts itself to the small number of bid contracts awarded. |
Derivatives
Derivatives | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | |||||||||||||||
Derivatives | ' | |||||||||||||||
Derivatives | ||||||||||||||||
ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. | ||||||||||||||||
Cash Flow Hedging Strategy | ||||||||||||||||
The company uses derivative instruments in an attempt to manage its exposure to foreign currency exchange risk and interest rate risk. Foreign currency forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the company’s fixed and floating-rate borrowings. | ||||||||||||||||
The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. | ||||||||||||||||
During the first nine months of 2013 and 2012, the company was a party to interest rate swap agreements that qualified as cash flow hedges and effectively converted floating-rate debt to fixed-rate debt, so the company could avoid the risk of changes in market interest rates. The gains or losses on interest rate swaps are reflected in interest expense on the consolidated statement of comprehensive income (loss). | ||||||||||||||||
To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months. | ||||||||||||||||
The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 60% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $51,251,000 and $131,923,000 matured during the three and nine months ended September 30, 2013 compared to forward contracts with a total notional amount in USD of $50,244,000 and $134,402,000 that matured during the three and nine months ended September 30, 2012. | ||||||||||||||||
Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Notional | Unrealized | Notional | Unrealized | |||||||||||||
Amount | Net Gain | Amount | Net Gain | |||||||||||||
(Loss) | (Loss) | |||||||||||||||
USD / AUD | $ | 579 | $ | 46 | $ | — | $ | — | ||||||||
USD / CAD | 10,330 | (85 | ) | 17,620 | (6 | ) | ||||||||||
USD / CNY | 3,320 | 55 | — | — | ||||||||||||
USD / CHF | 232 | 7 | — | — | ||||||||||||
USD / EUR | 14,433 | (368 | ) | 59,510 | (797 | ) | ||||||||||
USD / GBP | 692 | 22 | 2,519 | (3 | ) | |||||||||||
USD / NZD | 465 | 4 | — | — | ||||||||||||
USD / SEK | 3,499 | 115 | — | — | ||||||||||||
USD / MXP | 2,846 | 11 | 6,954 | 141 | ||||||||||||
EUR / CAD | 450 | 12 | — | — | ||||||||||||
EUR / CHF | 1,555 | 17 | — | — | ||||||||||||
EUR / GBP | 5,389 | (40 | ) | 2,077 | 46 | |||||||||||
EUR / SEK | 415 | 25 | — | — | ||||||||||||
EUR / NZD | 1,748 | 23 | 5,749 | 105 | ||||||||||||
GBP / CHF | 304 | (8 | ) | — | — | |||||||||||
GBP / SEK | 1,099 | 52 | 4,154 | 25 | ||||||||||||
DKK / SEK | 1,051 | (9 | ) | 6,397 | (47 | ) | ||||||||||
NOK / SEK | 926 | 66 | 3,428 | (4 | ) | |||||||||||
$ | 49,333 | $ | (55 | ) | $ | 108,408 | $ | (540 | ) | |||||||
Derivatives Not Qualifying or Designated for Hedge Accounting Treatment | ||||||||||||||||
The company also utilizes foreign currency forward exchange contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward exchange contract. No material net gain or loss was realized by the company in 2013 or 2012 related to these contracts and the associated short-term intercompany trading receivables and payables. | ||||||||||||||||
Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2013 and 2012, respectively, and outstanding were as follows (in thousands USD): | ||||||||||||||||
September 30, 2013 | September 30, 2012 | |||||||||||||||
Notional | Gain | Notional | Gain | |||||||||||||
Amount | (Loss) | Amount | (Loss) | |||||||||||||
CAD / USD | $ | 4,840 | $ | 4 | $ | 14,801 | $ | 434 | ||||||||
EUR / USD | 12,273 | 166 | 9,906 | 134 | ||||||||||||
CHF / USD | — | — | 785 | 13 | ||||||||||||
DKK / USD | 13,517 | 62 | — | — | ||||||||||||
GBP / USD | 6,361 | 67 | — | — | ||||||||||||
NOK / USD | 4,486 | 12 | — | — | ||||||||||||
NZD / USD | 2,161 | (8 | ) | 3,146 | 40 | |||||||||||
SEK / USD | 6,502 | 32 | — | — | ||||||||||||
EUR / AUD | — | — | 1,908 | 5 | ||||||||||||
EUR / CAD | — | — | 239 | (15 | ) | |||||||||||
EUR / DKK | — | — | (11,203 | ) | (27 | ) | ||||||||||
AUD / CAD | 878 | (4 | ) | 3,056 | (38 | ) | ||||||||||
AUD / EUR | 1,788 | 248 | — | — | ||||||||||||
AUD / GBP | 298 | 38 | — | — | ||||||||||||
AUD / NZD | — | — | 1,048 | 15 | ||||||||||||
EUR / NZD | — | — | 90 | (10 | ) | |||||||||||
EUR / NOK | — | — | 6 | — | ||||||||||||
$ | 53,104 | $ | 617 | $ | 23,782 | $ | 551 | |||||||||
The fair values of the company’s derivative instruments were as follows (in thousands): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Assets | Liabilities | Assets | Liabilities | |||||||||||||
Derivatives designated as hedging instruments under ASC 815 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 626 | $ | 681 | $ | 375 | $ | 915 | ||||||||
Interest rate swap contracts | — | 22 | — | 316 | ||||||||||||
Derivatives not designated as hedging instruments under ASC 815 | ||||||||||||||||
Foreign currency forward exchange contracts | 685 | 68 | 687 | 142 | ||||||||||||
Total derivatives | $ | 1,311 | $ | 771 | $ | 1,062 | $ | 1,373 | ||||||||
The fair values of the company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets. | ||||||||||||||||
The effect of derivative instruments on the Statement of Comprehensive Income (Loss) and Other Comprehensive Income (OCI) was as follows (in thousands): | ||||||||||||||||
Derivatives in ASC 815 cash flow hedge | Amount of Gain | Amount of Gain (Loss) | Amount of Gain (Loss) | |||||||||||||
relationships | (Loss) Recognized in OCI on Derivatives | Reclassified from | Recognized in Income on | |||||||||||||
(Effective Portion) | Accumulated OCI into | Derivatives (Ineffective Portion | ||||||||||||||
Income (Effective | and Amount Excluded from | |||||||||||||||
Portion) | Effectiveness Testing) | |||||||||||||||
Three months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | (207 | ) | $ | 83 | $ | 2 | |||||||||
Interest rate swap contracts | 33 | (13 | ) | — | ||||||||||||
$ | (174 | ) | $ | 70 | $ | 2 | ||||||||||
Nine months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 505 | $ | (20 | ) | $ | 37 | |||||||||
Interest rate swap contracts | 433 | (139 | ) | — | ||||||||||||
$ | 938 | $ | (159 | ) | $ | 37 | ||||||||||
Three months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | (2,522 | ) | $ | 1,241 | $ | (38 | ) | ||||||||
Interest rate swap contracts | (3 | ) | — | — | ||||||||||||
$ | (2,525 | ) | $ | 1,241 | $ | (38 | ) | |||||||||
Nine months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | (2,956 | ) | $ | 2,706 | $ | (9 | ) | ||||||||
Interest rate swap contracts | (99 | ) | — | — | ||||||||||||
$ | (3,055 | ) | $ | 2,706 | $ | (9 | ) | |||||||||
Derivatives not designated as hedging | Amount of Gain (Loss) | |||||||||||||||
instruments under ASC 815 | Recognized in Income on Derivatives | |||||||||||||||
Three months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 361 | ||||||||||||||
Nine months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 617 | ||||||||||||||
Three months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 569 | ||||||||||||||
Nine months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 551 | ||||||||||||||
The pre-tax gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward exchange contracts are recognized in net sales for hedges of inventory sales or cost of product sold for hedges of inventory purchases. For the three and nine months ended September 30, 2013, net sales were increased by $54,000 and $496,000 and cost of product sold was increased by $128,000 and increased by $453,000 for net realized loss of $74,000 and $43,000. For the three and nine months ended September 30, 2012, net sales were decreased by $146,000 and increased by $49,000, respectively, and cost of product sold was decreased by $1,487,000 and $2,804,000, respectively, for net realized gains of $1,341,000 and $2,853,000, respectively. | ||||||||||||||||
The company recognized expense of $23,000 and $328,000 for the three and nine months ended September 30, 2013, respectively, compared to expense of $147,000 and $419,000 for the three and nine months ended September 30, 2012, respectively, related to interest rate swap agreements, which is reflected in interest expense on the consolidated statement of comprehensive income (loss). | ||||||||||||||||
Gains of $361,000 and $617,000 versus gains of $569,000 and $551,000 were recognized in selling, general and administrative (SG&A) expenses for the three and nine months ended September 30, 2013 and September 30, 2012, respectively, on ineffective forward contracts and forward contracts not designated as hedging instruments that are entered into to offset gains/losses also recorded in SG&A expenses on intercompany trade payables. Any gains/losses on the non designated hedging instruments were substantially offset by gains/losses also recorded in SG&A expenses on intercompany trade payables. | ||||||||||||||||
The company has entered into foreign currency forward exchange contracts and interest rate swap contracts (the “agreements”) with various bank counterparties, each of which are subject to provisions which are similar to a master netting agreement. The agreements provide for a net settlement payment in a single currency upon a default by the company. Furthermore, the agreements provide the counterparty with a right of set off in the event of a default that would enable the counterparty to offset any net payment due by the counterparty to the company under the applicable agreement by any amount due by the company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the company's Credit Agreement to reduce any derivative settlement amounts owed to the company under the derivative contract by any amounts owed to the counterparty by the company under the Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the company under the agreement in the event of a default by the company under another agreement with the same counterparty. The company does not present any derivatives on a net basis in its financial statements and all derivative balances presented are subject to provisions that are similar to master netting agreements. |
Fair_Value_of_Financial_Instru
Fair Value of Financial Instruments | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||
Fair Value of Financial Instruments | ' | |||||||||||||||
Fair Values | ||||||||||||||||
Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable. | ||||||||||||||||
The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands). | ||||||||||||||||
Basis for Fair Value Measurements at Reporting Date | ||||||||||||||||
Quoted Prices in Active | Significant | Significant | ||||||||||||||
Markets for Identical | Other | Other | ||||||||||||||
Assets / (Liabilities) | Observable | Unobservable | ||||||||||||||
Inputs | Inputs | |||||||||||||||
Total | Level I | Level II | Level III | |||||||||||||
30-Sep-13 | ||||||||||||||||
Forward Exchange Contracts—net | $ | 562 | — | $ | 562 | — | ||||||||||
Interest Rate Swap Agreements—net | (22 | ) | — | (22 | ) | — | ||||||||||
December 31, 2012: | ||||||||||||||||
Forward Exchange Contracts—net | $ | 5 | — | $ | 5 | — | ||||||||||
Interest Rate Swap Agreements—net | (316 | ) | — | (316 | ) | — | ||||||||||
Forward Contracts: The company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany and third party sales or payments as well as intercompany loans. In an attempt to reduce this exposure, foreign currency forward exchange contracts are utilized and accounted for as hedging instruments. The contracts are used to hedge the following currencies: AUD, CAD, CHF, CNY, DKK, EUR, GBP, MXP, NOK, NZD, SEK and USD. The company does not use derivative financial instruments for speculative purposes. Fair values for the company’s foreign currency forward exchange contracts are based on quoted market prices for contracts with similar maturities. | ||||||||||||||||
The carrying values and fair values of the company’s financial instruments are as follows (in thousands): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Carrying | Fair Value | Carrying | Fair Value | |||||||||||||
Value | Value | |||||||||||||||
Cash and cash equivalents | $ | 32,625 | $ | 32,625 | $ | 38,791 | $ | 38,791 | ||||||||
Other investments | 1,190 | 1,190 | 1,171 | 1,171 | ||||||||||||
Installment receivables, net of reserves | 2,236 | 2,236 | 2,594 | 2,594 | ||||||||||||
Long-term debt (including current maturities of long-term debt) | (56,069 | ) | (56,115 | ) | (234,802 | ) | (234,072 | ) | ||||||||
Forward contracts in Other Current Assets | 1,311 | 1,311 | 1,062 | 1,062 | ||||||||||||
Forward contracts in Accrued Expenses | (749 | ) | (749 | ) | (1,057 | ) | (1,057 | ) | ||||||||
Interest rate swap agreements in Accrued Expenses | (22 | ) | (22 | ) | (316 | ) | (316 | ) | ||||||||
The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions: | ||||||||||||||||
Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value. | ||||||||||||||||
Other investments: The company has made other investments in limited partnerships and non-marketable equity securities, which are accounted for using the cost method, adjusted for any estimated declines in value. These investments were acquired in private placements and there are no quoted market prices or stated rates of return and the company does not have the ability to easily sell these investments. | ||||||||||||||||
Installment receivables: The carrying value reported in the balance sheet for installment receivables approximates its fair value. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value. | ||||||||||||||||
Long-term debt: Fair values for the company’s convertible debt and revolving credit facility are based upon the company’s estimate of the market for similar borrowing arrangements. | ||||||||||||||||
Forward contracts and interest rate swaps: Fair values for the company’s foreign currency forward exchange contracts are based on quoted market prices, while the fair values of the interest rate swaps are based on model-derived calculations using inputs that are observable in active markets. |
Business_Segments
Business Segments | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||
Business Segments | ' | |||||||||||||||
Business Segments | ||||||||||||||||
The company operates in four primary business segments: North America/Home Medical Equipment (North America/HME), Institutional Products Group (IPG), Europe and Asia/Pacific. The North America/HME segment sells each of three primary product lines, which includes: lifestyle, mobility and seating and respiratory therapy products. IPG sells or rents long-term care medical equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell product lines similar to North America/HME and IPG. Each business segment sells to the home health care, retail and extended care markets. | ||||||||||||||||
The company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance except for Asia/Pacific due to its significant intercompany sales volume relative to the segment. | ||||||||||||||||
The information by segment is as follows (in thousands): | ||||||||||||||||
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Revenues from external customers | ||||||||||||||||
North America/HME | $ | 151,052 | $ | 170,701 | $ | 462,261 | $ | 527,103 | ||||||||
Institutional Products Group | 28,083 | 33,557 | 87,135 | 95,726 | ||||||||||||
Europe | 150,265 | 141,705 | 429,650 | 401,721 | ||||||||||||
Asia/Pacific | 11,776 | 15,555 | 38,327 | 53,217 | ||||||||||||
Consolidated | $ | 341,176 | $ | 361,518 | $ | 1,017,373 | $ | 1,077,767 | ||||||||
Intersegment revenues | ||||||||||||||||
North America/HME | $ | 20,501 | $ | 24,813 | $ | 59,735 | $ | 81,985 | ||||||||
Institutional Products Group | 1,254 | 1,941 | 4,243 | 5,471 | ||||||||||||
Europe | 1,890 | 3,239 | 6,156 | 8,448 | ||||||||||||
Asia/Pacific | 6,411 | 7,737 | 19,417 | 27,177 | ||||||||||||
Consolidated | $ | 30,056 | $ | 37,730 | $ | 89,551 | $ | 123,081 | ||||||||
Restructuring charges before income taxes | ||||||||||||||||
North America/HME | $ | 1,210 | $ | 352 | $ | 4,837 | $ | 2,214 | ||||||||
Institutional Products Group | 36 | — | 237 | 35 | ||||||||||||
Europe | 542 | 481 | 722 | 772 | ||||||||||||
Asia/Pacific | 96 | 342 | 1,202 | 721 | ||||||||||||
Consolidated | $ | 1,884 | $ | 1,175 | $ | 6,998 | $ | 3,742 | ||||||||
Earnings (loss) before income taxes | ||||||||||||||||
North America/HME | $ | (10,191 | ) | $ | (28 | ) | $ | (33,593 | ) | $ | 8,086 | |||||
Institutional Products Group | 1,009 | 579 | 1,955 | 4,820 | ||||||||||||
Europe | 13,136 | 10,218 | 27,344 | 23,504 | ||||||||||||
Asia/Pacific | (2,233 | ) | (2,301 | ) | (9,871 | ) | (4,139 | ) | ||||||||
All Other (1) | (6,354 | ) | (5,460 | ) | (17,515 | ) | (17,411 | ) | ||||||||
Consolidated | $ | (4,633 | ) | $ | 3,008 | $ | (31,680 | ) | $ | 14,860 | ||||||
________________________ | ||||||||||||||||
-1 | Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. In addition, the “All Other” earnings (loss) before income taxes includes loss on debt extinguishment including debt finance charges, interest and fees. |
Contingencies
Contingencies | 9 Months Ended |
Sep. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Contingencies | ' |
Contingencies | |
General | |
In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits in the United States have been referred to the company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. | |
As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting and other practices of health care suppliers and manufacturers are all subject to government scrutiny. The company's facilities are subject to periodic inspection by the FDA. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, including disqualification from Medicare and other reimbursement programs, which could have a material adverse effect on the company's business. | |
FDA Matters | |
The FDA regulates virtually all aspects of the development, testing, manufacturing, labeling, promotion, distribution and marketing of a medical device. The company's failure to comply with the regulatory requirements of the FDA and other applicable U.S. medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions. These sanctions include warning letters, civil penalties, criminal penalties, injunctions, consent decrees, product seizure or detention, product recalls and total or partial suspension of production. | |
As previously disclosed, the company entered into a consent decree of injunction with the FDA related to the company's Corporate facility and its Taylor Street wheelchair manufacturing facility in Elyria, Ohio in December 2012. The consent decree was approved and made effective by the U.S. District Court for the Northern District of Ohio on December 21, 2012. The consent decree limits the company's manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility. The decree also temporarily limited design activities related to wheelchairs and power beds that take place at the impacted Elyria, Ohio facilities. The company is entitled to continue to produce from the Taylor Street manufacturing facility certain medically necessary products, as well as ongoing replacement, service and repair of products already in use, under terms delineated in the consent decree. Under the terms of the consent decree, in order to resume full operations at the impacted facilities, the company must successfully complete a third-party expert certification audit at the impacted Elyria facilities, which is comprised of three distinct reports that must be submitted to, and accepted by, the FDA. After the expert's final certification report is submitted to the FDA, along with the company’s own report as to its compliance as well as responses to any observations in the certification report, the FDA will perform an inspection of the company's Corporate and Taylor Street facilities to determine whether they are in compliance with the FDA's Quality System Regulation. The FDA has the authority to reinspect at any time. Once satisfied with the company's compliance, the FDA will provide written notification that the company is permitted to resume full operations at the impacted facilities. | |
At the time of filing this Quarterly Report on Form 10-Q, the company has completed the first two of its third-party expert certification audits, and the FDA has found the results of both to be acceptable. In these reports, the third-party expert certified that the company's equipment and process validation procedures and its design control systems were compliant with the FDA's Quality System Regulation. As a result of the FDA's approval of the first certification audit report on May 13, 2013, the Taylor Street facility was able to resume supplying parts and components for the further manufacturing of medical devices at other company facilities. The company's receipt of the FDA's approval on the second certification audit report on July 15, 2013 resulted in the company being able to resume design activities related to power wheelchairs and power beds. The third, most comprehensive third-party certification audit is a comprehensive review of the company's compliance with the FDA's Quality System Regulation at the impacted Elyria facilities. | |
The company is targeting to have the third, final and most comprehensive third-party certification report completed and filed with the FDA by mid-November 2013. There remains some scheduling issues and final work to complete in order to reach the targeted timing. Under the terms of the consent decree, the company must submit its own report to the FDA on the actions taken to correct any violations that may have been brought to the company’s attention by the expert and the actions the company has taken to ensure that the affected facilities are operated, and will continue to be operated, in conformity with the FDA’s Quality System Regulation. Within thirty (30) days after FDA’s receipt of the expert’s report and the company’s report, the FDA will commence its own inspection. It is not possible for the company to estimate the timing or potential response of the FDA's inspection and subsequent written notifications. Following successful completion of the FDA inspection and the company's receipt of written notification from the FDA that the Corporate and Taylor Street facilities appear to be in compliance, the company may resume full operations at those facilities. | |
As described above, because the limitations on production will only be temporary in nature, and partial production will be allowed, the company does not anticipate any major repair, replacement or scrapping of its fixed assets at the Taylor Street manufacturing facility. Based on the company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the time frame for completion of the third-party expert certification audits and FDA inspection and with respect to future cash flows from production at the Taylor Street manufacturing facility, the company concluded that there is no impairment in the value of the fixed assets related to the Taylor Street manufacturing facility at September 30, 2013. | |
The majority of the production from the Taylor Street facility is "made to order" custom wheelchairs for customers and, as a result, there was not a significant amount of finished goods inventory on hand at September 30, 2013. At the time of filing this Quarterly Report on Form 10-Q, the company believes that it would be able to obtain substantially all of the documentation required under the consent decree in order to complete the manufacture and shipment from the Taylor Street facility of the orders in the company's order fulfillment system and thus, the company concluded that there was not an impairment of the work in process and finished goods at the Taylor Street facility at September 30, 2013. Further, based on its analysis of the raw material inventory at the Taylor Street facility and the company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the time frame for completion of the third-party expert certification audits and FDA inspection, the company concluded that the value of the inventory was not excessive or impaired at September 30, 2013. However, if the company's expectations regarding the impacts of the limitations in the consent decree or the time frame for completion of the third-party expert certification audits and FDA inspection were to change, the company may, in future periods, conclude that an impairment exists with respect to its fixed assets or inventory at the Taylor Street facility. | |
The North America/HME segment is the segment primarily impacted by the limitations in the FDA consent decree. However, the Asia/Pacific segment also is negatively affected as a result of the consent decree due to the lower sales volume of microprocessor controllers. During 2012, before the effective date of the consent decree, the company started to experience decreases in net sales in this segment. Those decreases were primarily related to delays in new product introductions, uncertainty on the part of the company's customers as they coped with prepayment reviews and post-payment audits by the Centers for Medicare and Medicaid Services ("CMS") and contemplated their participation in the next round of National Competitive Bidding ("NCB"), and, the company believes, uncertainty regarding the resolution of the consent decree which limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. The negative effect of the consent decree on customer orders and net sales has been considerable, and the company expects to experience continued low levels in net sales as a result of the limitations imposed by the consent decree. The company expects to continue to experience lower levels of net sales in the segment at least until it has successfully completed the previously-described third-party expert certification audit and FDA inspection and has received written notification from the FDA that the company may resume full operations at the Corporate and Taylor Street facilities. Even after the company is permitted to resume full operations at the affected facilities, it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, the limitations in the consent decree had, and likely will continue to have, a material adverse effect on the company's business, financial condition and results of operations. | |
In the second quarter of 2013, the company recorded a warranty reserve of $3,800,000 related to a power wheelchair joystick recall. The estimate was calculated based on discussions with the FDA and the company's resultant expectation that an end user notification was not adequate and that a recall would be initiated involving the replacement of the potentially affected joysticks, which are sold globally. The power wheelchair joystick performance issue relates to an anomaly discovered in a fraction of a percentage of the components in the field. The company's warranty reserve for this power wheelchair component recall is based upon estimates derived from the company's actual experience with prior recalls. No changes were made in the warranty reserve recorded related to this issue in the third quarter of 2013. However, the reserve is subject to adjustment as new developments or experiences change the company's estimate of the total cost of this matter. | |
For additional information regarding the consent decree, please see the following sections of the company's Annual Report on Form 10-K for the year ending December 31, 2012: Item 1. Business - Government Regulation and Item 1A. Risk Factors and the following sections of this Quarterly Report on Form 10-Q: Item 1. Legal Proceedings; and Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Outlook and - Liquidity and Capital Resources. | |
In addition, in December 2010, the company received a warning letter from the FDA related to quality system processes and procedures at the company's Sanford, Florida facility. The company has taken actions which it believes address all of the FDA's concerns in the warning letter. However, the results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA warning letter could materially and adversely affect the company's business, financial condition, and results of operations. | |
Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations. |
Supplemental_Guarantor_Informa
Supplemental Guarantor Information | 9 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||
Supplemental Guarantor Information [Abstract] | ' | |||||||||||||||||||
Supplemental Guarantor Information | ' | |||||||||||||||||||
Supplemental Guarantor Information | ||||||||||||||||||||
Effective February 12, 2007, substantially all of the domestic subsidiaries (the “Guarantor Subsidiaries”) of the company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Convertible Senior Subordinated Debentures due 2027 (the “Debentures”) with an original aggregate principal amount of $135,000,000. The majority of the company’s subsidiaries are not guaranteeing the indebtedness of the Debentures (the “Non-Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium, and interest related to the Debentures and each of the Guarantor Subsidiaries are directly or indirectly 100%-owned subsidiaries of the company. Specifically, the Debentures are guaranteed on an unsecured senior subordinated basis by all of our existing domestic subsidiaries (other than our captive insurance subsidiary and any receivables subsidiaries) and certain future direct and indirect 100% owned domestic subsidiaries. All of the guarantors are released and relieved of any liability under such guarantees upon the satisfaction and discharge of the indenture governing the debentures and the payment in full of the debentures. Additionally, in the event any subsidiary guarantor no longer guarantees any of our existing or future senior debt incurred in a public or private U.S. capital markets transaction, such guarantor shall be released and relieved of any liability which it has under the indenture governing the debentures. | ||||||||||||||||||||
Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented. | ||||||||||||||||||||
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Three month period ended September 30, 2013 | (in thousands) | |||||||||||||||||||
Net sales | $ | 60,641 | $ | 119,548 | $ | 184,299 | $ | (23,312 | ) | $ | 341,176 | |||||||||
Cost of products sold | 52,454 | 86,978 | 128,232 | (23,312 | ) | 244,352 | ||||||||||||||
Gross Profit | 8,187 | 32,570 | 56,067 | — | 96,824 | |||||||||||||||
Selling, general and administrative expenses | 29,046 | 25,363 | 44,310 | — | 98,719 | |||||||||||||||
Charge related to restructuring activities | 1,597 | 36 | 251 | — | 1,884 | |||||||||||||||
Asset write-downs to intangibles and investments | — | 167 | — | — | 167 | |||||||||||||||
Income (loss) from equity investee | 32,513 | 8,935 | 22 | (41,470 | ) | — | ||||||||||||||
Interest expense (income)—net | (603 | ) | 1,213 | 77 | — | 687 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 10,660 | 14,726 | 11,451 | (41,470 | ) | (4,633 | ) | |||||||||||||
Income taxes (benefit) | (5,442 | ) | — | 6,192 | — | 750 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 16,102 | 14,726 | 5,259 | (41,470 | ) | (5,383 | ) | |||||||||||||
Net Earnings from Discontinued Operations | — | 21,485 | — | — | 21,485 | |||||||||||||||
Net Earnings (loss) | $ | 16,102 | $ | 36,211 | $ | 5,259 | $ | (41,470 | ) | $ | 16,102 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | 9,874 | 220 | 10,135 | (10,355 | ) | 9,874 | ||||||||||||||
Comprehensive Income (Loss) | $ | 25,976 | $ | 36,431 | $ | 15,394 | $ | (51,825 | ) | $ | 25,976 | |||||||||
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Three month period ended September 30, 2012 | (in thousands) | |||||||||||||||||||
Net sales | $ | 90,406 | $ | 116,339 | $ | 183,801 | $ | (29,028 | ) | $ | 361,518 | |||||||||
Cost of products sold | 70,600 | 83,685 | 126,852 | (29,031 | ) | 252,106 | ||||||||||||||
Gross Profit | 19,806 | 32,654 | 56,949 | 3 | 109,412 | |||||||||||||||
Selling, general and administrative expenses | 33,712 | 20,356 | 45,492 | 3,721 | 103,281 | |||||||||||||||
Charge related to restructuring activities | 334 | 18 | 823 | — | 1,175 | |||||||||||||||
Loss on debt extinguishment including debt finance charges and associated fees | — | — | — | — | — | |||||||||||||||
Income (loss) from equity investee | 17,302 | (4,264 | ) | 228 | (13,266 | ) | — | |||||||||||||
Interest expense (income)—net | (1,024 | ) | 2,201 | 771 | — | 1,948 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 4,086 | 5,815 | 10,091 | (16,984 | ) | 3,008 | ||||||||||||||
Income taxes (benefit) | 1,222 | (3,028 | ) | 4,251 | — | 2,445 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 2,864 | 8,843 | 5,840 | (16,984 | ) | 563 | ||||||||||||||
Net Earnings from Discontinued Operations | — | 2,301 | — | — | 2,301 | |||||||||||||||
Net Earnings (loss) | $ | 2,864 | $ | 11,144 | $ | 5,840 | $ | (16,984 | ) | $ | 2,864 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | 14,518 | 3,164 | 11,412 | (14,576 | ) | 14,518 | ||||||||||||||
Comprehensive Income (Loss) | $ | 17,382 | $ | 14,308 | $ | 17,252 | $ | (31,560 | ) | $ | 17,382 | |||||||||
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2013 | ||||||||||||||||||||
Net sales | $ | 186,453 | $ | 364,005 | $ | 535,805 | $ | (68,890 | ) | $ | 1,017,373 | |||||||||
Cost of products sold | 159,884 | 264,501 | 378,287 | (69,264 | ) | 733,408 | ||||||||||||||
Gross Profit | 26,569 | 99,504 | 157,518 | 374 | 283,965 | |||||||||||||||
Selling, general and administrative expenses | 99,338 | 72,370 | 131,640 | 2,694 | 306,042 | |||||||||||||||
Charge related to restructuring activities | 5,078 | 49 | 1,871 | — | 6,998 | |||||||||||||||
Asset write-downs to intangibles and investments | — | 167 | — | — | 167 | |||||||||||||||
Income (loss) from equity investee | 105,501 | 21,472 | (93 | ) | (126,880 | ) | — | |||||||||||||
Interest expense (income)—net | (1,418 | ) | 3,141 | 715 | — | 2,438 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 29,072 | 45,249 | 23,199 | (129,200 | ) | (31,680 | ) | |||||||||||||
Income taxes (benefit) | (9,749 | ) | — | 13,649 | — | 3,900 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 38,821 | 45,249 | 9,550 | (129,200 | ) | (35,580 | ) | |||||||||||||
Net Earnings from Discontinued Operations | — | 74,401 | — | — | 74,401 | |||||||||||||||
Net Earnings (loss) | $ | 38,821 | $ | 119,650 | $ | 9,550 | $ | (129,200 | ) | $ | 38,821 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | 1,845 | (415 | ) | 2,228 | (1,813 | ) | 1,845 | |||||||||||||
Comprehensive Income (Loss) | $ | 40,666 | $ | 119,235 | $ | 11,778 | $ | (131,013 | ) | $ | 40,666 | |||||||||
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2012 | (in thousands) | |||||||||||||||||||
Net sales | $ | 275,742 | $ | 355,378 | $ | 540,535 | $ | (93,888 | ) | $ | 1,077,767 | |||||||||
Cost of products sold | 211,115 | 256,854 | 371,855 | (93,455 | ) | 746,369 | ||||||||||||||
Gross Profit | 64,627 | 98,524 | 168,680 | (433 | ) | 331,398 | ||||||||||||||
Selling, general and administrative expenses | 99,736 | 64,452 | 138,207 | 4,360 | 306,755 | |||||||||||||||
Charge related to restructuring activities | 2,085 | 39 | 1,618 | — | 3,742 | |||||||||||||||
Loss on debt extinguishment including debt finance charges and associated fees | 312 | — | — | — | 312 | |||||||||||||||
Income (loss) from equity investee | 45,175 | 1,954 | 391 | (47,520 | ) | — | ||||||||||||||
Interest expense (income)—net | (3,041 | ) | 6,396 | 2,374 | — | 5,729 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 10,710 | 29,591 | 26,872 | (52,313 | ) | 14,860 | ||||||||||||||
Income taxes (benefit) | 1,590 | (5,164 | ) | 18,060 | — | 14,486 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 9,120 | 34,755 | 8,812 | (52,313 | ) | 374 | ||||||||||||||
Net Earnings from Discontinued Operations | — | 8,746 | — | — | 8,746 | |||||||||||||||
Net Earnings (loss) | $ | 9,120 | $ | 43,501 | $ | 8,812 | $ | (52,313 | ) | $ | 9,120 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | (24,673 | ) | 3,179 | (27,878 | ) | 24,699 | (24,673 | ) | ||||||||||||
Comprehensive Income (Loss) | $ | (15,553 | ) | $ | 46,680 | $ | (19,066 | ) | $ | (27,614 | ) | $ | (15,553 | ) | ||||||
CONSOLIDATING CONDENSED BALANCE SHEETS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
September 30, 2013 | (in thousands) | |||||||||||||||||||
Assets | ||||||||||||||||||||
Current Assets | ||||||||||||||||||||
Cash and cash equivalents | $ | 3,148 | $ | — | $ | 29,477 | $ | — | $ | 32,625 | ||||||||||
Trade receivables, net | 69,633 | 29,453 | 92,378 | — | 191,464 | |||||||||||||||
Installment receivables, net | — | 569 | 991 | — | 1,560 | |||||||||||||||
Inventories, net | 37,797 | 27,784 | 104,970 | (3,183 | ) | 167,368 | ||||||||||||||
Intercompany advances, net | 5,055 | 664 | 43,145 | (48,864 | ) | — | ||||||||||||||
Other current assets | 6,371 | 570 | 34,129 | (7,240 | ) | 33,830 | ||||||||||||||
Total Current Assets | 122,004 | 59,040 | 305,090 | (59,287 | ) | 426,847 | ||||||||||||||
Investment in subsidiaries | 1,433,252 | 440,197 | — | (1,873,449 | ) | — | ||||||||||||||
Intercompany advances, net | 937,116 | 1,592,785 | 178,180 | (2,708,081 | ) | — | ||||||||||||||
Other Assets | 38,961 | 463 | 903 | — | 40,327 | |||||||||||||||
Other Intangibles | 553 | 19,139 | 45,413 | — | 65,105 | |||||||||||||||
Property and Equipment, net | 36,783 | 18,621 | 52,987 | — | 108,391 | |||||||||||||||
Goodwill | — | 16,660 | 434,067 | — | 450,727 | |||||||||||||||
Total Assets | $ | 2,568,669 | $ | 2,146,905 | $ | 1,016,640 | $ | (4,640,817 | ) | $ | 1,091,397 | |||||||||
Liabilities and Shareholders’ Equity | ||||||||||||||||||||
Current Liabilities | ||||||||||||||||||||
Accounts payable | $ | 50,462 | $ | 8,237 | $ | 58,985 | $ | — | $ | 117,684 | ||||||||||
Accrued expenses | 30,864 | 17,737 | 89,118 | (7,240 | ) | 130,479 | ||||||||||||||
Accrued income taxes | 5,540 | — | 1,661 | — | 7,201 | |||||||||||||||
Intercompany advances, net | 41,889 | 1,481 | 5,494 | (48,864 | ) | — | ||||||||||||||
Short-term debt and current maturities of long-term obligations | 556 | 7 | 731 | — | 1,294 | |||||||||||||||
Total Current Liabilities | 129,311 | 27,462 | 155,989 | (56,104 | ) | 256,658 | ||||||||||||||
Long-Term Debt | 22,476 | 82 | 32,217 | — | 54,775 | |||||||||||||||
Other Long-Term Obligations | 54,176 | — | 60,597 | — | 114,773 | |||||||||||||||
Intercompany advances, net | 1,707,515 | 936,722 | 63,844 | (2,708,081 | ) | — | ||||||||||||||
Total Shareholders’ Equity | 655,191 | 1,182,639 | 703,993 | (1,876,632 | ) | 665,191 | ||||||||||||||
Total Liabilities and Shareholders’ Equity | $ | 2,568,669 | $ | 2,146,905 | $ | 1,016,640 | $ | (4,640,817 | ) | $ | 1,091,397 | |||||||||
CONSOLIDATING CONDENSED BALANCE SHEETS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
December 31, 2012 | (in thousands) | |||||||||||||||||||
Assets | ||||||||||||||||||||
Current Assets | ||||||||||||||||||||
Cash and cash equivalents | $ | 5,774 | $ | 1,018 | $ | 31,999 | $ | — | $ | 38,791 | ||||||||||
Trade receivables, net | 71,622 | 37,223 | 89,946 | — | 198,791 | |||||||||||||||
Installment receivables, net | — | 829 | 1,359 | — | 2,188 | |||||||||||||||
Inventories, net | 40,278 | 31,455 | 114,169 | (2,656 | ) | 183,246 | ||||||||||||||
Intercompany advances, net | 4,077 | 763 | 64,570 | (69,410 | ) | — | ||||||||||||||
Other current assets | 12,727 | 473 | 34,606 | (6,030 | ) | 41,776 | ||||||||||||||
Assets held for sale - current | — | 103,157 | — | — | 103,157 | |||||||||||||||
Total Current Assets | 134,478 | 174,918 | 336,649 | (78,096 | ) | 567,949 | ||||||||||||||
Investment in subsidiaries | 1,536,898 | 523,176 | 6,888 | (2,066,962 | ) | — | ||||||||||||||
Intercompany advances, net | 863,973 | 1,468,405 | 173,903 | (2,506,281 | ) | — | ||||||||||||||
Other Assets | 41,006 | 314 | 942 | — | 42,262 | |||||||||||||||
Other Intangibles | 663 | 22,211 | 48,778 | — | 71,652 | |||||||||||||||
Property and Equipment, net | 39,911 | 19,957 | 58,363 | — | 118,231 | |||||||||||||||
Goodwill | — | 32,937 | 429,263 | — | 462,200 | |||||||||||||||
Total Assets | $ | 2,616,929 | $ | 2,241,918 | $ | 1,054,786 | $ | (4,651,339 | ) | $ | 1,262,294 | |||||||||
Liabilities and Shareholders’ Equity | ||||||||||||||||||||
Current Liabilities | ||||||||||||||||||||
Accounts payable | $ | 63,812 | $ | 9,465 | $ | 59,771 | $ | — | $ | 133,048 | ||||||||||
Accrued expenses | 36,716 | 18,155 | 86,348 | (6,030 | ) | 135,189 | ||||||||||||||
Accrued income taxes | 1,545 | — | 1,168 | — | 2,713 | |||||||||||||||
Intercompany advances, net | 61,368 | 2,369 | 5,673 | (69,410 | ) | — | ||||||||||||||
Short-term debt and current maturities of long-term obligations | 4,552 | 7 | 868 | — | 5,427 | |||||||||||||||
Liabilities held for sale - current | — | 23,358 | — | — | 23,358 | |||||||||||||||
Total Current Liabilities | 167,993 | 53,354 | 153,828 | (75,440 | ) | 299,735 | ||||||||||||||
Long-Term Debt | 223,014 | 143 | 6,218 | — | 229,375 | |||||||||||||||
Other Long-Term Obligations | 52,957 | — | 59,238 | — | 112,195 | |||||||||||||||
Intercompany advances, net | 1,551,976 | 863,585 | 90,720 | (2,506,281 | ) | — | ||||||||||||||
Total Shareholders’ Equity | 620,989 | 1,324,836 | 744,782 | (2,069,618 | ) | 620,989 | ||||||||||||||
Total Liabilities and Shareholders’ Equity | $ | 2,616,929 | $ | 2,241,918 | $ | 1,054,786 | $ | (4,651,339 | ) | $ | 1,262,294 | |||||||||
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2013 | (in thousands) | |||||||||||||||||||
Net Cash Provided (Used) by Operating Activities | $ | 35,179 | $ | (81,077 | ) | $ | (20,736 | ) | $ | 65,389 | $ | (1,245 | ) | |||||||
Investing Activities | ||||||||||||||||||||
Purchases of property and equipment | (3,234 | ) | (3,611 | ) | (4,241 | ) | — | (11,086 | ) | |||||||||||
Proceeds from sale of property and equipment | — | 11 | 845 | — | 856 | |||||||||||||||
Proceeds from sale of business | — | 187,552 | — | — | 187,552 | |||||||||||||||
Other long-term assets | 783 | — | 166 | — | 949 | |||||||||||||||
Other | 171,353 | (103,417 | ) | — | (68,083 | ) | (147 | ) | ||||||||||||
Net Cash Provided (Used) for Investing Activities | 168,902 | 80,535 | (3,230 | ) | (68,083 | ) | 178,124 | |||||||||||||
Financing Activities | ||||||||||||||||||||
Proceeds from revolving lines of credit and long-term borrowings | 226,189 | — | 23,935 | — | 250,124 | |||||||||||||||
Payments on revolving lines of credit and long-term borrowings | (431,709 | ) | (476 | ) | — | — | (432,185 | ) | ||||||||||||
Payment of dividends | (1,187 | ) | — | (2,694 | ) | 2,694 | (1,187 | ) | ||||||||||||
Net Cash Provided (Used) by Financing Activities | (206,707 | ) | (476 | ) | 21,241 | 2,694 | (183,248 | ) | ||||||||||||
Effect of exchange rate changes on cash | — | — | 203 | — | 203 | |||||||||||||||
Decrease in cash and cash equivalents | (2,626 | ) | (1,018 | ) | (2,522 | ) | — | (6,166 | ) | |||||||||||
Cash and cash equivalents at beginning of year | 5,774 | 1,018 | 31,999 | — | 38,791 | |||||||||||||||
Cash and cash equivalents at end of period | $ | 3,148 | $ | — | $ | 29,477 | $ | — | $ | 32,625 | ||||||||||
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2012 | (in thousands) | |||||||||||||||||||
Net Cash Provided (Used) by Operating Activities | $ | 18,260 | $ | 5,405 | $ | 7,527 | $ | (4,370 | ) | $ | 26,822 | |||||||||
Investing Activities | ||||||||||||||||||||
Purchases of property and equipment | (1,353 | ) | (7,854 | ) | (5,568 | ) | — | (14,775 | ) | |||||||||||
Proceeds from sale of property and equipment | 18 | 14 | 65 | — | 97 | |||||||||||||||
Other long-term assets | (214 | ) | — | 623 | — | 409 | ||||||||||||||
Other | (158 | ) | (117 | ) | 56 | — | (219 | ) | ||||||||||||
Net Cash Used for Investing Activities | (1,707 | ) | (7,957 | ) | (4,824 | ) | — | (14,488 | ) | |||||||||||
Financing Activities | ||||||||||||||||||||
Proceeds from revolving lines of credit and long-term borrowings | 252,590 | 3,113 | — | — | 255,703 | |||||||||||||||
Payments on revolving lines of credit and long-term borrowings | (266,182 | ) | — | (539 | ) | — | (266,721 | ) | ||||||||||||
Payment of financing costs | (1 | ) | — | — | — | (1 | ) | |||||||||||||
Payment of dividends | (1,183 | ) | — | (4,370 | ) | 4,370 | (1,183 | ) | ||||||||||||
Net Cash Provided (Used) by Financing Activities | (14,776 | ) | 3,113 | (4,909 | ) | 4,370 | (12,202 | ) | ||||||||||||
Effect of exchange rate changes on cash | — | — | 226 | — | 226 | |||||||||||||||
Increase (Decrease) in cash and cash equivalents | 1,777 | 561 | (1,980 | ) | — | 358 | ||||||||||||||
Cash and cash equivalents at beginning of year | 3,642 | 2,104 | 29,178 | — | 34,924 | |||||||||||||||
Cash and cash equivalents at end of period | $ | 5,419 | $ | 2,665 | $ | 27,198 | $ | — | $ | 35,282 | ||||||||||
Accounting_Policies_Policies
Accounting Policies (Policies) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Accounting Policies [Abstract] | ' | |||||||||||||||
Principles of Consolidation | ' | |||||||||||||||
Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of September 30, 2013, the results of its operations for the three and nine months ended September 30, 2013 and changes in its cash flow for the nine months ended September 30, 2013 and 2012, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using an August 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year. | ||||||||||||||||
Use of Estimates | ' | |||||||||||||||
Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. | ||||||||||||||||
Stock-Based Compensation | ' | |||||||||||||||
Stock-Based Compensation Plans: The company accounts for share-based compensation under the provisions of Compensation-Stock Compensation, ASC 718. The company has not made any modifications to the terms of any previously granted options and no significant changes have been made regarding the valuation methodologies used to determine the fair value of options granted. The company continues to use a Black-Scholes valuation model. | ||||||||||||||||
Stock options awarded have been granted at exercise prices equal to the market value of the underlying stock on the date of grant. Restricted stock awards granted without cost to the recipients are expensed on a straight-line basis over the vesting periods. The amounts of stock-based compensation expense recognized were as follows (in thousands): | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Stock-based compensation expense recognized as part of selling, general and administrative expense | $ | 2,147 | $ | 2,208 | $ | 4,721 | $ | 5,198 | ||||||||
The amounts above reflect compensation expense related to restricted stock awards and nonqualified stock options awarded under the 2003 Performance Plan and the 2013 Equity Compensation Plan. Stock-based compensation is not allocated to the business segments, but is reported as part of All Other as shown in the company's Business Segment Note to the Consolidated Financial Statements. |
Accounting_Policies_Tables
Accounting Policies (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Accounting Policies [Abstract] | ' | |||||||||||||||
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | ' | |||||||||||||||
The amounts of stock-based compensation expense recognized were as follows (in thousands): | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Stock-based compensation expense recognized as part of selling, general and administrative expense | $ | 2,147 | $ | 2,208 | $ | 4,721 | $ | 5,198 | ||||||||
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | 9 Months Ended | ||||||||||||
Dec. 31, 2012 | Sep. 30, 2013 | |||||||||||||
ISG [Member] | Champion [Member] | |||||||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ||||||||||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures | ' | ' | ||||||||||||
The assets and liabilities of ISG that were sold are shown as held for sale in the company's Consolidated Balance Sheets and are comprised of the following (in thousands): | ||||||||||||||
August 6, | December 31, | |||||||||||||
December 31, | 2013 | 2012 | ||||||||||||
2012 | ||||||||||||||
Trade receivables, net | $ | 3,030 | $ | 2,375 | ||||||||||
Trade receivables, net | $ | 44,196 | ||||||||||||
Inventories, net | 1,689 | 1,617 | ||||||||||||
Inventories, net | 25,165 | |||||||||||||
Other current assets | 92 | 21 | ||||||||||||
Other current assets | 9,355 | |||||||||||||
Property and Equipment, net | 309 | 237 | ||||||||||||
Property and Equipment, net | 1,368 | |||||||||||||
Goodwill | 16,277 | 16,277 | ||||||||||||
Goodwill | 23,073 | |||||||||||||
Assets sold | $ | 21,397 | $ | 20,527 | ||||||||||
Assets held for sale - current | $ | 103,157 | ||||||||||||
Accounts payable | $ | 936 | $ | 475 | ||||||||||
Accounts payable | $ | 17,692 | ||||||||||||
Accrued expenses | 352 | 318 | ||||||||||||
Accrued expenses | 4,602 | |||||||||||||
Accrued income taxes | — | 200 | ||||||||||||
Accrued income taxes | 1,064 | |||||||||||||
Liabilities sold | $ | 1,288 | $ | 993 | ||||||||||
Liabilities held for sale - current | $ | 23,358 | ||||||||||||
Receivables_Tables
Receivables (Tables) | 9 Months Ended | |||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||
Receivables [Abstract] | ' | |||||||||||||||||||||||
Installment Receivables [Table Text Block] | ' | |||||||||||||||||||||||
Installment receivables consist of the following (in thousands): | ||||||||||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||||||||||
Current | Long- | Total | Current | Long- | Total | |||||||||||||||||||
Term | Term | |||||||||||||||||||||||
Installment receivables | $ | 3,554 | $ | 2,394 | $ | 5,948 | $ | 4,982 | $ | 1,506 | $ | 6,488 | ||||||||||||
Less: Unearned interest | (70 | ) | — | (70 | ) | (71 | ) | — | (71 | ) | ||||||||||||||
3,484 | 2,394 | 5,878 | 4,911 | 1,506 | 6,417 | |||||||||||||||||||
Allowance for doubtful accounts | (1,924 | ) | (1,718 | ) | (3,642 | ) | (2,723 | ) | (1,100 | ) | (3,823 | ) | ||||||||||||
$ | 1,560 | $ | 676 | $ | 2,236 | $ | 2,188 | $ | 406 | $ | 2,594 | |||||||||||||
Schedule of Installment Receivables Allowance for Doubtful Accounts [Table Text Block] | ' | |||||||||||||||||||||||
The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): | ||||||||||||||||||||||||
Nine Months Ended June 30, 2013 | Year Ended December 31, 2012 | |||||||||||||||||||||||
Balance as of beginning of period | $ | 3,823 | $ | 4,273 | ||||||||||||||||||||
Current period provision | 943 | 458 | ||||||||||||||||||||||
Direct write-offs charged against the allowance | (1,124 | ) | (908 | ) | ||||||||||||||||||||
Balance as of end of period | $ | 3,642 | $ | 3,823 | ||||||||||||||||||||
Schedule of Installment Receivables by Class [Table Text Block] | ' | |||||||||||||||||||||||
Installment receivables by class as of September 30, 2013 consist of the following (in thousands): | ||||||||||||||||||||||||
Total | Unpaid | Related | Interest | |||||||||||||||||||||
Installment | Principal | Allowance | Income | |||||||||||||||||||||
Receivables | Balance | for | Recognized | |||||||||||||||||||||
Doubtful | ||||||||||||||||||||||||
Accounts | ||||||||||||||||||||||||
U.S. | ||||||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | $ | 4,510 | $ | 4,510 | $ | 3,477 | $ | — | ||||||||||||||||
Canada | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,273 | 1,203 | — | 76 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 165 | 165 | 165 | — | ||||||||||||||||||||
Total Canadian Installment Receivables | $ | 1,438 | $ | 1,368 | $ | 165 | $ | 76 | ||||||||||||||||
Total | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,273 | 1,203 | — | 76 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 4,675 | 4,675 | 3,642 | — | ||||||||||||||||||||
Total Installment Receivables | $ | 5,948 | $ | 5,878 | $ | 3,642 | $ | 76 | ||||||||||||||||
Installment receivables by class as of December 31, 2012 consist of the following (in thousands): | ||||||||||||||||||||||||
Total | Unpaid | Related | Interest | |||||||||||||||||||||
Installment | Principal | Allowance | Income | |||||||||||||||||||||
Receivables | Balance | for | Recognized | |||||||||||||||||||||
Doubtful | ||||||||||||||||||||||||
Accounts | ||||||||||||||||||||||||
U.S. | ||||||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | $ | 4,508 | $ | 4,508 | $ | 3,365 | $ | — | ||||||||||||||||
Canada | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,522 | 1,451 | — | 120 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 458 | 458 | 458 | — | ||||||||||||||||||||
Total Canadian Installment Receivables | $ | 1,980 | $ | 1,909 | $ | 458 | $ | 120 | ||||||||||||||||
Total | ||||||||||||||||||||||||
Non-Impaired Installment receivables with no related allowance recorded | 1,522 | 1,451 | — | 120 | ||||||||||||||||||||
Impaired Installment receivables with a related allowance recorded | 4,966 | 4,966 | 3,823 | — | ||||||||||||||||||||
Total Installment Receivables | $ | 6,488 | $ | 6,417 | $ | 3,823 | $ | 120 | ||||||||||||||||
Schedule of Aging of Installment Receivables [Table Text Block] | ' | |||||||||||||||||||||||
The aging of the company’s installment receivables was as follows (in thousands): | ||||||||||||||||||||||||
September 30, 2013 | 31-Dec-12 | |||||||||||||||||||||||
Total | U.S. | Canada | Total | U.S. | Canada | |||||||||||||||||||
Current | $ | 1,218 | $ | — | $ | 1,218 | $ | 1,467 | $ | — | $ | 1,467 | ||||||||||||
0-30 Days Past Due | 9 | — | 9 | 43 | — | 43 | ||||||||||||||||||
31-60 Days Past Due | 6 | — | 6 | 2 | — | 2 | ||||||||||||||||||
61-90 Days Past Due | — | — | — | — | — | — | ||||||||||||||||||
90+ Days Past Due | 4,715 | 4,510 | 205 | 4,976 | 4,508 | 468 | ||||||||||||||||||
$ | 5,948 | $ | 4,510 | $ | 1,438 | $ | 6,488 | $ | 4,508 | $ | 1,980 | |||||||||||||
Inventories_Tables
Inventories (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Inventory, Net [Abstract] | ' | |||||||
Inventories [Table Text Block] | ' | |||||||
Inventories consist of the following (in thousands): | ||||||||
30-Sep-13 | 31-Dec-12 | |||||||
Finished goods | $ | 90,422 | $ | 94,675 | ||||
Raw materials | 61,642 | 71,596 | ||||||
Work in process | 15,304 | 16,975 | ||||||
$ | 167,368 | $ | 183,246 | |||||
Other_Current_Assets_Tables
Other Current Assets (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Other Current Assets [Abstract] | ' | |||||||
Schedule of Other Assets [Table Text Block] | ' | |||||||
Other current assets consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Value added tax receivables | $ | 15,004 | $ | 18,002 | ||||
Recoverable income taxes | 3,457 | 6,192 | ||||||
Derivatives (foreign currency forward contracts) | 1,311 | 1,062 | ||||||
Prepaid insurance | 300 | 2,241 | ||||||
Prepaids and other current assets | 13,758 | 14,279 | ||||||
$ | 33,830 | $ | 41,776 | |||||
Other_LongTerm_Assets_Tables
Other Long-Term Assets (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Text Block [Abstract] | ' | |||||||
Schedule of Other Assets, Noncurrent [Table Text Block] | ' | |||||||
Other long-term assets consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Cash surrender value of life insurance policies | $ | 35,772 | $ | 36,375 | ||||
Deferred Financing Fees | 1,356 | 2,728 | ||||||
Investments | 1,190 | 1,171 | ||||||
Long-term installment receivables | 676 | 406 | ||||||
Other | 1,333 | 1,582 | ||||||
$ | 40,327 | $ | 42,262 | |||||
Property_And_Equipment_Tables
Property And Equipment (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property, Plant and Equipment [Table Text Block] | ' | |||||||
Property and Equipment | ||||||||
Property and equipment consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Machinery and equipment | $ | 356,935 | $ | 356,512 | ||||
Land, buildings and improvements | 90,234 | 95,047 | ||||||
Furniture and fixtures | 12,998 | 13,397 | ||||||
Leasehold improvements | 14,886 | 14,975 | ||||||
475,053 | 479,931 | |||||||
Less allowance for depreciation | (366,662 | ) | (361,700 | ) | ||||
$ | 108,391 | $ | 118,231 | |||||
Other_Intangibles_Tables
Other Intangibles (Tables) | 9 Months Ended |
Sep. 30, 2013 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ' |
Schedule of Definite and Indefinite Lived Intangible Assets [Table Text Block] | ' |
Th |
Current_Liabilities_Tables
Current Liabilities (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Payables and Accruals [Abstract] | ' | |||||||
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | ' | |||||||
Accrued expenses consist of accruals for the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Salaries and wages | $ | 37,480 | $ | 41,813 | ||||
Taxes other than income taxes, primarily Value Added Taxes | 23,225 | 24,600 | ||||||
Warranty cost | 25,020 | 21,451 | ||||||
Freight | 7,806 | 7,853 | ||||||
Professional | 7,355 | 7,595 | ||||||
Product liability, current portion | 3,572 | 3,323 | ||||||
Rebates | 2,136 | 3,635 | ||||||
Insurance | 2,726 | 2,674 | ||||||
Interest | 921 | 1,268 | ||||||
Derivative liabilities | 771 | 1,373 | ||||||
Severance | 3,481 | 5,211 | ||||||
Other items, principally trade accruals | 15,986 | 14,393 | ||||||
$ | 130,479 | $ | 135,189 | |||||
Warrany_Costs_Tables
Warrany Costs (Tables) | 9 Months Ended | |||
Sep. 30, 2013 | ||||
Accrued Liabilities, Current [Abstract] | ' | |||
Accrued Warranty Costs [Table Text Block] | ' | |||
The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): | ||||
Balance as of January 1, 2013 | $ | 21,451 | ||
Warranties provided during the period | 7,843 | |||
Settlements made during the period | (8,741 | ) | ||
Changes in liability for pre-existing warranties during the period, including expirations | 4,467 | |||
Balance as of September 30, 2013 | $ | 25,020 | ||
LongTerm_Debt_Tables
Long-Term Debt (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Schedule of Debt [Table Text Block] | ' | |||||||
The liability components of the company’s convertible debt consist of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Principal amount of liability component | $ | 13,350 | $ | 13,350 | ||||
Unamortized discount | (2,874 | ) | (3,341 | ) | ||||
Net carrying amount of liability component | $ | 10,476 | $ | 10,009 | ||||
Schedule of Long-term Debt Instruments [Table Text Block] | ' | |||||||
Debt consists of the following (in thousands): | ||||||||
September 30, 2013 | December 31, 2012 | |||||||
Senior secured revolving credit facility, due in October 2015 | $ | 38,968 | $ | 217,494 | ||||
Convertible senior subordinated debentures at 4.125%, due in February 2027 | 10,476 | 10,009 | ||||||
Other notes and lease obligations | 6,625 | 7,299 | ||||||
56,069 | 234,802 | |||||||
Less current maturities of long-term debt | (1,294 | ) | (5,427 | ) | ||||
$ | 54,775 | $ | 229,375 | |||||
Shareholders_Equity_Transactio1
Shareholders' Equity Transactions (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | |||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||||
The following table summarizes information about stock option activity for the nine months ended September 30, 2013: | ||||||||||||||||
September 30, 2013 | Weighted | |||||||||||||||
Average | ||||||||||||||||
Exercise | ||||||||||||||||
Price | ||||||||||||||||
Options outstanding at January 1, 2013 | 4,664,634 | $ | 26.21 | |||||||||||||
Granted | 756,700 | 14.47 | ||||||||||||||
Exercised | — | — | ||||||||||||||
Canceled | (792,584 | ) | 28.74 | |||||||||||||
Options outstanding at September 30, 2013 | 4,628,750 | $ | 23.86 | |||||||||||||
Options exercise price range at September 30, 2013 | $ 12.42 to | |||||||||||||||
$ | 47.8 | |||||||||||||||
Options exercisable at September 30, 2013 | 3,070,364 | |||||||||||||||
Options available for grant at September 30, 2013* | 4,460,337 | |||||||||||||||
Schedule of Share-based Compensation, Stock Options Outstanding [Table Text Block] | ' | |||||||||||||||
The following table summarizes information about stock options outstanding at September 30, 2013: | ||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||
Exercise Prices | Number | Weighted Average | Weighted Average | Number | Weighted Average | |||||||||||
Outstanding | Remaining | Exercise Price | Exercisable | Exercise Price | ||||||||||||
At 9/30/13 | Contractual Life (Years) | At 9/30/13 | ||||||||||||||
$ 12.42 – $15.00 | 1,354,435 | 9.2 | $ | 13.95 | 166,045 | $ | 13.38 | |||||||||
$ 15.01 – $25.00 | 1,613,291 | 5.6 | 22.51 | 1,364,559 | 22.21 | |||||||||||
$ 25.01 – $35.00 | 950,109 | 5.7 | 25.81 | 828,846 | 25.85 | |||||||||||
$ 35.01 – $47.80 | 710,915 | 1.4 | 43.21 | 710,914 | 43.21 | |||||||||||
Total | 4,628,750 | 6 | $ | 23.86 | 3,070,364 | $ | 27.57 | |||||||||
Accumulated_Other_Comprehensiv1
Accumulated Other Comprehensive Income (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Abstract] | ' | |||||||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | ' | |||||||||||||||
Foreign Currency | Long-Term Notes | Defined Benefit Plans | Derivatives | Total | ||||||||||||
June 30, 2013 | 117,817 | (6,743 | ) | (6,419 | ) | 59 | 104,714 | |||||||||
OCI before reclassifications | 17,852 | (8,062 | ) | 265 | (197 | ) | 9,858 | |||||||||
Amount reclassified from accumulated OCI | — | — | (62 | ) | 78 | 16 | ||||||||||
Net current-period OCI | 17,852 | (8,062 | ) | 203 | (119 | ) | 9,874 | |||||||||
30-Sep-13 | 135,669 | (14,805 | ) | (6,216 | ) | (60 | ) | 114,588 | ||||||||
Changes in OCI during the nine months ended September 30, 2013 were as follows (in thousands): | ||||||||||||||||
Foreign Currency | Long-Term Notes | Defined Benefit Plans | Derivatives | Total | ||||||||||||
December 31, 2012 | 117,465 | 2,845 | (6,785 | ) | (782 | ) | 112,743 | |||||||||
OCI before reclassifications | 18,204 | (17,650 | ) | 750 | 650 | 1,954 | ||||||||||
Amount reclassified from accumulated OCI | — | — | (181 | ) | 72 | (109 | ) | |||||||||
Net current-period OCI | 18,204 | (17,650 | ) | 569 | 722 | 1,845 | ||||||||||
30-Sep-13 | 135,669 | (14,805 | ) | (6,216 | ) | (60 | ) | 114,588 | ||||||||
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] | ' | |||||||||||||||
Reclassifications out of accumulated OCI for the three and nine months ended September 30, 2013 were as follows (in thousands): | ||||||||||||||||
Amount reclassified from OCI | Affected line item in the Statement of Comprehensive Income (Loss) | |||||||||||||||
Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2013 | |||||||||||||||
Defined Benefit Plans | ||||||||||||||||
Service and interest costs | (64 | ) | (187 | ) | Selling, General and Administrative | |||||||||||
Tax | 2 | 6 | Income Taxes | |||||||||||||
Total after tax | (62 | ) | (181 | ) | ||||||||||||
Derivatives | ||||||||||||||||
Foreign currency forward contracts hedging sales | (54 | ) | (496 | ) | Net Sales | |||||||||||
Foreign currency forward contracts hedging purchases | 128 | 453 | Cost of Products Sold | |||||||||||||
Interest rate swaps | 13 | 139 | Interest Expense | |||||||||||||
Total before tax | 87 | 96 | ||||||||||||||
Tax | (9 | ) | (24 | ) | Income Taxes | |||||||||||
Total after tax | 78 | 72 | ||||||||||||||
Charges_Related_To_Restructuri1
Charges Related To Restructuring Activities (Tables) | 9 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||||||||||
Schedule of Restructuring and Related Costs [Table Text Block] | ' | |||||||||||||||||||
A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands): | ||||||||||||||||||||
Severance | Product Line | Contract | Other | Total | ||||||||||||||||
Discontinuance | Terminations | |||||||||||||||||||
December 31, 2010 Balance | ||||||||||||||||||||
Total | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||
Charges | ||||||||||||||||||||
NA/HME | 4,755 | — | — | 4 | 4,759 | |||||||||||||||
IPG | 123 | — | — | — | 123 | |||||||||||||||
Europe | 3,288 | 277 | 1,788 | 113 | 5,466 | |||||||||||||||
Asia/Pacific | 186 | — | — | — | 186 | |||||||||||||||
Total | 8,352 | 277 | 1,788 | 117 | 10,534 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (1,663 | ) | — | — | (4 | ) | (1,667 | ) | ||||||||||||
IPG | (52 | ) | — | — | — | (52 | ) | |||||||||||||
Europe | (1,546 | ) | (277 | ) | (1,714 | ) | (113 | ) | (3,650 | ) | ||||||||||
Asia/Pacific | (186 | ) | — | — | — | (186 | ) | |||||||||||||
Total | (3,447 | ) | (277 | ) | (1,714 | ) | (117 | ) | (5,555 | ) | ||||||||||
December 31, 2011 Balance | ||||||||||||||||||||
NA/HME | 3,092 | — | — | — | 3,092 | |||||||||||||||
IPG | 71 | — | — | — | 71 | |||||||||||||||
Europe | 1,742 | — | 74 | — | 1,816 | |||||||||||||||
Asia/Pacific | — | — | — | — | — | |||||||||||||||
Total | 4,905 | — | 74 | — | 4,979 | |||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | 4,242 | — | 5 | — | 4,247 | |||||||||||||||
IPG | 35 | — | — | — | 35 | |||||||||||||||
Europe | 817 | — | 53 | 1,223 | 2,093 | |||||||||||||||
Asia/Pacific | 1,681 | 491 | 1,667 | 1,181 | 5,020 | |||||||||||||||
Total | 6,775 | 491 | 1,725 | 2,404 | 11,395 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (3,587 | ) | — | (5 | ) | — | (3,592 | ) | ||||||||||||
IPG | (106 | ) | — | — | — | (106 | ) | |||||||||||||
Europe | (1,964 | ) | — | (127 | ) | (1,223 | ) | (3,314 | ) | |||||||||||
Asia/Pacific | (812 | ) | (340 | ) | (42 | ) | (1,175 | ) | (2,369 | ) | ||||||||||
Total | $ | (6,469 | ) | $ | (340 | ) | $ | (174 | ) | $ | (2,398 | ) | $ | (9,381 | ) | |||||
Severance | Product Line | Contract | Other | Total | ||||||||||||||||
Discontinuance | Terminations | |||||||||||||||||||
December 31, 2012 Balance | ||||||||||||||||||||
NA/HME | $ | 3,747 | $ | — | $ | — | $ | — | $ | 3,747 | ||||||||||
IPG | — | — | — | — | — | |||||||||||||||
Europe | 595 | — | — | — | 595 | |||||||||||||||
Asia/Pacific | 869 | 151 | 1,625 | 6 | 2,651 | |||||||||||||||
Total | 5,211 | 151 | 1,625 | 6 | 6,993 | |||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | 1,679 | — | — | — | 1,679 | |||||||||||||||
IPG | 189 | — | — | — | 189 | |||||||||||||||
Europe | 115 | — | — | — | 115 | |||||||||||||||
Asia/Pacific | 453 | — | 86 | — | 539 | |||||||||||||||
Total | 2,436 | — | 86 | — | 2,522 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (2,005 | ) | — | — | — | (2,005 | ) | |||||||||||||
IPG | (17 | ) | — | — | — | (17 | ) | |||||||||||||
Europe | (461 | ) | — | — | — | (461 | ) | |||||||||||||
Asia/Pacific | (618 | ) | (151 | ) | (766 | ) | (4 | ) | (1,539 | ) | ||||||||||
Total | (3,101 | ) | (151 | ) | (766 | ) | (4 | ) | (4,022 | ) | ||||||||||
March 31, 2013 Balance | ||||||||||||||||||||
NA/HME | 3,421 | — | — | — | 3,421 | |||||||||||||||
IPG | 172 | — | — | — | 172 | |||||||||||||||
Europe | 249 | — | — | — | 249 | |||||||||||||||
Asia/Pacific | 704 | — | 945 | 2 | 1,651 | |||||||||||||||
4,546 | — | 945 | 2 | 5,493 | ||||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | 1,948 | — | — | — | 1,948 | |||||||||||||||
IPG | 13 | — | — | — | 13 | |||||||||||||||
Europe | 65 | — | — | — | 65 | |||||||||||||||
Asia/Pacific | 480 | — | 86 | — | 566 | |||||||||||||||
Total | 2,506 | — | 86 | — | 2,592 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (1,795 | ) | — | — | — | (1,795 | ) | |||||||||||||
IPG | (26 | ) | — | — | — | (26 | ) | |||||||||||||
Europe | (182 | ) | — | — | — | (182 | ) | |||||||||||||
Asia/Pacific | (129 | ) | — | (49 | ) | (2 | ) | (180 | ) | |||||||||||
Total | (2,132 | ) | — | (49 | ) | (2 | ) | (2,183 | ) | |||||||||||
June 30, 2013 Balance | ||||||||||||||||||||
NA/HME | 3,574 | — | — | — | 3,574 | |||||||||||||||
IPG | 159 | — | — | — | 159 | |||||||||||||||
Europe | 132 | — | — | — | 132 | |||||||||||||||
Asia/Pacific | 1,055 | — | 982 | — | 2,037 | |||||||||||||||
$ | 4,920 | $ | — | $ | 982 | $ | — | $ | 5,902 | |||||||||||
Severance | Product Line | Contract | Other | Total | ||||||||||||||||
Discontinuance | Terminations | |||||||||||||||||||
Charges | ||||||||||||||||||||
NA/HME | $ | 644 | $ | — | $ | 213 | $ | 353 | $ | 1,210 | ||||||||||
IPG | 36 | — | — | — | 36 | |||||||||||||||
Europe | 739 | — | — | (198 | ) | 541 | ||||||||||||||
Asia/Pacific | 15 | — | 79 | 3 | 97 | |||||||||||||||
Total | 1,434 | — | 292 | 158 | 1,884 | |||||||||||||||
Payments | ||||||||||||||||||||
NA/HME | (1,624 | ) | — | (85 | ) | (305 | ) | (2,014 | ) | |||||||||||
IPG | (52 | ) | — | — | — | (52 | ) | |||||||||||||
Europe | (157 | ) | — | — | 198 | 41 | ||||||||||||||
Asia/Pacific | (1,040 | ) | — | (557 | ) | (3 | ) | (1,600 | ) | |||||||||||
Total | (2,873 | ) | — | (642 | ) | (110 | ) | (3,625 | ) | |||||||||||
September 30, 2013 Balance | ||||||||||||||||||||
NA/HME | 2,594 | — | 128 | 48 | 2,770 | |||||||||||||||
IPG | 143 | — | — | — | 143 | |||||||||||||||
Europe | 714 | — | — | — | 714 | |||||||||||||||
Asia/Pacific | 30 | — | 504 | — | 534 | |||||||||||||||
$ | 3,481 | $ | — | $ | 632 | $ | 48 | $ | 4,161 | |||||||||||
Net_Earnings_Loss_Per_Common_S1
Net Earnings (Loss) Per Common Share (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Earnings Per Share [Abstract] | ' | |||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | ' | |||||||||||||||
The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated. | ||||||||||||||||
(In thousands except per share data) | For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Basic | ||||||||||||||||
Average common shares outstanding | 31,902 | 31,877 | 31,902 | 31,838 | ||||||||||||
Net earnings (loss) from continuing operations | $ | (5,383 | ) | $ | 563 | $ | (35,580 | ) | $ | 374 | ||||||
Net earnings from discontinued operations | $ | 21,485 | $ | 2,301 | $ | 74,401 | $ | 8,746 | ||||||||
Net earnings | $ | 16,102 | $ | 2,864 | $ | 38,821 | $ | 9,120 | ||||||||
Net earnings (loss) per common share from continuing operations | $ | (0.17 | ) | $ | 0.02 | $ | (1.12 | ) | $ | 0.01 | ||||||
Net earnings per common share from discontinued operations | $ | 0.67 | $ | 0.07 | $ | 2.33 | $ | 0.27 | ||||||||
Net earnings per common share | $ | 0.5 | $ | 0.09 | $ | 1.21 | $ | 0.28 | ||||||||
Diluted | ||||||||||||||||
Average common shares outstanding | 31,902 | 31,877 | 31,902 | 31,838 | ||||||||||||
Shares related to convertible debt | — | — | — | — | ||||||||||||
Stock options and awards | 164 | 24 | 107 | 9 | ||||||||||||
Average common shares assuming dilution | 32,066 | 31,901 | 32,009 | 31,847 | ||||||||||||
Net earnings (loss) from continuing operations | $ | (5,383 | ) | $ | 563 | $ | (35,580 | ) | $ | 374 | ||||||
Net earnings from discontinued operations | $ | 21,485 | $ | 2,301 | $ | 74,401 | $ | 8,746 | ||||||||
Net earnings | $ | 16,102 | $ | 2,864 | $ | 38,821 | $ | 9,120 | ||||||||
Net earnings (loss) per common share from continuing operations * | $ | (0.17 | ) | $ | 0.02 | $ | (1.12 | ) | $ | 0.01 | ||||||
Net earnings per common share from discontinued operations | $ | 0.67 | $ | 0.07 | $ | 2.32 | $ | 0.27 | ||||||||
Net earnings per common share * | $ | 0.5 | $ | 0.09 | $ | 1.2 | $ | 0.28 | ||||||||
Derivatives_Tables
Derivatives (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | |||||||||||||||
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] | ' | |||||||||||||||
oreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Notional | Unrealized | Notional | Unrealized | |||||||||||||
Amount | Net Gain | Amount | Net Gain | |||||||||||||
(Loss) | (Loss) | |||||||||||||||
USD / AUD | $ | 579 | $ | 46 | $ | — | $ | — | ||||||||
USD / CAD | 10,330 | (85 | ) | 17,620 | (6 | ) | ||||||||||
USD / CNY | 3,320 | 55 | — | — | ||||||||||||
USD / CHF | 232 | 7 | — | — | ||||||||||||
USD / EUR | 14,433 | (368 | ) | 59,510 | (797 | ) | ||||||||||
USD / GBP | 692 | 22 | 2,519 | (3 | ) | |||||||||||
USD / NZD | 465 | 4 | — | — | ||||||||||||
USD / SEK | 3,499 | 115 | — | — | ||||||||||||
USD / MXP | 2,846 | 11 | 6,954 | 141 | ||||||||||||
EUR / CAD | 450 | 12 | — | — | ||||||||||||
EUR / CHF | 1,555 | 17 | — | — | ||||||||||||
EUR / GBP | 5,389 | (40 | ) | 2,077 | 46 | |||||||||||
EUR / SEK | 415 | 25 | — | — | ||||||||||||
EUR / NZD | 1,748 | 23 | 5,749 | 105 | ||||||||||||
GBP / CHF | 304 | (8 | ) | — | — | |||||||||||
GBP / SEK | 1,099 | 52 | 4,154 | 25 | ||||||||||||
DKK / SEK | 1,051 | (9 | ) | 6,397 | (47 | ) | ||||||||||
NOK / SEK | 926 | 66 | 3,428 | (4 | ) | |||||||||||
$ | 49,333 | $ | (55 | ) | $ | 108,408 | $ | (540 | ) | |||||||
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] | ' | |||||||||||||||
Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2013 and 2012, respectively, and outstanding were as follows (in thousands USD): | ||||||||||||||||
September 30, 2013 | September 30, 2012 | |||||||||||||||
Notional | Gain | Notional | Gain | |||||||||||||
Amount | (Loss) | Amount | (Loss) | |||||||||||||
CAD / USD | $ | 4,840 | $ | 4 | $ | 14,801 | $ | 434 | ||||||||
EUR / USD | 12,273 | 166 | 9,906 | 134 | ||||||||||||
CHF / USD | — | — | 785 | 13 | ||||||||||||
DKK / USD | 13,517 | 62 | — | — | ||||||||||||
GBP / USD | 6,361 | 67 | — | — | ||||||||||||
NOK / USD | 4,486 | 12 | — | — | ||||||||||||
NZD / USD | 2,161 | (8 | ) | 3,146 | 40 | |||||||||||
SEK / USD | 6,502 | 32 | — | — | ||||||||||||
EUR / AUD | — | — | 1,908 | 5 | ||||||||||||
EUR / CAD | — | — | 239 | (15 | ) | |||||||||||
EUR / DKK | — | — | (11,203 | ) | (27 | ) | ||||||||||
AUD / CAD | 878 | (4 | ) | 3,056 | (38 | ) | ||||||||||
AUD / EUR | 1,788 | 248 | — | — | ||||||||||||
AUD / GBP | 298 | 38 | — | — | ||||||||||||
AUD / NZD | — | — | 1,048 | 15 | ||||||||||||
EUR / NZD | — | — | 90 | (10 | ) | |||||||||||
EUR / NOK | — | — | 6 | — | ||||||||||||
$ | 53,104 | $ | 617 | $ | 23,782 | $ | 551 | |||||||||
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] | ' | |||||||||||||||
The fair values of the company’s derivative instruments were as follows (in thousands): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Assets | Liabilities | Assets | Liabilities | |||||||||||||
Derivatives designated as hedging instruments under ASC 815 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 626 | $ | 681 | $ | 375 | $ | 915 | ||||||||
Interest rate swap contracts | — | 22 | — | 316 | ||||||||||||
Derivatives not designated as hedging instruments under ASC 815 | ||||||||||||||||
Foreign currency forward exchange contracts | 685 | 68 | 687 | 142 | ||||||||||||
Total derivatives | $ | 1,311 | $ | 771 | $ | 1,062 | $ | 1,373 | ||||||||
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] | ' | |||||||||||||||
The effect of derivative instruments on the Statement of Comprehensive Income (Loss) and Other Comprehensive Income (OCI) was as follows (in thousands): | ||||||||||||||||
Derivatives in ASC 815 cash flow hedge | Amount of Gain | Amount of Gain (Loss) | Amount of Gain (Loss) | |||||||||||||
relationships | (Loss) Recognized in OCI on Derivatives | Reclassified from | Recognized in Income on | |||||||||||||
(Effective Portion) | Accumulated OCI into | Derivatives (Ineffective Portion | ||||||||||||||
Income (Effective | and Amount Excluded from | |||||||||||||||
Portion) | Effectiveness Testing) | |||||||||||||||
Three months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | (207 | ) | $ | 83 | $ | 2 | |||||||||
Interest rate swap contracts | 33 | (13 | ) | — | ||||||||||||
$ | (174 | ) | $ | 70 | $ | 2 | ||||||||||
Nine months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 505 | $ | (20 | ) | $ | 37 | |||||||||
Interest rate swap contracts | 433 | (139 | ) | — | ||||||||||||
$ | 938 | $ | (159 | ) | $ | 37 | ||||||||||
Three months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | (2,522 | ) | $ | 1,241 | $ | (38 | ) | ||||||||
Interest rate swap contracts | (3 | ) | — | — | ||||||||||||
$ | (2,525 | ) | $ | 1,241 | $ | (38 | ) | |||||||||
Nine months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | (2,956 | ) | $ | 2,706 | $ | (9 | ) | ||||||||
Interest rate swap contracts | (99 | ) | — | — | ||||||||||||
$ | (3,055 | ) | $ | 2,706 | $ | (9 | ) | |||||||||
Derivatives not designated as hedging | Amount of Gain (Loss) | |||||||||||||||
instruments under ASC 815 | Recognized in Income on Derivatives | |||||||||||||||
Three months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 361 | ||||||||||||||
Nine months ended September 30, 2013 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 617 | ||||||||||||||
Three months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 569 | ||||||||||||||
Nine months ended September 30, 2012 | ||||||||||||||||
Foreign currency forward exchange contracts | $ | 551 | ||||||||||||||
Fair_Values_of_Financial_Instr
Fair Values of Financial Instruments (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | ' | |||||||||||||||
The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands). | ||||||||||||||||
Basis for Fair Value Measurements at Reporting Date | ||||||||||||||||
Quoted Prices in Active | Significant | Significant | ||||||||||||||
Markets for Identical | Other | Other | ||||||||||||||
Assets / (Liabilities) | Observable | Unobservable | ||||||||||||||
Inputs | Inputs | |||||||||||||||
Total | Level I | Level II | Level III | |||||||||||||
30-Sep-13 | ||||||||||||||||
Forward Exchange Contracts—net | $ | 562 | — | $ | 562 | — | ||||||||||
Interest Rate Swap Agreements—net | (22 | ) | — | (22 | ) | — | ||||||||||
December 31, 2012: | ||||||||||||||||
Forward Exchange Contracts—net | $ | 5 | — | $ | 5 | — | ||||||||||
Interest Rate Swap Agreements—net | (316 | ) | — | (316 | ) | — | ||||||||||
Fair Value, by Balance Sheet Grouping [Table Text Block] | ' | |||||||||||||||
The carrying values and fair values of the company’s financial instruments are as follows (in thousands): | ||||||||||||||||
September 30, 2013 | December 31, 2012 | |||||||||||||||
Carrying | Fair Value | Carrying | Fair Value | |||||||||||||
Value | Value | |||||||||||||||
Cash and cash equivalents | $ | 32,625 | $ | 32,625 | $ | 38,791 | $ | 38,791 | ||||||||
Other investments | 1,190 | 1,190 | 1,171 | 1,171 | ||||||||||||
Installment receivables, net of reserves | 2,236 | 2,236 | 2,594 | 2,594 | ||||||||||||
Long-term debt (including current maturities of long-term debt) | (56,069 | ) | (56,115 | ) | (234,802 | ) | (234,072 | ) | ||||||||
Forward contracts in Other Current Assets | 1,311 | 1,311 | 1,062 | 1,062 | ||||||||||||
Forward contracts in Accrued Expenses | (749 | ) | (749 | ) | (1,057 | ) | (1,057 | ) | ||||||||
Interest rate swap agreements in Accrued Expenses | (22 | ) | (22 | ) | (316 | ) | (316 | ) |
Business_Segments_Tables
Business Segments (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] | ' | |||||||||||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | ' | |||||||||||||||
The information by segment is as follows (in thousands): | ||||||||||||||||
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Revenues from external customers | ||||||||||||||||
North America/HME | $ | 151,052 | $ | 170,701 | $ | 462,261 | $ | 527,103 | ||||||||
Institutional Products Group | 28,083 | 33,557 | 87,135 | 95,726 | ||||||||||||
Europe | 150,265 | 141,705 | 429,650 | 401,721 | ||||||||||||
Asia/Pacific | 11,776 | 15,555 | 38,327 | 53,217 | ||||||||||||
Consolidated | $ | 341,176 | $ | 361,518 | $ | 1,017,373 | $ | 1,077,767 | ||||||||
Intersegment revenues | ||||||||||||||||
North America/HME | $ | 20,501 | $ | 24,813 | $ | 59,735 | $ | 81,985 | ||||||||
Institutional Products Group | 1,254 | 1,941 | 4,243 | 5,471 | ||||||||||||
Europe | 1,890 | 3,239 | 6,156 | 8,448 | ||||||||||||
Asia/Pacific | 6,411 | 7,737 | 19,417 | 27,177 | ||||||||||||
Consolidated | $ | 30,056 | $ | 37,730 | $ | 89,551 | $ | 123,081 | ||||||||
Restructuring charges before income taxes | ||||||||||||||||
North America/HME | $ | 1,210 | $ | 352 | $ | 4,837 | $ | 2,214 | ||||||||
Institutional Products Group | 36 | — | 237 | 35 | ||||||||||||
Europe | 542 | 481 | 722 | 772 | ||||||||||||
Asia/Pacific | 96 | 342 | 1,202 | 721 | ||||||||||||
Consolidated | $ | 1,884 | $ | 1,175 | $ | 6,998 | $ | 3,742 | ||||||||
Earnings (loss) before income taxes | ||||||||||||||||
North America/HME | $ | (10,191 | ) | $ | (28 | ) | $ | (33,593 | ) | $ | 8,086 | |||||
Institutional Products Group | 1,009 | 579 | 1,955 | 4,820 | ||||||||||||
Europe | 13,136 | 10,218 | 27,344 | 23,504 | ||||||||||||
Asia/Pacific | (2,233 | ) | (2,301 | ) | (9,871 | ) | (4,139 | ) | ||||||||
All Other (1) | (6,354 | ) | (5,460 | ) | (17,515 | ) | (17,411 | ) | ||||||||
Consolidated | $ | (4,633 | ) | $ | 3,008 | $ | (31,680 | ) | $ | 14,860 | ||||||
________________________ | ||||||||||||||||
-1 | Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. In addition, the “All Other” earnings (loss) before income taxes includes loss on debt extinguishment including debt finance charges, interest and fees. |
Supplemental_Guarantor_Informa1
Supplemental Guarantor Information Supplemental Guarantor Information (Tables) | 9 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||
Supplemental Guarantor Information [Abstract] | ' | |||||||||||||||||||
Schedule of Guarantor Obligations [Table Text Block] | ' | |||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2012 | (in thousands) | |||||||||||||||||||
Net sales | $ | 275,742 | $ | 355,378 | $ | 540,535 | $ | (93,888 | ) | $ | 1,077,767 | |||||||||
Cost of products sold | 211,115 | 256,854 | 371,855 | (93,455 | ) | 746,369 | ||||||||||||||
Gross Profit | 64,627 | 98,524 | 168,680 | (433 | ) | 331,398 | ||||||||||||||
Selling, general and administrative expenses | 99,736 | 64,452 | 138,207 | 4,360 | 306,755 | |||||||||||||||
Charge related to restructuring activities | 2,085 | 39 | 1,618 | — | 3,742 | |||||||||||||||
Loss on debt extinguishment including debt finance charges and associated fees | 312 | — | — | — | 312 | |||||||||||||||
Income (loss) from equity investee | 45,175 | 1,954 | 391 | (47,520 | ) | — | ||||||||||||||
Interest expense (income)—net | (3,041 | ) | 6,396 | 2,374 | — | 5,729 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 10,710 | 29,591 | 26,872 | (52,313 | ) | 14,860 | ||||||||||||||
Income taxes (benefit) | 1,590 | (5,164 | ) | 18,060 | — | 14,486 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 9,120 | 34,755 | 8,812 | (52,313 | ) | 374 | ||||||||||||||
Net Earnings from Discontinued Operations | — | 8,746 | — | — | 8,746 | |||||||||||||||
Net Earnings (loss) | $ | 9,120 | $ | 43,501 | $ | 8,812 | $ | (52,313 | ) | $ | 9,120 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | (24,673 | ) | 3,179 | (27,878 | ) | 24,699 | (24,673 | ) | ||||||||||||
Comprehensive Income (Loss) | $ | (15,553 | ) | $ | 46,680 | $ | (19,066 | ) | $ | (27,614 | ) | $ | (15,553 | ) | ||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2013 | ||||||||||||||||||||
Net sales | $ | 186,453 | $ | 364,005 | $ | 535,805 | $ | (68,890 | ) | $ | 1,017,373 | |||||||||
Cost of products sold | 159,884 | 264,501 | 378,287 | (69,264 | ) | 733,408 | ||||||||||||||
Gross Profit | 26,569 | 99,504 | 157,518 | 374 | 283,965 | |||||||||||||||
Selling, general and administrative expenses | 99,338 | 72,370 | 131,640 | 2,694 | 306,042 | |||||||||||||||
Charge related to restructuring activities | 5,078 | 49 | 1,871 | — | 6,998 | |||||||||||||||
Asset write-downs to intangibles and investments | — | 167 | — | — | 167 | |||||||||||||||
Income (loss) from equity investee | 105,501 | 21,472 | (93 | ) | (126,880 | ) | — | |||||||||||||
Interest expense (income)—net | (1,418 | ) | 3,141 | 715 | — | 2,438 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 29,072 | 45,249 | 23,199 | (129,200 | ) | (31,680 | ) | |||||||||||||
Income taxes (benefit) | (9,749 | ) | — | 13,649 | — | 3,900 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 38,821 | 45,249 | 9,550 | (129,200 | ) | (35,580 | ) | |||||||||||||
Net Earnings from Discontinued Operations | — | 74,401 | — | — | 74,401 | |||||||||||||||
Net Earnings (loss) | $ | 38,821 | $ | 119,650 | $ | 9,550 | $ | (129,200 | ) | $ | 38,821 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | 1,845 | (415 | ) | 2,228 | (1,813 | ) | 1,845 | |||||||||||||
Comprehensive Income (Loss) | $ | 40,666 | $ | 119,235 | $ | 11,778 | $ | (131,013 | ) | $ | 40,666 | |||||||||
CONSOLIDATING CONDENSED BALANCE SHEETS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
December 31, 2012 | (in thousands) | |||||||||||||||||||
Assets | ||||||||||||||||||||
Current Assets | ||||||||||||||||||||
Cash and cash equivalents | $ | 5,774 | $ | 1,018 | $ | 31,999 | $ | — | $ | 38,791 | ||||||||||
Trade receivables, net | 71,622 | 37,223 | 89,946 | — | 198,791 | |||||||||||||||
Installment receivables, net | — | 829 | 1,359 | — | 2,188 | |||||||||||||||
Inventories, net | 40,278 | 31,455 | 114,169 | (2,656 | ) | 183,246 | ||||||||||||||
Intercompany advances, net | 4,077 | 763 | 64,570 | (69,410 | ) | — | ||||||||||||||
Other current assets | 12,727 | 473 | 34,606 | (6,030 | ) | 41,776 | ||||||||||||||
Assets held for sale - current | — | 103,157 | — | — | 103,157 | |||||||||||||||
Total Current Assets | 134,478 | 174,918 | 336,649 | (78,096 | ) | 567,949 | ||||||||||||||
Investment in subsidiaries | 1,536,898 | 523,176 | 6,888 | (2,066,962 | ) | — | ||||||||||||||
Intercompany advances, net | 863,973 | 1,468,405 | 173,903 | (2,506,281 | ) | — | ||||||||||||||
Other Assets | 41,006 | 314 | 942 | — | 42,262 | |||||||||||||||
Other Intangibles | 663 | 22,211 | 48,778 | — | 71,652 | |||||||||||||||
Property and Equipment, net | 39,911 | 19,957 | 58,363 | — | 118,231 | |||||||||||||||
Goodwill | — | 32,937 | 429,263 | — | 462,200 | |||||||||||||||
Total Assets | $ | 2,616,929 | $ | 2,241,918 | $ | 1,054,786 | $ | (4,651,339 | ) | $ | 1,262,294 | |||||||||
Liabilities and Shareholders’ Equity | ||||||||||||||||||||
Current Liabilities | ||||||||||||||||||||
Accounts payable | $ | 63,812 | $ | 9,465 | $ | 59,771 | $ | — | $ | 133,048 | ||||||||||
Accrued expenses | 36,716 | 18,155 | 86,348 | (6,030 | ) | 135,189 | ||||||||||||||
Accrued income taxes | 1,545 | — | 1,168 | — | 2,713 | |||||||||||||||
Intercompany advances, net | 61,368 | 2,369 | 5,673 | (69,410 | ) | — | ||||||||||||||
Short-term debt and current maturities of long-term obligations | 4,552 | 7 | 868 | — | 5,427 | |||||||||||||||
Liabilities held for sale - current | — | 23,358 | — | — | 23,358 | |||||||||||||||
Total Current Liabilities | 167,993 | 53,354 | 153,828 | (75,440 | ) | 299,735 | ||||||||||||||
Long-Term Debt | 223,014 | 143 | 6,218 | — | 229,375 | |||||||||||||||
Other Long-Term Obligations | 52,957 | — | 59,238 | — | 112,195 | |||||||||||||||
Intercompany advances, net | 1,551,976 | 863,585 | 90,720 | (2,506,281 | ) | — | ||||||||||||||
Total Shareholders’ Equity | 620,989 | 1,324,836 | 744,782 | (2,069,618 | ) | 620,989 | ||||||||||||||
Total Liabilities and Shareholders’ Equity | $ | 2,616,929 | $ | 2,241,918 | $ | 1,054,786 | $ | (4,651,339 | ) | $ | 1,262,294 | |||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Three month period ended September 30, 2012 | (in thousands) | |||||||||||||||||||
Net sales | $ | 90,406 | $ | 116,339 | $ | 183,801 | $ | (29,028 | ) | $ | 361,518 | |||||||||
Cost of products sold | 70,600 | 83,685 | 126,852 | (29,031 | ) | 252,106 | ||||||||||||||
Gross Profit | 19,806 | 32,654 | 56,949 | 3 | 109,412 | |||||||||||||||
Selling, general and administrative expenses | 33,712 | 20,356 | 45,492 | 3,721 | 103,281 | |||||||||||||||
Charge related to restructuring activities | 334 | 18 | 823 | — | 1,175 | |||||||||||||||
Loss on debt extinguishment including debt finance charges and associated fees | — | — | — | — | — | |||||||||||||||
Income (loss) from equity investee | 17,302 | (4,264 | ) | 228 | (13,266 | ) | — | |||||||||||||
Interest expense (income)—net | (1,024 | ) | 2,201 | 771 | — | 1,948 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 4,086 | 5,815 | 10,091 | (16,984 | ) | 3,008 | ||||||||||||||
Income taxes (benefit) | 1,222 | (3,028 | ) | 4,251 | — | 2,445 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 2,864 | 8,843 | 5,840 | (16,984 | ) | 563 | ||||||||||||||
Net Earnings from Discontinued Operations | — | 2,301 | — | — | 2,301 | |||||||||||||||
Net Earnings (loss) | $ | 2,864 | $ | 11,144 | $ | 5,840 | $ | (16,984 | ) | $ | 2,864 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | 14,518 | 3,164 | 11,412 | (14,576 | ) | 14,518 | ||||||||||||||
Comprehensive Income (Loss) | $ | 17,382 | $ | 14,308 | $ | 17,252 | $ | (31,560 | ) | $ | 17,382 | |||||||||
CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Three month period ended September 30, 2013 | (in thousands) | |||||||||||||||||||
Net sales | $ | 60,641 | $ | 119,548 | $ | 184,299 | $ | (23,312 | ) | $ | 341,176 | |||||||||
Cost of products sold | 52,454 | 86,978 | 128,232 | (23,312 | ) | 244,352 | ||||||||||||||
Gross Profit | 8,187 | 32,570 | 56,067 | — | 96,824 | |||||||||||||||
Selling, general and administrative expenses | 29,046 | 25,363 | 44,310 | — | 98,719 | |||||||||||||||
Charge related to restructuring activities | 1,597 | 36 | 251 | — | 1,884 | |||||||||||||||
Asset write-downs to intangibles and investments | — | 167 | — | — | 167 | |||||||||||||||
Income (loss) from equity investee | 32,513 | 8,935 | 22 | (41,470 | ) | — | ||||||||||||||
Interest expense (income)—net | (603 | ) | 1,213 | 77 | — | 687 | ||||||||||||||
Earnings (Loss) from Continuing Operations before Income Taxes | 10,660 | 14,726 | 11,451 | (41,470 | ) | (4,633 | ) | |||||||||||||
Income taxes (benefit) | (5,442 | ) | — | 6,192 | — | 750 | ||||||||||||||
Net Earnings (Loss) from Continuing Operations | 16,102 | 14,726 | 5,259 | (41,470 | ) | (5,383 | ) | |||||||||||||
Net Earnings from Discontinued Operations | — | 21,485 | — | — | 21,485 | |||||||||||||||
Net Earnings (loss) | $ | 16,102 | $ | 36,211 | $ | 5,259 | $ | (41,470 | ) | $ | 16,102 | |||||||||
Other Comprehensive Income (Loss), Net of Tax | 9,874 | 220 | 10,135 | (10,355 | ) | 9,874 | ||||||||||||||
Comprehensive Income (Loss) | $ | 25,976 | $ | 36,431 | $ | 15,394 | $ | (51,825 | ) | $ | 25,976 | |||||||||
CONSOLIDATING CONDENSED BALANCE SHEETS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
September 30, 2013 | (in thousands) | |||||||||||||||||||
Assets | ||||||||||||||||||||
Current Assets | ||||||||||||||||||||
Cash and cash equivalents | $ | 3,148 | $ | — | $ | 29,477 | $ | — | $ | 32,625 | ||||||||||
Trade receivables, net | 69,633 | 29,453 | 92,378 | — | 191,464 | |||||||||||||||
Installment receivables, net | — | 569 | 991 | — | 1,560 | |||||||||||||||
Inventories, net | 37,797 | 27,784 | 104,970 | (3,183 | ) | 167,368 | ||||||||||||||
Intercompany advances, net | 5,055 | 664 | 43,145 | (48,864 | ) | — | ||||||||||||||
Other current assets | 6,371 | 570 | 34,129 | (7,240 | ) | 33,830 | ||||||||||||||
Total Current Assets | 122,004 | 59,040 | 305,090 | (59,287 | ) | 426,847 | ||||||||||||||
Investment in subsidiaries | 1,433,252 | 440,197 | — | (1,873,449 | ) | — | ||||||||||||||
Intercompany advances, net | 937,116 | 1,592,785 | 178,180 | (2,708,081 | ) | — | ||||||||||||||
Other Assets | 38,961 | 463 | 903 | — | 40,327 | |||||||||||||||
Other Intangibles | 553 | 19,139 | 45,413 | — | 65,105 | |||||||||||||||
Property and Equipment, net | 36,783 | 18,621 | 52,987 | — | 108,391 | |||||||||||||||
Goodwill | — | 16,660 | 434,067 | — | 450,727 | |||||||||||||||
Total Assets | $ | 2,568,669 | $ | 2,146,905 | $ | 1,016,640 | $ | (4,640,817 | ) | $ | 1,091,397 | |||||||||
Liabilities and Shareholders’ Equity | ||||||||||||||||||||
Current Liabilities | ||||||||||||||||||||
Accounts payable | $ | 50,462 | $ | 8,237 | $ | 58,985 | $ | — | $ | 117,684 | ||||||||||
Accrued expenses | 30,864 | 17,737 | 89,118 | (7,240 | ) | 130,479 | ||||||||||||||
Accrued income taxes | 5,540 | — | 1,661 | — | 7,201 | |||||||||||||||
Intercompany advances, net | 41,889 | 1,481 | 5,494 | (48,864 | ) | — | ||||||||||||||
Short-term debt and current maturities of long-term obligations | 556 | 7 | 731 | — | 1,294 | |||||||||||||||
Total Current Liabilities | 129,311 | 27,462 | 155,989 | (56,104 | ) | 256,658 | ||||||||||||||
Long-Term Debt | 22,476 | 82 | 32,217 | — | 54,775 | |||||||||||||||
Other Long-Term Obligations | 54,176 | — | 60,597 | — | 114,773 | |||||||||||||||
Intercompany advances, net | 1,707,515 | 936,722 | 63,844 | (2,708,081 | ) | — | ||||||||||||||
Total Shareholders’ Equity | 655,191 | 1,182,639 | 703,993 | (1,876,632 | ) | 665,191 | ||||||||||||||
Total Liabilities and Shareholders’ Equity | $ | 2,568,669 | $ | 2,146,905 | $ | 1,016,640 | $ | (4,640,817 | ) | $ | 1,091,397 | |||||||||
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2013 | (in thousands) | |||||||||||||||||||
Net Cash Provided (Used) by Operating Activities | $ | 35,179 | $ | (81,077 | ) | $ | (20,736 | ) | $ | 65,389 | $ | (1,245 | ) | |||||||
Investing Activities | ||||||||||||||||||||
Purchases of property and equipment | (3,234 | ) | (3,611 | ) | (4,241 | ) | — | (11,086 | ) | |||||||||||
Proceeds from sale of property and equipment | — | 11 | 845 | — | 856 | |||||||||||||||
Proceeds from sale of business | — | 187,552 | — | — | 187,552 | |||||||||||||||
Other long-term assets | 783 | — | 166 | — | 949 | |||||||||||||||
Other | 171,353 | (103,417 | ) | — | (68,083 | ) | (147 | ) | ||||||||||||
Net Cash Provided (Used) for Investing Activities | 168,902 | 80,535 | (3,230 | ) | (68,083 | ) | 178,124 | |||||||||||||
Financing Activities | ||||||||||||||||||||
Proceeds from revolving lines of credit and long-term borrowings | 226,189 | — | 23,935 | — | 250,124 | |||||||||||||||
Payments on revolving lines of credit and long-term borrowings | (431,709 | ) | (476 | ) | — | — | (432,185 | ) | ||||||||||||
Payment of dividends | (1,187 | ) | — | (2,694 | ) | 2,694 | (1,187 | ) | ||||||||||||
Net Cash Provided (Used) by Financing Activities | (206,707 | ) | (476 | ) | 21,241 | 2,694 | (183,248 | ) | ||||||||||||
Effect of exchange rate changes on cash | — | — | 203 | — | 203 | |||||||||||||||
Decrease in cash and cash equivalents | (2,626 | ) | (1,018 | ) | (2,522 | ) | — | (6,166 | ) | |||||||||||
Cash and cash equivalents at beginning of year | 5,774 | 1,018 | 31,999 | — | 38,791 | |||||||||||||||
Cash and cash equivalents at end of period | $ | 3,148 | $ | — | $ | 29,477 | $ | — | $ | 32,625 | ||||||||||
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS | ||||||||||||||||||||
The | Combined | Combined | Eliminations | Total | ||||||||||||||||
Company | Guarantor | Non-Guarantor | ||||||||||||||||||
(Parent) | Subsidiaries | Subsidiaries | ||||||||||||||||||
Nine month period ended September 30, 2012 | (in thousands) | |||||||||||||||||||
Net Cash Provided (Used) by Operating Activities | $ | 18,260 | $ | 5,405 | $ | 7,527 | $ | (4,370 | ) | $ | 26,822 | |||||||||
Investing Activities | ||||||||||||||||||||
Purchases of property and equipment | (1,353 | ) | (7,854 | ) | (5,568 | ) | — | (14,775 | ) | |||||||||||
Proceeds from sale of property and equipment | 18 | 14 | 65 | — | 97 | |||||||||||||||
Other long-term assets | (214 | ) | — | 623 | — | 409 | ||||||||||||||
Other | (158 | ) | (117 | ) | 56 | — | (219 | ) | ||||||||||||
Net Cash Used for Investing Activities | (1,707 | ) | (7,957 | ) | (4,824 | ) | — | (14,488 | ) | |||||||||||
Financing Activities | ||||||||||||||||||||
Proceeds from revolving lines of credit and long-term borrowings | 252,590 | 3,113 | — | — | 255,703 | |||||||||||||||
Payments on revolving lines of credit and long-term borrowings | (266,182 | ) | — | (539 | ) | — | (266,721 | ) | ||||||||||||
Payment of financing costs | (1 | ) | — | — | — | (1 | ) | |||||||||||||
Payment of dividends | (1,183 | ) | — | (4,370 | ) | 4,370 | (1,183 | ) | ||||||||||||
Net Cash Provided (Used) by Financing Activities | (14,776 | ) | 3,113 | (4,909 | ) | 4,370 | (12,202 | ) | ||||||||||||
Effect of exchange rate changes on cash | — | — | 226 | — | 226 | |||||||||||||||
Increase (Decrease) in cash and cash equivalents | 1,777 | 561 | (1,980 | ) | — | 358 | ||||||||||||||
Cash and cash equivalents at beginning of year | 3,642 | 2,104 | 29,178 | — | 34,924 | |||||||||||||||
Cash and cash equivalents at end of period | $ | 5,419 | $ | 2,665 | $ | 27,198 | $ | — | $ | 35,282 | ||||||||||
Accounting_Policies_Details
Accounting Policies (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Significant Accounting Policies [Line Items] | ' | ' | ' | ' |
Share-based Compensation | $2,147 | $2,208 | $4,721 | $5,198 |
Discontinued_Operations_Detail
Discontinued Operations (Details) (USD $) | 9 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Jan. 18, 2013 | Dec. 21, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Aug. 06, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | |
ISG [Member] | ISG [Member] | ISG [Member] | ISG [Member] | ISG [Member] | ISG [Member] | ISG [Member] | Champion [Member] | Champion [Member] | Champion [Member] | Champion [Member] | Champion [Member] | Champion [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Agreement to Sell Operations Date | ' | ' | ' | ' | 21-Dec-12 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Disposal Date | ' | ' | ' | 18-Jan-13 | ' | ' | ' | ' | ' | ' | 6-Aug-13 | ' | ' | ' | ' | ' |
Proceeds from Divestiture of Businesses | ' | ' | ' | ' | ' | ' | ' | $150,800,000 | ' | ' | ' | ' | ' | $45,000,000 | ' | ' |
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal | -82,163,000 | 0 | ' | ' | ' | ' | ' | 59,402,000 | ' | ' | ' | ' | ' | 22,761,000 | ' | ' |
Disposal Group, Expenses Related to Sale of Business | ' | ' | ' | ' | ' | ' | ' | 5,350,000 | ' | ' | ' | ' | ' | 2,130,000 | ' | ' |
Disposal Group, Expenses Related to Sale of Business, cash paid | ' | ' | ' | ' | ' | ' | ' | 3,392,000 | ' | ' | ' | ' | ' | 1,367,000 | ' | ' |
Disposal Group Assets and Liabilities Sold [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Trade receivables, net | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44,196,000 | 3,030,000 | ' | ' | ' | ' | 2,375,000 |
Inventories, net | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,165,000 | 1,689,000 | ' | ' | ' | ' | 1,617,000 |
Other current assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,355,000 | 92,000 | ' | ' | ' | ' | 21,000 |
Property and Equipment, net | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,368,000 | 309,000 | ' | ' | ' | ' | 237,000 |
Goodwill | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,073,000 | 16,277,000 | ' | ' | ' | ' | 16,277,000 |
Assets Held-for-sale, Current | 0 | ' | 103,157,000 | ' | ' | ' | ' | ' | ' | 103,157,000 | ' | ' | ' | ' | ' | ' |
Assets Sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 21,397,000 | ' | ' | ' | ' | 20,527,000 |
Disposal Group, Including Discontinued Operation, Accounts Payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,692,000 | 936,000 | ' | ' | ' | ' | 475,000 |
Disposal Group, Including Discontinued Operation, Accrued Liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,602,000 | 352,000 | ' | ' | ' | ' | 318,000 |
Net Sales from Discontinued Operations | ' | ' | ' | ' | ' | 0 | 85,763,000 | 18,498,000 | 246,433,000 | ' | ' | 2,643,000 | 5,700,000 | 15,857,000 | 17,271,000 | ' |
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax | ' | ' | ' | ' | ' | 0 | 3,894,000 | 402,000 | 10,703,000 | ' | ' | 484,000 | 1,037,000 | 3,156,000 | 3,307,000 | ' |
Liabilities Sold | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,288,000 | ' | ' | ' | ' | 993,000 |
Interest Expense Allocation from Continuing to Discontinuing Operations | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 78,000 | 198,000 | 449,000 | 594,000 | ' |
Disposal Group, Including Discontinued Operation, Accrued Income Taxes Payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,064,000 | 0 | ' | ' | ' | ' | 200,000 |
Liabilities of Assets Held-for-sale | 0 | ' | 23,358,000 | ' | ' | ' | ' | ' | ' | 23,358,000 | ' | ' | ' | ' | ' | ' |
Discontinued Operations, Allocated Goodwill | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $16,205,000 | ' | ' | ' | ' | ' |
Receivables_Narrative_Details
Receivables Narrative (Details) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Dec. 31, 2012 | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Allowance for Doubtful Accounts Receivable | $20,836,000 | $22,213,000 |
Number of Missed Payments before Delinquent | 3 | ' |
Typical Financing Period | '12 months | ' |
Credit amount requiring additional analysis | 250,000 | ' |
Average Period of Adjudication | '18 months | ' |
Installment receivable purchased from DLL | $2,415,000 | ' |
Receivables_Details
Receivables (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' | ' |
Total Installment Receivables | $5,948 | $6,488 | ' |
Installment Receivables, Net of Unearned Interest | 5,878 | 6,417 | ' |
Allowance for doubtful accounts | -3,642 | -3,823 | ' |
Installment receivables, net | 1,560 | 2,188 | ' |
Installment receivables, net, long-term | 676 | 406 | ' |
Installment Receivables [Member] | ' | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' | ' |
Installment Receivables, Current | 3,554 | 4,982 | ' |
Installment Receivables, Long-Term | 2,394 | 1,506 | ' |
Total Installment Receivables | 5,948 | 6,488 | ' |
Unearned Interest, Current | -70 | -71 | ' |
Unearned Interest, Noncurrent | 0 | 0 | ' |
Total Unearned Interest | -70 | -71 | ' |
Installment Receivables Net of Unearned Interest Current | 3,484 | 4,911 | ' |
Installment Receivables Net of Unearned Interest Noncurrent | 2,394 | 1,506 | ' |
Installment Receivables, Net of Unearned Interest | 5,878 | 6,417 | ' |
Allowance for doubtful accounts, current | -1,924 | -2,723 | ' |
Allowance for doubtful accounts, long-term | -1,718 | -1,100 | ' |
Allowance for doubtful accounts | -3,642 | -3,823 | -4,273 |
Installment receivables, net | 1,560 | 2,188 | ' |
Installment receivables, net, long-term | 676 | 406 | ' |
Installment receivables, net | $2,236 | $2,594 | ' |
Receivables_Rollforward_of_All
Receivables Rollforward of Allowance for Doubtful Accounts (Details) (USD $) | 9 Months Ended | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 |
Installment Receivables [Member] | Installment Receivables [Member] | |||
Allowance for Doubtful Accounts [Roll Forward] | ' | ' | ' | ' |
Balance as of January 1 | $3,823 | ' | $3,823 | $4,273 |
Current period provision | 3,160 | 4,252 | 943 | 458 |
Direct write-offs charged against the allowance | ' | ' | -1,124 | -908 |
Balance as of December 31 | $3,642 | ' | $3,642 | $3,823 |
Receivables_Installment_Receiv
Receivables Installment Receivables by Class (Details) (USD $) | 9 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Dec. 31, 2012 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | $5,948 | $6,488 |
Unpaid Principal Balance | 5,878 | 6,417 |
Related Allowance for Doubtful Accounts | 3,642 | 3,823 |
Interest Income Recognized | 76 | 120 |
CANADA | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | 1,438 | 1,980 |
Unpaid Principal Balance | 1,368 | 1,909 |
Related Allowance for Doubtful Accounts | 165 | 458 |
Interest Income Recognized | 76 | 120 |
Impaired Installment Receivables with Related Allowance [Member] | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | 4,675 | 4,966 |
Unpaid Principal Balance | 4,675 | 4,966 |
Related Allowance for Doubtful Accounts | 3,642 | 3,823 |
Interest Income Recognized | 0 | 0 |
Impaired Installment Receivables with Related Allowance [Member] | U.S. | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | 4,510 | 4,508 |
Unpaid Principal Balance | 4,510 | 4,508 |
Related Allowance for Doubtful Accounts | 3,477 | 3,365 |
Interest Income Recognized | 0 | 0 |
Impaired Installment Receivables with Related Allowance [Member] | CANADA | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | 165 | 458 |
Unpaid Principal Balance | 165 | 458 |
Related Allowance for Doubtful Accounts | 165 | 458 |
Interest Income Recognized | 0 | 0 |
Installment Receivables [Member] | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | 1,273 | 1,522 |
Unpaid Principal Balance | 1,203 | 1,451 |
Related Allowance for Doubtful Accounts | 0 | 0 |
Interest Income Recognized | 76 | 120 |
Installment Receivables [Member] | CANADA | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Total Installment Receivables | 1,273 | 1,522 |
Unpaid Principal Balance | 1,203 | 1,451 |
Related Allowance for Doubtful Accounts | 0 | 0 |
Interest Income Recognized | $76 | $120 |
Receivables_Aging_of_Installme
Receivables Aging of Installment Receivables (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Current | $1,218 | $1,467 |
0-30 Days Past Due | 9 | 43 |
31-60 Days Past Due | 6 | 2 |
61-90 Days Past Due | 0 | 0 |
Greater than 90 Days Past Due | 4,715 | 4,976 |
Total Installment Receivables Past Due | 5,948 | 6,488 |
U.S. | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Current | 0 | 0 |
0-30 Days Past Due | 0 | 0 |
31-60 Days Past Due | 0 | 0 |
61-90 Days Past Due | 0 | 0 |
Greater than 90 Days Past Due | 4,510 | 4,508 |
Total Installment Receivables Past Due | 4,510 | 4,508 |
CANADA | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Current | 1,218 | 1,467 |
0-30 Days Past Due | 9 | 43 |
31-60 Days Past Due | 6 | 2 |
61-90 Days Past Due | 0 | 0 |
Greater than 90 Days Past Due | 205 | 468 |
Total Installment Receivables Past Due | $1,438 | $1,980 |
Inventories_Details
Inventories (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Inventory, Net [Abstract] | ' | ' |
Finished goods | $90,422 | $94,675 |
Raw materials | 61,642 | 71,596 |
Work in process | 15,304 | 16,975 |
Inventory, Net | $167,368 | $183,246 |
Other_Current_Assets_Details
Other Current Assets (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Other Current Assets [Abstract] | ' | ' |
Value Added Tax Receivable, Current | $15,004 | $18,002 |
Income Taxes Receivable, Current | 3,457 | 6,192 |
Derivative Assets | 1,311 | 1,062 |
Prepaid Insurance | 300 | 2,241 |
Prepaid Expense and Other Assets, Current | 13,758 | 14,279 |
Other current assets | $33,830 | $41,776 |
Other_LongTerm_Assets_Details
Other Long-Term Assets (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Text Block [Abstract] | ' | ' |
Cash Surrender Value of Life Insurance | $35,772 | $36,375 |
Deferred Finance Costs, Noncurrent, Net | 1,356 | 2,728 |
Long-term Investments | 1,190 | 1,171 |
Installment receivables, net, long-term | 676 | 406 |
Prepaid Expense and Other Assets, Noncurrent | 1,333 | 1,582 |
Other Assets | $40,327 | $42,262 |
Property_And_Equipment_Details
Property And Equipment (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | $475,053 | $479,931 |
Less allowance for depreciation | -366,662 | -361,700 |
Property and Equipment, net | 108,391 | 118,231 |
Machinery and Equipment [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 356,935 | 356,512 |
Land, Buildings and Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 90,234 | 95,047 |
Furniture and Fixtures [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | 12,998 | 13,397 |
Leasehold Improvements [Member] | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, Plant and Equipment, Gross | $14,886 | $14,975 |
Goodwill_Goodwill_Details
Goodwill Goodwill (Details) (Champion [Member], USD $) | Aug. 06, 2013 | Dec. 31, 2012 |
Champion [Member] | ' | ' |
Goodwill [Line Items] | ' | ' |
Goodwill | $16,277,000 | $16,277,000 |
Other_Intangibles_Narrative_De
Other Intangibles Narrative (Details) (USD $) | 9 Months Ended | 9 Months Ended | ||||
Sep. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
Trademarks [Member] | Trademarks [Member] | NA/HME [Member] | Minimum [Member] | Maximum [Member] | ||
Customer Lists [Member] | ||||||
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' | ' | ' | ' |
Indefinite-lived Intangible Assets | ' | $31,299,000 | $31,280,000 | ' | ' | ' |
Finite-Lived Intangible Assets, Useful Life, Minimum | ' | ' | ' | ' | '3 years | '17 years |
Finite Lived Intangible Assets, Useful Life Minimum for Majority of Assets | '10 years | ' | ' | ' | ' | ' |
Finite-Lived Intangible Assets, Average Useful Life | '13 years | ' | ' | ' | ' | ' |
Finite-Lived Intangible Assets, Amortization Expense | 6,937,000 | ' | ' | ' | ' | ' |
Impairment of Intangible Assets, Finite-lived | ' | ' | ' | $167,000 | ' | ' |
Other_Intangibles_Details
Other Intangibles (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Intangible Assets, Gross | $147,379,000 | $151,345,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 82,274,000 | 79,693,000 |
Customer Lists [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Intangible Assets, Gross | 91,344,000 | 93,572,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 61,888,000 | 58,447,000 |
Licensing Agreements [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Intangible Assets, Gross | 1,428,000 | 3,212,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 1,428,000 | 3,212,000 |
Developed Technology Rights [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Intangible Assets, Gross | 9,712,000 | 9,650,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 6,098,000 | 5,588,000 |
Patents [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Intangible Assets, Gross | 6,115,000 | 6,060,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 5,472,000 | 5,234,000 |
Other Intangible Assets [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Intangible Assets, Gross | 7,481,000 | 7,571,000 |
Finite-Lived Intangible Assets, Accumulated Amortization | 7,388,000 | 7,212,000 |
Trademarks [Member] | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Finite-Lived Intangible Assets, Accumulated Amortization | 0 | 0 |
Indefinite-lived Intangible Assets | $31,299,000 | $31,280,000 |
Other_Intangibles_FiniteLived_
Other Intangibles Finite-Lived Intangible Asset Future Amortization Expense (Details) (USD $) | Sep. 30, 2013 |
Finite-Lived Intangible Assets [Line Items] | ' |
Future Amortization Expense, Entire Fiscal Year | $9,182,000 |
Future Amortization Expense, Year One | 8,670,000 |
Future Amortization Expense, Year Two | 7,174,000 |
Future Amortization Expense, Year Three | 5,796,000 |
Future Amortization Expense, Year Four | 2,290,000 |
Future Amortization Expense, Year Five | $2,290,000 |
Current_Liabilities_Details
Current Liabilities (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Payables and Accruals [Abstract] | ' | ' |
Accrued Salaries, Current | $37,480 | $41,813 |
Accrual for Taxes Other than Income Taxes, Current | 23,225 | 24,600 |
Product Warranty Accrual, Current | 25,020 | 21,451 |
Accrued Freight Expense, Current | 7,806 | 7,853 |
Accrued Professional Fees, Current | 7,355 | 7,595 |
Product Liability, Current | 3,572 | 3,323 |
Accrued Rebates, Current | 2,136 | 3,635 |
Accrued Insurance, Current | 2,726 | 2,674 |
Interest Payable, Current | 921 | 1,268 |
Derivative Liabilities, Current | 771 | 1,373 |
Other Employee Related Liabilities, Current | 3,481 | 5,211 |
Other Accrued Liabilities, Current | 15,986 | 14,393 |
Accrued expenses | $130,479 | $135,189 |
Warrany_Costs_Warranty_Schedul
Warrany Costs Warranty Schedule (Details) (USD $) | 9 Months Ended |
Sep. 30, 2013 | |
Accrued Liabilities, Current [Abstract] | ' |
Loss Contingency Accrual, at Carrying Value | $3,800,000 |
Balance as of January 1 | 21,451,000 |
Warranties provided during the period | 7,843,000 |
Settlements made during the period | -8,741,000 |
Changes in liability for pre-existing warranties during the period, including expirations | 4,467,000 |
Balance as of June 30 | $25,020,000 |
LongTerm_Debt_Details
Long-Term Debt (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Debt Instrument [Line Items] | ' | ' |
Long-term Debt | $56,069 | $234,802 |
Long-term Debt, Current Maturities | -1,294 | -5,427 |
Long-term Debt, Excluding Current Maturities | 54,775 | 229,375 |
Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term Debt | 38,968 | 217,494 |
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term Debt | 10,476 | 10,009 |
Notes Payable, Other Payables [Member] | Other Notes and Lease Obligations [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Long-term Debt | $6,625 | $7,299 |
LongTerm_Debt_Line_of_Credit_D
Long-Term Debt Line of Credit (Details) (USD $) | 0 Months Ended | 9 Months Ended | |||||
30-May-13 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | 28-May-13 | Sep. 30, 2013 | 28-May-13 | |
Convertible Subordinated Debt [Member] | Maximum [Member] | Maximum [Member] | Minimum [Member] | Minimum [Member] | |||
Convertible Senior Subordinated Debentures February 2027 [Member] | Line of Credit [Member] | Line of Credit [Member] | Line of Credit [Member] | Line of Credit [Member] | |||
Senior Secured Revolving Credit Facility October 2015 [Member] | Senior Secured Revolving Credit Facility October 2015 [Member] | Senior Secured Revolving Credit Facility October 2015 [Member] | Senior Secured Revolving Credit Facility October 2015 [Member] | ||||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Debt Amendment Date | 30-May-13 | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | $400,000,000 | $250,000,000 | ' | ' | ' | ' | ' |
Line of Credit Facility, Current Borrowing Capacity | ' | 200,000,000 | ' | ' | ' | ' | ' |
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization | ' | ' | ' | 4 | 3.5 | ' | ' |
Ratio of Earnings before Interest Taxes Depreciation and Amortization to Interest Expense | ' | ' | ' | ' | ' | 3 | 3.5 |
Future One-Time Cash Restructuring Charges Added Back to EBITDA | ' | 15,000,000 | ' | ' | ' | ' | ' |
Increase in Basis Points in the Margin Applicable to Determing the Interest Rate on New Debt | 25 | ' | ' | ' | ' | ' | ' |
Increase in Basis Points for Commitment Fees for New Debt | 10 | ' | ' | ' | ' | ' | ' |
Payments of Debt Issuance Costs | ' | 436,000 | ' | ' | ' | ' | ' |
Write off of Deferred Debt Issuance Cost | ' | ' | $1,216,000 | ' | ' | ' | ' |
LongTerm_Debt_Convertible_Debt
Long-Term Debt Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $) | 9 Months Ended | ||
Sep. 30, 2013 | Dec. 31, 2012 | Feb. 17, 2007 | |
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member] | ' | ' | ' |
Debt Instrument [Line Items] | ' | ' | ' |
Debt Instrument, Unamortized Discount | ($2,874,000) | ($3,341,000) | ' |
Principal Amount | ' | ' | $135,000,000 |
Interest Rate | 4.13% | ' | ' |
LongTerm_Debt_Interest_Rate_Sw
Long-Term Debt Interest Rate Swaps (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Derivative [Line Items] | ' | ' |
Long-term Debt, Weighted Average Interest Rate | 2.45% | 2.21% |
Interest Rate Derivative, April 2014, .54% [Member] | Interest Rate Swap [Member] | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount of Interest Rate Derivatives | 12,000,000 | ' |
Derivative, Fixed Interest Rate on LIBOR Component | 0.54% | ' |
Derivative, Effective Aggregate Interest Rate | 3.04% | ' |
LongTerm_Debt_Components_of_Co
Long-Term Debt Components of Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Principal amount of liability component | $13,350 | $13,350 |
Debt Instrument, Unamortized Discount | -2,874 | -3,341 |
Convertible Debt | $10,476 | $10,009 |
Shareholders_Equity_Transactio2
Shareholders' Equity Transactions Narrative (Details) (USD $) | 0 Months Ended | 9 Months Ended | |||
21-May-13 | 16-May-13 | Mar. 27, 2013 | Sep. 30, 2013 | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | '10 years | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | ' | 4,460,337 | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | ' | ' | ' | 756,700 | |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date | 21-May-13 | ' | ' | ' | |
Annual Shareholder Meeting Date | ' | 16-May-13 | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Adoption date | ' | ' | 27-Mar-13 | ' | |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized | ' | ' | ' | $13,264,000 | |
Restricted Stock [Member] | ' | ' | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | '4 years | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | ' | ' | ' | 362,323 | |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized | ' | ' | ' | 4,169,000 | |
Allocated Share-based Compensation Expense | ' | ' | ' | $1,568,000 | |
Stock Options [Member] | ' | ' | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | '4 years | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | ' | ' | ' | 4,460,337 | [1] |
[1] | *Options available for grant as of SeptemberB 30, 2013 reduced by net restricted stock award activity of 793,351. |
Shareholders_Equity_Transactio3
Shareholders' Equity Transactions Options Activity (Details) (USD $) | 9 Months Ended | ||
Sep. 30, 2013 | 16-May-13 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | ' | ' | |
Options outstanding at beginning of period | 4,664,634 | ' | |
Granted | 756,700 | ' | |
Excercised | 0 | ' | |
Canceled | -792,584 | ' | |
Options outstanding at end of period | 4,628,750 | ' | |
Options outstanding at beginning of period Weighted Average Exercise Price | $26.21 | ' | |
Granted Weighted Average Exercise Price | $14.47 | ' | |
Excercised Weighted Average Exercise Price | $0 | ' | |
Canceled Weighted Average Exercise Price | $28.74 | ' | |
Options outstanding at end of period Weighted Average Exercise Price | $23.86 | ' | |
Options exercise price range at end of period, Lower Limit | $12.42 | ' | |
Options exercise price range at end of period, Upper Limit | $47.80 | ' | |
Options exercisable at end of period | 3,070,364 | ' | |
Options available for grant at end of period | ' | 4,460,337 | |
Stock Options [Member] | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | ' | ' | |
Options available for grant at end of period | 4,460,337 | [1] | ' |
Restricted Stock [Member] | ' | ' | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | |
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity | 793,351 | ' | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 114,700 | ' | |
[1] | *Options available for grant as of SeptemberB 30, 2013 reduced by net restricted stock award activity of 793,351. |
Shareholders_Equity_Transactio4
Shareholders' Equity Transactions Stock Options Outstanding by Exercise Price (Details) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Dec. 31, 2012 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | '10 years | ' |
Range of Exercise Price, Lower Limit | $12.42 | ' |
Range of Exercise Price, Upper Limit | $47.80 | ' |
Number Outstanding at end of period | 4,628,750 | ' |
Weighted Average Remaining Contractual Life | '6 years 0 months 13 days | ' |
Weighted Average Exercise Price | $23.86 | $26.21 |
Number Exercisable At end of period | 3,070,364 | ' |
Weighted Average Exercise Price | $27.57 | ' |
Range of Exercise Price 12.42 to 15.00 [Member] | ' | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' |
Range of Exercise Price, Lower Limit | $12.42 | ' |
Range of Exercise Price, Upper Limit | $15 | ' |
Number Outstanding at end of period | 1,354,435 | ' |
Weighted Average Remaining Contractual Life | '9 years 2 months 13 days | ' |
Weighted Average Exercise Price | $13.95 | ' |
Number Exercisable At end of period | 166,045 | ' |
Weighted Average Exercise Price | $13.38 | ' |
Range of Exercise Price 15.01 to 25.00 [Member] | ' | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' |
Range of Exercise Price, Lower Limit | $15.01 | ' |
Range of Exercise Price, Upper Limit | $25 | ' |
Number Outstanding at end of period | 1,613,291 | ' |
Weighted Average Remaining Contractual Life | '5 years 7 months 13 days | ' |
Weighted Average Exercise Price | $22.51 | ' |
Number Exercisable At end of period | 1,364,559 | ' |
Weighted Average Exercise Price | $22.21 | ' |
Range of Exercise Price 25.01 to 35.00 [Member] | ' | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' |
Range of Exercise Price, Lower Limit | $25.01 | ' |
Range of Exercise Price, Upper Limit | $35 | ' |
Number Outstanding at end of period | 950,109 | ' |
Weighted Average Remaining Contractual Life | '5 years 8 months 13 days | ' |
Weighted Average Exercise Price | $25.81 | ' |
Number Exercisable At end of period | 828,846 | ' |
Weighted Average Exercise Price | $25.85 | ' |
Range of Exercise Price 35.01 to 47.80 [Member] | ' | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' | ' |
Range of Exercise Price, Lower Limit | $35.01 | ' |
Range of Exercise Price, Upper Limit | $47.80 | ' |
Number Outstanding at end of period | 710,915 | ' |
Weighted Average Remaining Contractual Life | '1 year 4 months 13 days | ' |
Weighted Average Exercise Price | $43.21 | ' |
Number Exercisable At end of period | 710,914 | ' |
Weighted Average Exercise Price | $43.21 | ' |
Accumulated_Other_Comprehensiv2
Accumulated Other Comprehensive Income (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ' | ' | ' | ' |
Beginning Balance | $104,714 | ' | $112,743 | ' |
OCI before reclassifications | 9,858 | ' | 1,954 | ' |
Amount reclassified from accumulated OCI | 16 | ' | -109 | ' |
Net current-period OCI | 9,874 | 14,518 | 1,845 | -24,673 |
Ending Balance | 114,588 | ' | 114,588 | ' |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Cost of Products Sold | 244,352 | 252,106 | 733,408 | 746,369 |
Interest Expense | -687 | -1,948 | -2,438 | -5,729 |
Tax | -750 | -2,445 | -3,900 | -14,486 |
Accumulated Translation Adjustment [Member] | ' | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ' | ' | ' | ' |
Beginning Balance | 117,817 | ' | 117,465 | ' |
OCI before reclassifications | 17,852 | ' | 18,204 | ' |
Amount reclassified from accumulated OCI | 0 | ' | 0 | ' |
Net current-period OCI | 17,852 | ' | 18,204 | ' |
Ending Balance | 135,669 | ' | 135,669 | ' |
Accumulated Long-Term Notes Adjustment [Member] | ' | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ' | ' | ' | ' |
Beginning Balance | -6,743 | ' | 2,845 | ' |
OCI before reclassifications | -8,062 | ' | -17,650 | ' |
Amount reclassified from accumulated OCI | 0 | ' | 0 | ' |
Net current-period OCI | -8,062 | ' | -17,650 | ' |
Ending Balance | -14,805 | ' | -14,805 | ' |
Accumulated Defined Benefit Plans Adjustment [Member] | ' | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ' | ' | ' | ' |
Beginning Balance | -6,419 | ' | -6,785 | ' |
OCI before reclassifications | 265 | ' | 750 | ' |
Amount reclassified from accumulated OCI | -62 | ' | -181 | ' |
Net current-period OCI | 203 | ' | 569 | ' |
Ending Balance | -6,216 | ' | -6,216 | ' |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Service and interest costs | -64 | ' | -187 | ' |
Tax | 2 | ' | 6 | ' |
Total after tax | -62 | ' | -181 | ' |
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | ' | ' | ' | ' |
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ' | ' | ' | ' |
Beginning Balance | 59 | ' | -782 | ' |
OCI before reclassifications | -197 | ' | 650 | ' |
Amount reclassified from accumulated OCI | 78 | ' | 72 | ' |
Net current-period OCI | -119 | ' | 722 | ' |
Ending Balance | -60 | ' | -60 | ' |
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | ' | ' | ' | ' |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Total before tax | 87 | ' | 96 | ' |
Tax | -9 | ' | -24 | ' |
Total after tax | 78 | ' | 72 | ' |
Foreign Exchange Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | ' | ' | ' | ' |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Net Sales | -54 | ' | -496 | ' |
Commodity Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | ' | ' | ' | ' |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Cost of Products Sold | 128 | ' | 453 | ' |
Interest Rate Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | ' | ' | ' | ' |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract] | ' | ' | ' | ' |
Interest Expense | $13 | ' | $139 | ' |
Charges_Related_To_Restructuri2
Charges Related To Restructuring Activities (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | $5,902,000 | $5,493,000 | $6,993,000 | $6,993,000 | $4,979,000 | $0 |
Restructuring Charges including Inventory Markdowns | 1,884,000 | 2,592,000 | 2,522,000 | 6,998,000 | 11,395,000 | 10,534,000 |
Restructuring Reserve, Settled with Cash | -3,625,000 | -2,183,000 | -4,022,000 | -9,830,000 | -9,381,000 | -5,555,000 |
Restructuring Reserve, Ending Balance | 4,161,000 | 5,902,000 | 5,493,000 | 4,161,000 | 6,993,000 | 4,979,000 |
Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 4,920,000 | 4,546,000 | 5,211,000 | 5,211,000 | 4,905,000 | 0 |
Restructuring Charges including Inventory Markdowns | 1,434,000 | 2,506,000 | 2,436,000 | ' | 6,775,000 | 8,352,000 |
Restructuring Reserve, Settled with Cash | -2,873,000 | -2,132,000 | -3,101,000 | ' | -6,469,000 | -3,447,000 |
Restructuring Reserve, Ending Balance | 3,481,000 | 4,920,000 | 4,546,000 | 3,481,000 | 5,211,000 | 4,905,000 |
Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 151,000 | 151,000 | 0 | 0 |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 491,000 | 277,000 |
Restructuring Reserve, Settled with Cash | 0 | 0 | -151,000 | ' | -340,000 | -277,000 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 151,000 | 0 |
Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 982,000 | 945,000 | 1,625,000 | 1,625,000 | 74,000 | 0 |
Restructuring Charges including Inventory Markdowns | 292,000 | 86,000 | 86,000 | ' | 1,725,000 | 1,788,000 |
Restructuring Reserve, Settled with Cash | -642,000 | -49,000 | -766,000 | ' | -174,000 | -1,714,000 |
Restructuring Reserve, Ending Balance | 632,000 | 982,000 | 945,000 | 632,000 | 1,625,000 | 74,000 |
Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 2,000 | 6,000 | 6,000 | 0 | 0 |
Restructuring Charges including Inventory Markdowns | 158,000 | 0 | 0 | ' | 2,404,000 | 117,000 |
Restructuring Reserve, Settled with Cash | -110,000 | -2,000 | -4,000 | ' | -2,398,000 | -117,000 |
Restructuring Reserve, Ending Balance | 48,000 | 0 | 2,000 | 48,000 | 6,000 | 0 |
NA/HME [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 3,574,000 | 3,421,000 | 3,747,000 | 3,747,000 | 3,092,000 | ' |
Restructuring Charges including Inventory Markdowns | 1,210,000 | 1,948,000 | 1,679,000 | ' | 4,247,000 | 4,759,000 |
Restructuring Reserve, Settled with Cash | -2,014,000 | -1,795,000 | -2,005,000 | ' | -3,592,000 | -1,667,000 |
Restructuring Reserve, Ending Balance | 2,770,000 | 3,574,000 | 3,421,000 | 2,770,000 | 3,747,000 | 3,092,000 |
NA/HME [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 3,574,000 | 3,421,000 | 3,747,000 | 3,747,000 | 3,092,000 | ' |
Restructuring Charges including Inventory Markdowns | 644,000 | 1,948,000 | 1,679,000 | ' | 4,242,000 | 4,755,000 |
Restructuring Reserve, Settled with Cash | -1,624,000 | -1,795,000 | -2,005,000 | ' | -3,587,000 | -1,663,000 |
Restructuring Reserve, Ending Balance | 2,594,000 | 3,574,000 | 3,421,000 | 2,594,000 | 3,747,000 | 3,092,000 |
NA/HME [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 0 |
NA/HME [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 213,000 | 0 | 0 | ' | 5,000 | 0 |
Restructuring Reserve, Settled with Cash | -85,000 | 0 | 0 | ' | -5,000 | 0 |
Restructuring Reserve, Ending Balance | 128,000 | 0 | 0 | 128,000 | 0 | 0 |
NA/HME [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 353,000 | 0 | 0 | ' | 0 | 4,000 |
Restructuring Reserve, Settled with Cash | -305,000 | 0 | 0 | ' | 0 | -4,000 |
Restructuring Reserve, Ending Balance | 48,000 | 0 | 0 | 48,000 | 0 | 0 |
IPG [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 159,000 | 172,000 | 0 | 0 | 71,000 | ' |
Restructuring Charges including Inventory Markdowns | 36,000 | 13,000 | 189,000 | ' | 35,000 | 123,000 |
Restructuring Reserve, Settled with Cash | -52,000 | -26,000 | -17,000 | ' | -106,000 | -52,000 |
Restructuring Reserve, Ending Balance | 143,000 | 159,000 | 172,000 | 143,000 | 0 | 71,000 |
IPG [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 159,000 | 172,000 | 0 | 0 | 71,000 | ' |
Restructuring Charges including Inventory Markdowns | 36,000 | 13,000 | 189,000 | ' | 35,000 | 123,000 |
Restructuring Reserve, Settled with Cash | -52,000 | -26,000 | -17,000 | ' | -106,000 | -52,000 |
Restructuring Reserve, Ending Balance | 143,000 | 159,000 | 172,000 | 143,000 | 0 | 71,000 |
IPG [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 0 |
IPG [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 0 |
IPG [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 0 |
Europe [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 132,000 | 249,000 | 595,000 | 595,000 | 1,816,000 | ' |
Restructuring Charges including Inventory Markdowns | 541,000 | 65,000 | 115,000 | ' | 2,093,000 | 5,466,000 |
Restructuring Reserve, Settled with Cash | 41,000 | -182,000 | -461,000 | ' | -3,314,000 | -3,650,000 |
Restructuring Reserve, Ending Balance | 714,000 | 132,000 | 249,000 | 714,000 | 595,000 | 1,816,000 |
Europe [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 132,000 | 249,000 | 595,000 | 595,000 | 1,742,000 | ' |
Restructuring Charges including Inventory Markdowns | 739,000 | 65,000 | 115,000 | ' | 817,000 | 3,288,000 |
Restructuring Reserve, Settled with Cash | -157,000 | -182,000 | -461,000 | ' | -1,964,000 | -1,546,000 |
Restructuring Reserve, Ending Balance | 714,000 | 132,000 | 249,000 | 714,000 | 595,000 | 1,742,000 |
Europe [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 277,000 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | -277,000 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 0 |
Europe [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 74,000 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 53,000 | 1,788,000 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | -127,000 | -1,714,000 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 74,000 |
Europe [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 0 | 0 | 0 | ' |
Restructuring Charges including Inventory Markdowns | -198,000 | 0 | 0 | ' | 1,223,000 | 113,000 |
Restructuring Reserve, Settled with Cash | 198,000 | 0 | 0 | ' | -1,223,000 | -113,000 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 0 | 0 |
Asia/Pacific [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 2,037,000 | 1,651,000 | 2,651,000 | 2,651,000 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 97,000 | 566,000 | 539,000 | ' | 5,020,000 | 186,000 |
Restructuring Reserve, Settled with Cash | -1,600,000 | -180,000 | -1,539,000 | ' | -2,369,000 | -186,000 |
Restructuring Reserve, Ending Balance | 534,000 | 2,037,000 | 1,651,000 | 534,000 | 2,651,000 | 0 |
Asia/Pacific [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 1,055,000 | 704,000 | 869,000 | 869,000 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 15,000 | 480,000 | 453,000 | ' | 1,681,000 | 186,000 |
Restructuring Reserve, Settled with Cash | -1,040,000 | -129,000 | -618,000 | ' | -812,000 | -186,000 |
Restructuring Reserve, Ending Balance | 30,000 | 1,055,000 | 704,000 | 30,000 | 869,000 | 0 |
Asia/Pacific [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 0 | 151,000 | 151,000 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 491,000 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | -151,000 | ' | -340,000 | 0 |
Restructuring Reserve, Ending Balance | 0 | 0 | 0 | 0 | 151,000 | 0 |
Asia/Pacific [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 982,000 | 945,000 | 1,625,000 | 1,625,000 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 79,000 | 86,000 | 86,000 | ' | 1,667,000 | 0 |
Restructuring Reserve, Settled with Cash | -557,000 | -49,000 | -766,000 | ' | -42,000 | 0 |
Restructuring Reserve, Ending Balance | 504,000 | 982,000 | 945,000 | 504,000 | 1,625,000 | 0 |
Asia/Pacific [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Reserve, Beginning Balance | 0 | 2,000 | 6,000 | 6,000 | 0 | ' |
Restructuring Charges including Inventory Markdowns | 3,000 | 0 | 0 | ' | 1,181,000 | 0 |
Restructuring Reserve, Settled with Cash | -3,000 | -2,000 | -4,000 | ' | -1,175,000 | 0 |
Restructuring Reserve, Ending Balance | $0 | $0 | $2,000 | $0 | $6,000 | $0 |
Charges_Related_To_Restructuri3
Charges Related To Restructuring Activities Narrative (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | $1,884,000 | $2,592,000 | $2,522,000 | $6,998,000 | $11,395,000 | $10,534,000 |
Restructuring Reserve, Settled with Cash | 3,625,000 | 2,183,000 | 4,022,000 | 9,830,000 | 9,381,000 | 5,555,000 |
Restructuring and Related Activities, Expected Payout Period | ' | ' | ' | '12 months | ' | ' |
Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 1,434,000 | 2,506,000 | 2,436,000 | ' | 6,775,000 | 8,352,000 |
Restructuring Reserve, Settled with Cash | 2,873,000 | 2,132,000 | 3,101,000 | ' | 6,469,000 | 3,447,000 |
Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 292,000 | 86,000 | 86,000 | ' | 1,725,000 | 1,788,000 |
Restructuring Reserve, Settled with Cash | 642,000 | 49,000 | 766,000 | ' | 174,000 | 1,714,000 |
Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 491,000 | 277,000 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 151,000 | ' | 340,000 | 277,000 |
Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 158,000 | 0 | 0 | ' | 2,404,000 | 117,000 |
Restructuring Reserve, Settled with Cash | 110,000 | 2,000 | 4,000 | ' | 2,398,000 | 117,000 |
Europe [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 541,000 | 65,000 | 115,000 | ' | 2,093,000 | 5,466,000 |
Restructuring Reserve, Settled with Cash | -41,000 | 182,000 | 461,000 | ' | 3,314,000 | 3,650,000 |
Europe [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 739,000 | 65,000 | 115,000 | ' | 817,000 | 3,288,000 |
Restructuring Reserve, Settled with Cash | 157,000 | 182,000 | 461,000 | ' | 1,964,000 | 1,546,000 |
Europe [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 53,000 | 1,788,000 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 127,000 | 1,714,000 |
Europe [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 277,000 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | 277,000 |
Europe [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | -198,000 | 0 | 0 | ' | 1,223,000 | 113,000 |
Restructuring Reserve, Settled with Cash | -198,000 | 0 | 0 | ' | 1,223,000 | 113,000 |
Asia Pacific [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 97,000 | 566,000 | 539,000 | ' | 5,020,000 | 186,000 |
Restructuring Reserve, Settled with Cash | 1,600,000 | 180,000 | 1,539,000 | ' | 2,369,000 | 186,000 |
Asia Pacific [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 15,000 | 480,000 | 453,000 | ' | 1,681,000 | 186,000 |
Restructuring Reserve, Settled with Cash | 1,040,000 | 129,000 | 618,000 | ' | 812,000 | 186,000 |
Asia Pacific [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 79,000 | 86,000 | 86,000 | ' | 1,667,000 | 0 |
Restructuring Reserve, Settled with Cash | 557,000 | 49,000 | 766,000 | ' | 42,000 | 0 |
Asia Pacific [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 491,000 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 151,000 | ' | 340,000 | 0 |
Asia Pacific [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 3,000 | 0 | 0 | ' | 1,181,000 | 0 |
Restructuring Reserve, Settled with Cash | 3,000 | 2,000 | 4,000 | ' | 1,175,000 | 0 |
NA/HME [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 1,210,000 | 1,948,000 | 1,679,000 | ' | 4,247,000 | 4,759,000 |
Restructuring Reserve, Settled with Cash | 2,014,000 | 1,795,000 | 2,005,000 | ' | 3,592,000 | 1,667,000 |
NA/HME [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 644,000 | 1,948,000 | 1,679,000 | ' | 4,242,000 | 4,755,000 |
Restructuring Reserve, Settled with Cash | 1,624,000 | 1,795,000 | 2,005,000 | ' | 3,587,000 | 1,663,000 |
NA/HME [Member] | Contract Termination [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 213,000 | 0 | 0 | ' | 5,000 | 0 |
Restructuring Reserve, Settled with Cash | 85,000 | 0 | 0 | ' | 5,000 | 0 |
NA/HME [Member] | Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | 0 | 0 |
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | 0 | 0 |
NA/HME [Member] | Other [Member] | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' |
Restructuring Charges including Inventory Markdowns | 353,000 | 0 | 0 | ' | 0 | 4,000 |
Restructuring Reserve, Settled with Cash | $305,000 | $0 | $0 | ' | $0 | $4,000 |
Income_Taxes_Narrative_Details
Income Taxes (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Income Tax Disclosure [Abstract] | ' | ' | ' | ' |
Effective Income Tax Rate, Continuing Operations | 16.20% | 81.30% | 12.30% | 97.50% |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate | ' | ' | 35.00% | 35.00% |
Liability for Uncertain Tax Positions, Noncurrent | $3,143,000 | $9,173,000 | $3,143,000 | $9,173,000 |
Income Tax Examination, Foreign Tax Expense (Benefit), Per Share | ' | ' | ' | $0.29 |
Income Tax Examination, Penalties and Interest Accrued | ' | $3,178,000 | ' | $3,178,000 |
Net_Earnings_Loss_Per_Common_S2
Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Basic | ' | ' | ' | ' |
Average common shares outstanding | 31,902 | 31,877 | 31,902 | 31,838 |
Net Earnings (loss) | $16,102 | $2,864 | $38,821 | $9,120 |
Net earnings (loss) per common share | $0.50 | $0.09 | $1.21 | $0.28 |
Income (Loss) from Continuing Operations Attributable to Parent | -5,383 | 563 | -35,580 | 374 |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | 21,485 | 2,301 | 74,401 | 8,746 |
Income (Loss) from Continuing Operations, Per Basic Share | ($0.17) | $0.02 | ($1.12) | $0.01 |
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share | $0.67 | $0.07 | $2.33 | $0.27 |
Diluted | ' | ' | ' | ' |
Average common shares outstanding | 31,902 | 31,877 | 31,902 | 31,838 |
Shares related to convertible debt | 0 | 0 | 0 | 0 |
Stock options and awards | 164 | 24 | 107 | 9 |
Average common shares assuming dilution | 32,066 | 31,901 | 32,009 | 31,847 |
Net Earnings (loss) | $16,102 | $2,864 | $38,821 | $9,120 |
Net Earnings (loss) per Share - Assuming Dilution | $0.50 | $0.09 | $1.20 | $0.28 |
Income (Loss) from Continuing Operations, Per Diluted Share | ($0.17) | $0.02 | ($1.12) | $0.01 |
Income (Loss) from Discontinued Operations, Net of Tax, Per Diluted Share | $0.67 | $0.07 | $2.32 | $0.27 |
Net_Earnings_Loss_Per_Common_S3
Net Earnings (Loss) Per Common Share Textuals (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Earnings Per Share [Abstract] | ' | ' | ' | ' |
Antidilutive securities excluded from computation of earnings per share, amount | 4,375,829 | 4,639,809 | 4,406,045 | 4,679,093 |
Antidilutive Share Granted, Average Exercise Price | $41.87 | $41.87 | $41.87 | $41.87 |
Fair value stock price | $15.88 | $14.74 | $15.04 | $15.55 |
Concentration_Of_Credit_Risk_D
Concentration Of Credit Risk (Details) (USD $) | Sep. 30, 2013 |
Concentration Risk [Line Items] | ' |
Retained Recourse Obligation For Events Of Default Under Contracts | $7,074,000 |
Events of Default Under Contract by Third Party | $50,570,000 |
Derivatives_Notional_Amounts_D
Derivatives Notional Amounts (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | ||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | |
Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Minimum [Member] | Maximum [Member] | |
Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | |||||||
EUR / AUD [Member] | EUR / AUD [Member] | EUR / CAD [Member] | EUR / CAD [Member] | EUR / DKK [Member] | EUR / DKK [Member] | AUD / EUR [Member] | AUD / EUR [Member] | AUD / GBP [Member] | AUD / GBP [Member] | AUD / CAD [Member] | AUD / CAD [Member] | EUR / NZD [Member] | EUR / NZD [Member] | AUD / NZD [Member] | AUD / NZD [Member] | EUR / NOK [Member] | EUR / NOK [Member] | DKK / SEK [Member] | DKK / SEK [Member] | EUR / CAD [Member] | EUR / CAD [Member] | EUR / CHF [Member] | EUR / CHF [Member] | EUR / GBP [Member] | EUR / GBP [Member] | EUR / SEK [Member] | EUR / SEK [Member] | EUR / NZD [Member] | EUR / NZD [Member] | GBP / CHF [Member] | GBP / CHF [Member] | GBP / SEK [Member] | GBP / SEK [Member] | NOK / CHF [Member] | NOK / CHF [Member] | |||||||||||||||||||||||||||||||||||||||||||||
Derivative [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative, Percentage of Forcasted Transactions With Currency Rate Exposure | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 60.00% | 90.00% |
Notional Amount of Derivatives, Matured During Period | $51,251,000 | $50,244,000 | $131,923,000 | $134,402,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Notional Amount | ' | ' | ' | ' | 53,104,000 | 23,782,000 | 0 | 1,908,000 | 0 | 239,000 | 0 | -11,203,000 | 1,788,000 | 0 | 298,000 | 0 | 4,840,000 | 14,801,000 | 12,273,000 | 9,906,000 | 6,361,000 | 0 | 4,486,000 | 0 | 2,161,000 | 3,146,000 | 878,000 | 3,056,000 | 0 | 90,000 | 0 | 785,000 | 13,517,000 | 0 | 0 | 1,048,000 | 0 | 6,000 | 6,502,000 | 0 | 49,333,000 | 108,408,000 | 1,051,000 | 6,397,000 | 579,000 | 0 | 10,330,000 | 17,620,000 | 3,320,000 | 0 | 232,000 | 0 | 14,433,000 | 59,510,000 | 692,000 | 2,519,000 | 465,000 | 0 | 3,499,000 | 0 | 2,846,000 | 6,954,000 | 450,000 | 0 | 1,555,000 | 0 | 5,389,000 | 2,077,000 | 415,000 | 0 | 1,748,000 | 5,749,000 | 304,000 | 0 | 1,099,000 | 4,154,000 | 926,000 | 3,428,000 | ' | ' |
Unrealized Gain (Loss) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -55,000 | -540,000 | -9,000 | -47,000 | 46,000 | 0 | -85,000 | -6,000 | 55,000 | 0 | 7,000 | 0 | -368,000 | -797,000 | 22,000 | -3,000 | 4,000 | 0 | 115,000 | 0 | 11,000 | 141,000 | 12,000 | 0 | 17,000 | 0 | -40,000 | 46,000 | 25,000 | 0 | 23,000 | 105,000 | -8,000 | 0 | 52,000 | 25,000 | 66,000 | -4,000 | ' | ' |
Amount of Gain (Loss) Recognized in Income on Derivatives | $361,000 | $569,000 | $617,000 | $551,000 | $617,000 | $551,000 | $0 | $5,000 | $0 | ($15,000) | $0 | ($27,000) | $248,000 | $0 | $38,000 | $0 | $4,000 | $434,000 | $166,000 | $134,000 | $67,000 | $0 | $12,000 | $0 | ($8,000) | $40,000 | ($4,000) | ($38,000) | $0 | ($10,000) | $0 | $13,000 | $62,000 | $0 | $0 | $15,000 | $0 | $0 | $32,000 | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivatives_Balance_Sheet_Loca
Derivatives Balance Sheet Location (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 |
Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | |||
Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | Designated as Hedging Instrument [Member] | |||||||
Derivatives, Fair Value [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Notional Amount of Derivatives, Matured During Period | ' | ' | $51,251,000 | $50,244,000 | $131,923,000 | $134,402,000 | ' | ' | ' | ' | ' | ' |
Derivative Assets | 1,311,000 | 1,062,000 | ' | ' | ' | ' | 626,000 | 375,000 | 685,000 | 687,000 | 0 | 0 |
Liabilities | $771,000 | $1,373,000 | ' | ' | ' | ' | $681,000 | $915,000 | $68,000 | $142,000 | $22,000 | $316,000 |
Derivatives_Gain_Loss_in_State
Derivatives Gain (Loss) in Statement of Finacial Position (Details) (USD $) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2011 | |
Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Sales [Member] | Cost of Sales [Member] | Cost of Sales [Member] | Cost of Sales [Member] | Cost of Sales [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Interest Rate Swap [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | EUR / AUD [Member] | EUR / AUD [Member] | EUR / NOK [Member] | EUR / NOK [Member] | |
Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Selling General and Administrative Expense [Member] | Selling General and Administrative Expense [Member] | Selling General and Administrative Expense [Member] | Selling General and Administrative Expense [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | Not Designated as Hedging Instrument [Member] | |||||||||||||||||
Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | Foreign Exchange Forward [Member] | |||||||||||||||||||||||||||||||||||
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) | ($174,000) | ($2,525,000) | $938,000 | ($3,055,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($207,000) | ($2,522,000) | $505,000 | ($2,956,000) | ' | ' | ' | ' | $33,000 | ($3,000) | $433,000 | ($99,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) | 70,000 | 1,241,000 | -159,000 | 2,706,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 83,000 | 1,241,000 | -20,000 | 2,706,000 | ' | ' | ' | ' | -13,000 | 0 | -139,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative Instruments, Gain (Loss) Recognized in Income | ' | ' | ' | ' | 54,000 | -146,000 | 496,000 | 49,000 | ' | 1,487,000 | ' | 2,804,000 | ' | ' | ' | ' | ' | ' | ' | ' | 361,000 | ' | 617,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing) | 2,000 | -38,000 | 37,000 | -9,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000 | -38,000 | 37,000 | -9,000 | ' | ' | ' | ' | 0 | 0 | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amount of Gain (Loss) Recognized in Income on Derivatives | -74,000 | 1,341,000 | 43,000 | 2,853,000 | ' | ' | ' | ' | ' | ' | ' | ' | 361,000 | 569,000 | 617,000 | 551,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 617,000 | 551,000 | 0 | 5,000 | 0 | 0 |
Derivative Instruments, Gain (Loss) Recognized in Income | ' | ' | ' | ' | ' | ' | ' | ' | ($128,000) | ' | ($453,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $569,000 | ' | $551,000 | ' | ' | ' | ' | ($23,000) | ($147,000) | ($328,000) | ($419,000) | ' | ' | ' | ' | ' | ' |
Fair_Values_of_Financial_Instr1
Fair Values of Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (Fair Value, Measurements, Recurring [Member], USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Foreign Currency Contract, Asset, Fair Value Disclosure | $562 | $5 |
Interest Rate Derivative Liabilities, at Fair Value | -22 | -316 |
Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 |
Interest Rate Derivative Liabilities, at Fair Value | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Foreign Currency Contract, Asset, Fair Value Disclosure | 562 | 5 |
Interest Rate Derivative Liabilities, at Fair Value | -22 | -316 |
Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 |
Interest Rate Derivative Liabilities, at Fair Value | $0 | $0 |
Fair_Values_of_Financial_Instr2
Fair Values of Financial Instruments Details of Book Value and Fair Value of Financial Instruments (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | ||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Cash and Cash Equivalents, at Carrying Value | $32,625 | $38,791 | $35,282 | $34,924 |
Installment receivables, net | 1,560 | 2,188 | ' | ' |
Other current assets | 33,830 | 41,776 | ' | ' |
Cash and Cash Equivalents [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Cash and Cash Equivalents, at Carrying Value | 32,625 | 38,791 | ' | ' |
Cash and Cash Equivalents [Member] | Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Cash and Cash Equivalents | 32,625 | 38,791 | ' | ' |
Other Assets [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Other Investments | 1,190 | 1,171 | ' | ' |
Other Assets [Member] | Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Other Investments | 1,190 | 1,171 | ' | ' |
Accounts and Notes Receivable, Net [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Installment receivables, net | 2,236 | 2,594 | ' | ' |
Accounts and Notes Receivable, Net [Member] | Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Installment receivables, net | 2,236 | 2,594 | ' | ' |
Debt [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Long-term debt (including current maturities of long-term debt) | -56,069 | -234,802 | ' | ' |
Debt [Member] | Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Long-term debt (including current maturities of long-term debt) | -56,115 | -234,072 | ' | ' |
Foreign Exchange Forward [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Other current assets | 1,311 | 1,062 | ' | ' |
Accrued Expenses | -749 | -1,057 | ' | ' |
Foreign Exchange Forward [Member] | Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Other current assets | 1,311 | 1,062 | ' | ' |
Accrued Expenses | -749 | -1,057 | ' | ' |
Interest Rate Swap [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Accrued Expenses | -22 | -316 | ' | ' |
Interest Rate Swap [Member] | Estimate of Fair Value, Fair Value Disclosure [Member] | ' | ' | ' | ' |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' |
Accrued Expenses | ($22) | ($316) | ' | ' |
Business_Segments_Information_
Business Segments (Information by Segment) (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | |||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | $1,884,000 | $2,592,000 | $2,522,000 | ' | $6,998,000 | ' | $11,395,000 | $10,534,000 | ' | ||||
Revenue from external customers | 341,176,000 | ' | ' | 361,518,000 | 1,017,373,000 | 1,077,767,000 | ' | ' | ' | ||||
Intersegment revenues | 30,056,000 | ' | ' | 37,730,000 | 89,551,000 | 123,081,000 | ' | ' | ' | ||||
Restructuring Charges | 1,884,000 | ' | ' | 1,175,000 | 6,998,000 | 3,742,000 | ' | ' | ' | ||||
Earnings (loss) before income taxes | -4,633,000 | ' | ' | 3,008,000 | -31,680,000 | 14,860,000 | ' | ' | ' | ||||
Restructuring Reserve, Settled with Cash | -3,625,000 | -2,183,000 | -4,022,000 | ' | -9,830,000 | ' | -9,381,000 | -5,555,000 | ' | ||||
Restructuring Reserve | 4,161,000 | 5,902,000 | 5,493,000 | ' | 4,161,000 | ' | 6,993,000 | 4,979,000 | 0 | ||||
North America/HME [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Revenue from external customers | 151,052,000 | ' | ' | 170,701,000 | 462,261,000 | 527,103,000 | ' | ' | ' | ||||
Intersegment revenues | 20,501,000 | ' | ' | 24,813,000 | 59,735,000 | 81,985,000 | ' | ' | ' | ||||
Restructuring Charges | 1,210,000 | ' | ' | 352,000 | 4,837,000 | 2,214,000 | ' | ' | ' | ||||
Earnings (loss) before income taxes | -10,191,000 | ' | ' | -28,000 | -33,593,000 | 8,086,000 | ' | ' | ' | ||||
Institutional Products Group [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Revenue from external customers | 28,083,000 | ' | ' | 33,557,000 | 87,135,000 | 95,726,000 | ' | ' | ' | ||||
Intersegment revenues | 1,254,000 | ' | ' | 1,941,000 | 4,243,000 | 5,471,000 | ' | ' | ' | ||||
Restructuring Charges | 36,000 | ' | ' | 0 | 237,000 | 35,000 | ' | ' | ' | ||||
Earnings (loss) before income taxes | 1,009,000 | ' | ' | 579,000 | 1,955,000 | 4,820,000 | ' | ' | ' | ||||
Europe [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 541,000 | 65,000 | 115,000 | ' | ' | ' | 2,093,000 | 5,466,000 | ' | ||||
Revenue from external customers | 150,265,000 | ' | ' | 141,705,000 | 429,650,000 | 401,721,000 | ' | ' | ' | ||||
Intersegment revenues | 1,890,000 | ' | ' | 3,239,000 | 6,156,000 | 8,448,000 | ' | ' | ' | ||||
Restructuring Charges | 542,000 | ' | ' | 481,000 | 722,000 | 772,000 | ' | ' | ' | ||||
Earnings (loss) before income taxes | 13,136,000 | ' | ' | 10,218,000 | 27,344,000 | 23,504,000 | ' | ' | ' | ||||
Restructuring Reserve, Settled with Cash | 41,000 | -182,000 | -461,000 | ' | ' | ' | -3,314,000 | -3,650,000 | ' | ||||
Restructuring Reserve | 714,000 | 132,000 | 249,000 | ' | 714,000 | ' | 595,000 | 1,816,000 | ' | ||||
Asia Pacific [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 97,000 | 566,000 | 539,000 | ' | ' | ' | 5,020,000 | 186,000 | ' | ||||
Revenue from external customers | 11,776,000 | ' | ' | 15,555,000 | 38,327,000 | 53,217,000 | ' | ' | ' | ||||
Intersegment revenues | 6,411,000 | ' | ' | 7,737,000 | 19,417,000 | 27,177,000 | ' | ' | ' | ||||
Restructuring Charges | 96,000 | ' | ' | 342,000 | 1,202,000 | 721,000 | ' | ' | ' | ||||
Earnings (loss) before income taxes | -2,233,000 | ' | ' | -2,301,000 | -9,871,000 | -4,139,000 | ' | ' | ' | ||||
Restructuring Reserve, Settled with Cash | -1,600,000 | -180,000 | -1,539,000 | ' | ' | ' | -2,369,000 | -186,000 | ' | ||||
Restructuring Reserve | 534,000 | 2,037,000 | 1,651,000 | ' | 534,000 | ' | 2,651,000 | 0 | ' | ||||
All Other Segments [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Earnings (loss) before income taxes | -6,354,000 | [1] | ' | ' | -5,460,000 | [1] | -17,515,000 | [1] | -17,411,000 | [1] | ' | ' | ' |
NA/HME [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 1,210,000 | 1,948,000 | 1,679,000 | ' | ' | ' | 4,247,000 | 4,759,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -2,014,000 | -1,795,000 | -2,005,000 | ' | ' | ' | -3,592,000 | -1,667,000 | ' | ||||
Restructuring Reserve | 2,770,000 | 3,574,000 | 3,421,000 | ' | 2,770,000 | ' | 3,747,000 | 3,092,000 | ' | ||||
IPG [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 36,000 | 13,000 | 189,000 | ' | ' | ' | 35,000 | 123,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -52,000 | -26,000 | -17,000 | ' | ' | ' | -106,000 | -52,000 | ' | ||||
Restructuring Reserve | 143,000 | 159,000 | 172,000 | ' | 143,000 | ' | 0 | 71,000 | ' | ||||
Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 1,434,000 | 2,506,000 | 2,436,000 | ' | ' | ' | 6,775,000 | 8,352,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -2,873,000 | -2,132,000 | -3,101,000 | ' | ' | ' | -6,469,000 | -3,447,000 | ' | ||||
Restructuring Reserve | 3,481,000 | 4,920,000 | 4,546,000 | ' | 3,481,000 | ' | 5,211,000 | 4,905,000 | 0 | ||||
Severance [Member] | Europe [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 739,000 | 65,000 | 115,000 | ' | ' | ' | 817,000 | 3,288,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -157,000 | -182,000 | -461,000 | ' | ' | ' | -1,964,000 | -1,546,000 | ' | ||||
Restructuring Reserve | 714,000 | 132,000 | 249,000 | ' | 714,000 | ' | 595,000 | 1,742,000 | ' | ||||
Severance [Member] | Asia Pacific [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 15,000 | 480,000 | 453,000 | ' | ' | ' | 1,681,000 | 186,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -1,040,000 | -129,000 | -618,000 | ' | ' | ' | -812,000 | -186,000 | ' | ||||
Restructuring Reserve | 30,000 | 1,055,000 | 704,000 | ' | 30,000 | ' | 869,000 | 0 | ' | ||||
Severance [Member] | NA/HME [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 644,000 | 1,948,000 | 1,679,000 | ' | ' | ' | 4,242,000 | 4,755,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -1,624,000 | -1,795,000 | -2,005,000 | ' | ' | ' | -3,587,000 | -1,663,000 | ' | ||||
Restructuring Reserve | 2,594,000 | 3,574,000 | 3,421,000 | ' | 2,594,000 | ' | 3,747,000 | 3,092,000 | ' | ||||
Severance [Member] | IPG [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 36,000 | 13,000 | 189,000 | ' | ' | ' | 35,000 | 123,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -52,000 | -26,000 | -17,000 | ' | ' | ' | -106,000 | -52,000 | ' | ||||
Restructuring Reserve | 143,000 | 159,000 | 172,000 | ' | 143,000 | ' | 0 | 71,000 | ' | ||||
Product Line Discontinuance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 491,000 | 277,000 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | -151,000 | ' | ' | ' | -340,000 | -277,000 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 151,000 | 0 | 0 | ||||
Product Line Discontinuance [Member] | Europe [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 0 | 277,000 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | ' | ' | 0 | -277,000 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 0 | 0 | ' | ||||
Product Line Discontinuance [Member] | Asia Pacific [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 491,000 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | -151,000 | ' | ' | ' | -340,000 | 0 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 151,000 | 0 | ' | ||||
Product Line Discontinuance [Member] | NA/HME [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 0 | 0 | ' | ||||
Product Line Discontinuance [Member] | IPG [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 0 | 0 | ' | ||||
Contract Termination [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 292,000 | 86,000 | 86,000 | ' | ' | ' | 1,725,000 | 1,788,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -642,000 | -49,000 | -766,000 | ' | ' | ' | -174,000 | -1,714,000 | ' | ||||
Restructuring Reserve | 632,000 | 982,000 | 945,000 | ' | 632,000 | ' | 1,625,000 | 74,000 | 0 | ||||
Contract Termination [Member] | Europe [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 53,000 | 1,788,000 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | ' | ' | -127,000 | -1,714,000 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 0 | 74,000 | ' | ||||
Contract Termination [Member] | Asia Pacific [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 79,000 | 86,000 | 86,000 | ' | ' | ' | 1,667,000 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | -557,000 | -49,000 | -766,000 | ' | ' | ' | -42,000 | 0 | ' | ||||
Restructuring Reserve | 504,000 | 982,000 | 945,000 | ' | 504,000 | ' | 1,625,000 | 0 | ' | ||||
Contract Termination [Member] | NA/HME [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 213,000 | 0 | 0 | ' | ' | ' | 5,000 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | -85,000 | 0 | 0 | ' | ' | ' | -5,000 | 0 | ' | ||||
Restructuring Reserve | 128,000 | 0 | 0 | ' | 128,000 | ' | 0 | 0 | ' | ||||
Contract Termination [Member] | IPG [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 0 | 0 | ' | ||||
Other [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 158,000 | 0 | 0 | ' | ' | ' | 2,404,000 | 117,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -110,000 | -2,000 | -4,000 | ' | ' | ' | -2,398,000 | -117,000 | ' | ||||
Restructuring Reserve | 48,000 | 0 | 2,000 | ' | 48,000 | ' | 6,000 | 0 | 0 | ||||
Other [Member] | Europe [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | -198,000 | 0 | 0 | ' | ' | ' | 1,223,000 | 113,000 | ' | ||||
Restructuring Reserve, Settled with Cash | 198,000 | 0 | 0 | ' | ' | ' | -1,223,000 | -113,000 | ' | ||||
Restructuring Reserve | 0 | 0 | 0 | ' | 0 | ' | 0 | 0 | ' | ||||
Other [Member] | Asia Pacific [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 3,000 | 0 | 0 | ' | ' | ' | 1,181,000 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | -3,000 | -2,000 | -4,000 | ' | ' | ' | -1,175,000 | 0 | ' | ||||
Restructuring Reserve | 0 | 0 | 2,000 | ' | 0 | ' | 6,000 | 0 | ' | ||||
Other [Member] | NA/HME [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 353,000 | 0 | 0 | ' | ' | ' | 0 | 4,000 | ' | ||||
Restructuring Reserve, Settled with Cash | -305,000 | 0 | 0 | ' | ' | ' | 0 | -4,000 | ' | ||||
Restructuring Reserve | 48,000 | 0 | 0 | ' | 48,000 | ' | 0 | 0 | ' | ||||
Other [Member] | IPG [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Restructuring Charges including Inventory Markdowns | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve, Settled with Cash | 0 | 0 | 0 | ' | ' | ' | 0 | 0 | ' | ||||
Restructuring Reserve | $0 | $0 | $0 | ' | $0 | ' | $0 | $0 | ' | ||||
[1] | Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. In addition, the bAll Otherb earnings (loss) before income taxes includes loss on debt extinguishment including debt finance charges, interest and fees. |
Contingencies_Contingencies_De
Contingencies Contingencies (Details) (USD $) | 0 Months Ended | |
Dec. 21, 2012 | Sep. 30, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' | ' |
Consent Decree Court Approval Date | 21-Dec-12 | ' |
Loss Contingency Accrual, at Carrying Value | ' | $3,800,000 |
Supplemental_Guarantor_Informa2
Supplemental Guarantor Information Consolidating Condensed Statements of Operations (Details) (USD $) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Feb. 17, 2007 | |
The Company (Parent) [Member] | The Company (Parent) [Member] | The Company (Parent) [Member] | The Company (Parent) [Member] | Combined Guarantor Subsidiaries [Member] | Combined Guarantor Subsidiaries [Member] | Combined Guarantor Subsidiaries [Member] | Combined Guarantor Subsidiaries [Member] | Combined Non-Guarantor Subsidiaries [Member] | Combined Non-Guarantor Subsidiaries [Member] | Combined Non-Guarantor Subsidiaries [Member] | Combined Non-Guarantor Subsidiaries [Member] | Eliminations [Member] | Eliminations [Member] | Eliminations [Member] | Eliminations [Member] | Convertible Senior Subordinated Debentures February 2027 [Member] | Convertible Senior Subordinated Debentures February 2027 [Member] | |||||
Convertible Subordinated Debt [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||
Condensed Financial Statements, Captions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net sales | $341,176,000 | $361,518,000 | $1,017,373,000 | $1,077,767,000 | $60,641,000 | $90,406,000 | $186,453,000 | $275,742,000 | $119,548,000 | $116,339,000 | $364,005,000 | $355,378,000 | $184,299,000 | $183,801,000 | $535,805,000 | $540,535,000 | ($23,312,000) | ($29,028,000) | ($68,890,000) | ($93,888,000) | ' | ' |
Interest Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4.13% | ' |
Debt Instrument, Face Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 135,000,000 |
Cost of Goods Sold | 244,352,000 | 252,106,000 | 733,408,000 | 746,369,000 | 52,454,000 | 70,600,000 | 159,884,000 | 211,115,000 | 86,978,000 | 83,685,000 | 264,501,000 | 256,854,000 | 128,232,000 | 126,852,000 | 378,287,000 | 371,855,000 | -23,312,000 | -29,031,000 | -69,264,000 | -93,455,000 | ' | ' |
Gross Profit | 96,824,000 | 109,412,000 | 283,965,000 | 331,398,000 | 8,187,000 | 19,806,000 | 26,569,000 | 64,627,000 | 32,570,000 | 32,654,000 | 99,504,000 | 98,524,000 | 56,067,000 | 56,949,000 | 157,518,000 | 168,680,000 | 0 | 3,000 | 374,000 | -433,000 | ' | ' |
Selling, general and administrative expense | 98,719,000 | 103,281,000 | 306,042,000 | 306,755,000 | 29,046,000 | 33,712,000 | 99,338,000 | 99,736,000 | 25,363,000 | 20,356,000 | 72,370,000 | 64,452,000 | 44,310,000 | 45,492,000 | 131,640,000 | 138,207,000 | 0 | 3,721,000 | 2,694,000 | 4,360,000 | ' | ' |
Restructuring Charges | 1,884,000 | 1,175,000 | 6,998,000 | 3,742,000 | 1,597,000 | 334,000 | 5,078,000 | 2,085,000 | 36,000 | 18,000 | 49,000 | 39,000 | 251,000 | 823,000 | 1,871,000 | 1,618,000 | 0 | 0 | 0 | 0 | ' | ' |
Loss on debt extinguishment including debt finance charges and associated fees | 0 | 0 | 0 | 312,000 | ' | 0 | ' | 312,000 | ' | 0 | ' | 0 | ' | 0 | ' | 0 | ' | 0 | ' | 0 | ' | ' |
Asset Impairment Charges | 167,000 | 0 | 167,000 | 0 | 0 | ' | 0 | ' | 167,000 | ' | ' | ' | 0 | ' | 0 | ' | 0 | ' | 0 | ' | ' | ' |
Payment of Financing Costs | ' | ' | 0 | -1,000 | ' | ' | ' | -1,000 | ' | ' | ' | 0 | ' | ' | ' | 0 | ' | ' | ' | 0 | ' | ' |
Income (Loss) from Equity Method Investments | 0 | 0 | 0 | 0 | 32,513,000 | 17,302,000 | 105,501,000 | 45,175,000 | 8,935,000 | -4,264,000 | 21,472,000 | 1,954,000 | 22,000 | 228,000 | -93,000 | 391,000 | -41,470,000 | -13,266,000 | -126,880,000 | -47,520,000 | ' | ' |
Interest Income (Expense), Net | 687,000 | 1,948,000 | 2,438,000 | 5,729,000 | -603,000 | -1,024,000 | -1,418,000 | -3,041,000 | 1,213,000 | 2,201,000 | 3,141,000 | 6,396,000 | 77,000 | 771,000 | 715,000 | 2,374,000 | 0 | 0 | 0 | 0 | ' | ' |
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest | -4,633,000 | 3,008,000 | -31,680,000 | 14,860,000 | 10,660,000 | 4,086,000 | 29,072,000 | 10,710,000 | 14,726,000 | 5,815,000 | 45,249,000 | 29,591,000 | 11,451,000 | 10,091,000 | 23,199,000 | 26,872,000 | -41,470,000 | -16,984,000 | -129,200,000 | -52,313,000 | ' | ' |
Income Tax Expense (Benefit) | 750,000 | 2,445,000 | 3,900,000 | 14,486,000 | -5,442,000 | 1,222,000 | -9,749,000 | 1,590,000 | 0 | -3,028,000 | 0 | -5,164,000 | 6,192,000 | 4,251,000 | 13,649,000 | 18,060,000 | 0 | 0 | 0 | 0 | ' | ' |
Income (Loss) from Continuing Operations Attributable to Parent | -5,383,000 | 563,000 | -35,580,000 | 374,000 | 16,102,000 | 2,864,000 | 38,821,000 | 9,120,000 | 14,726,000 | 8,843,000 | 45,249,000 | 34,755,000 | 5,259,000 | 5,840,000 | 9,550,000 | 8,812,000 | -41,470,000 | -16,984,000 | -129,200,000 | -52,313,000 | ' | ' |
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | 21,485,000 | 2,301,000 | 74,401,000 | 8,746,000 | 0 | 0 | 0 | 0 | 21,485,000 | 2,301,000 | 74,401,000 | 8,746,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ' | ' |
Net Earnings (loss) | 16,102,000 | 2,864,000 | 38,821,000 | 9,120,000 | 16,102,000 | 2,864,000 | 38,821,000 | 9,120,000 | 36,211,000 | 11,144,000 | 119,650,000 | 43,501,000 | 5,259,000 | 5,840,000 | 9,550,000 | 8,812,000 | -41,470,000 | -16,984,000 | -129,200,000 | -52,313,000 | ' | ' |
Other Comprehensive Income (Loss), Net of Tax | 9,874,000 | 14,518,000 | 1,845,000 | -24,673,000 | 9,874,000 | 14,518,000 | 1,845,000 | -24,673,000 | 220,000 | 3,164,000 | -415,000 | 3,179,000 | 10,135,000 | 11,412,000 | 2,228,000 | -27,878,000 | -10,355,000 | -14,576,000 | -1,813,000 | 24,699,000 | ' | ' |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $25,976,000 | $17,382,000 | $40,666,000 | ($15,553,000) | $25,976,000 | $17,382,000 | $40,666,000 | ($15,553,000) | $36,431,000 | $14,308,000 | $119,235,000 | $46,680,000 | $15,394,000 | $17,252,000 | $11,778,000 | ($19,066,000) | ($51,825,000) | ($31,560,000) | ($131,013,000) | ($27,614,000) | ' | ' |
Supplemental_Guarantor_Informa3
Supplemental Guarantor Information Consolidating Condensed Balance Sheets (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2011 |
In Thousands, unless otherwise specified | ||||
Current Assets | ' | ' | ' | ' |
Cash and cash equivalents | $32,625 | $38,791 | $35,282 | $34,924 |
Trade receivables, net | 191,464 | 198,791 | ' | ' |
Installment receivables, net | 1,560 | 2,188 | ' | ' |
Inventories, net | 167,368 | 183,246 | ' | ' |
Due from Affiliate, Current | 0 | 0 | ' | ' |
Other current assets | 33,830 | 41,776 | ' | ' |
Assets Held-for-sale, Current | 0 | 103,157 | ' | ' |
Total Current Assets | 426,847 | 567,949 | ' | ' |
Investment in subsidiaries | 0 | 0 | ' | ' |
Intercompany advances, net | 0 | 0 | ' | ' |
Other Assets | 40,327 | 42,262 | ' | ' |
Other Intangibles | 65,105 | 71,652 | ' | ' |
Property and Equipment, net | 108,391 | 118,231 | ' | ' |
Goodwill | 450,727 | 462,200 | ' | ' |
Total Assets | 1,091,397 | 1,262,294 | ' | ' |
Current Liabilities | ' | ' | ' | ' |
Accounts payable | 117,684 | 133,048 | ' | ' |
Accrued expenses | 130,479 | 135,189 | ' | ' |
Accrued income taxes | 7,201 | 2,713 | ' | ' |
Due to Affiliate, Current | 0 | 0 | ' | ' |
Short-term debt and current maturities of long-term obligations | 1,294 | 5,427 | ' | ' |
Liabilities of Assets Held-for-sale | 0 | 23,358 | ' | ' |
Total Current Liabilities | 256,658 | 299,735 | ' | ' |
Long-Term Debt | 54,775 | 229,375 | ' | ' |
Other Long-Term Obligations | 114,773 | 112,195 | ' | ' |
Inercompany advances, net | 0 | 0 | ' | ' |
Total Shareholders' Equity | 665,191 | 620,989 | ' | ' |
Total Liabilities and Shareholders' Equity | 1,091,397 | 1,262,294 | ' | ' |
The Company (Parent) [Member] | ' | ' | ' | ' |
Current Assets | ' | ' | ' | ' |
Cash and cash equivalents | 3,148 | 5,774 | 5,419 | 3,642 |
Trade receivables, net | 69,633 | 71,622 | ' | ' |
Installment receivables, net | 0 | 0 | ' | ' |
Inventories, net | 37,797 | 40,278 | ' | ' |
Due from Affiliate, Current | 5,055 | 4,077 | ' | ' |
Other current assets | 6,371 | 12,727 | ' | ' |
Assets Held-for-sale, Current | ' | 0 | ' | ' |
Total Current Assets | 122,004 | 134,478 | ' | ' |
Investment in subsidiaries | 1,433,252 | 1,536,898 | ' | ' |
Intercompany advances, net | 937,116 | 863,973 | ' | ' |
Other Assets | 38,961 | 41,006 | ' | ' |
Other Intangibles | 553 | 663 | ' | ' |
Property and Equipment, net | 36,783 | 39,911 | ' | ' |
Goodwill | 0 | 0 | ' | ' |
Total Assets | 2,568,669 | 2,616,929 | ' | ' |
Current Liabilities | ' | ' | ' | ' |
Accounts payable | 50,462 | 63,812 | ' | ' |
Accrued expenses | 30,864 | 36,716 | ' | ' |
Accrued income taxes | 5,540 | 1,545 | ' | ' |
Due to Affiliate, Current | 41,889 | 61,368 | ' | ' |
Short-term debt and current maturities of long-term obligations | 556 | 4,552 | ' | ' |
Liabilities of Assets Held-for-sale | ' | 0 | ' | ' |
Total Current Liabilities | 129,311 | 167,993 | ' | ' |
Long-Term Debt | 22,476 | 223,014 | ' | ' |
Other Long-Term Obligations | 54,176 | 52,957 | ' | ' |
Inercompany advances, net | 1,707,515 | 1,551,976 | ' | ' |
Total Shareholders' Equity | 655,191 | 620,989 | ' | ' |
Total Liabilities and Shareholders' Equity | 2,568,669 | 2,616,929 | ' | ' |
Combined Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Current Assets | ' | ' | ' | ' |
Cash and cash equivalents | 0 | 1,018 | 2,665 | 2,104 |
Trade receivables, net | 29,453 | 37,223 | ' | ' |
Installment receivables, net | 569 | 829 | ' | ' |
Inventories, net | 27,784 | 31,455 | ' | ' |
Due from Affiliate, Current | 664 | 763 | ' | ' |
Other current assets | 570 | 473 | ' | ' |
Assets Held-for-sale, Current | ' | 103,157 | ' | ' |
Total Current Assets | 59,040 | 174,918 | ' | ' |
Investment in subsidiaries | 440,197 | 523,176 | ' | ' |
Intercompany advances, net | 1,592,785 | 1,468,405 | ' | ' |
Other Assets | 463 | 314 | ' | ' |
Other Intangibles | 19,139 | 22,211 | ' | ' |
Property and Equipment, net | 18,621 | 19,957 | ' | ' |
Goodwill | 16,660 | 32,937 | ' | ' |
Total Assets | 2,146,905 | 2,241,918 | ' | ' |
Current Liabilities | ' | ' | ' | ' |
Accounts payable | 8,237 | 9,465 | ' | ' |
Accrued expenses | 17,737 | 18,155 | ' | ' |
Accrued income taxes | 0 | 0 | ' | ' |
Due to Affiliate, Current | 1,481 | 2,369 | ' | ' |
Short-term debt and current maturities of long-term obligations | 7 | 7 | ' | ' |
Liabilities of Assets Held-for-sale | ' | 23,358 | ' | ' |
Total Current Liabilities | 27,462 | 53,354 | ' | ' |
Long-Term Debt | 82 | 143 | ' | ' |
Other Long-Term Obligations | 0 | 0 | ' | ' |
Inercompany advances, net | 936,722 | 863,585 | ' | ' |
Total Shareholders' Equity | 1,182,639 | 1,324,836 | ' | ' |
Total Liabilities and Shareholders' Equity | 2,146,905 | 2,241,918 | ' | ' |
Combined Non-Guarantor Subsidiaries [Member] | ' | ' | ' | ' |
Current Assets | ' | ' | ' | ' |
Cash and cash equivalents | 29,477 | 31,999 | 27,198 | 29,178 |
Trade receivables, net | 92,378 | 89,946 | ' | ' |
Installment receivables, net | 991 | 1,359 | ' | ' |
Inventories, net | 104,970 | 114,169 | ' | ' |
Due from Affiliate, Current | 43,145 | 64,570 | ' | ' |
Other current assets | 34,129 | 34,606 | ' | ' |
Assets Held-for-sale, Current | ' | 0 | ' | ' |
Total Current Assets | 305,090 | 336,649 | ' | ' |
Investment in subsidiaries | 0 | 6,888 | ' | ' |
Intercompany advances, net | 178,180 | 173,903 | ' | ' |
Other Assets | 903 | 942 | ' | ' |
Other Intangibles | 45,413 | 48,778 | ' | ' |
Property and Equipment, net | 52,987 | 58,363 | ' | ' |
Goodwill | 434,067 | 429,263 | ' | ' |
Total Assets | 1,016,640 | 1,054,786 | ' | ' |
Current Liabilities | ' | ' | ' | ' |
Accounts payable | 58,985 | 59,771 | ' | ' |
Accrued expenses | 89,118 | 86,348 | ' | ' |
Accrued income taxes | 1,661 | 1,168 | ' | ' |
Due to Affiliate, Current | 5,494 | 5,673 | ' | ' |
Short-term debt and current maturities of long-term obligations | 731 | 868 | ' | ' |
Liabilities of Assets Held-for-sale | ' | 0 | ' | ' |
Total Current Liabilities | 155,989 | 153,828 | ' | ' |
Long-Term Debt | 32,217 | 6,218 | ' | ' |
Other Long-Term Obligations | 60,597 | 59,238 | ' | ' |
Inercompany advances, net | 63,844 | 90,720 | ' | ' |
Total Shareholders' Equity | 703,993 | 744,782 | ' | ' |
Total Liabilities and Shareholders' Equity | 1,016,640 | 1,054,786 | ' | ' |
Eliminations [Member] | ' | ' | ' | ' |
Current Assets | ' | ' | ' | ' |
Cash and cash equivalents | 0 | 0 | 0 | 0 |
Trade receivables, net | 0 | 0 | ' | ' |
Installment receivables, net | 0 | 0 | ' | ' |
Inventories, net | -3,183 | -2,656 | ' | ' |
Due from Affiliate, Current | -48,864 | -69,410 | ' | ' |
Other current assets | -7,240 | -6,030 | ' | ' |
Assets Held-for-sale, Current | ' | 0 | ' | ' |
Total Current Assets | -59,287 | -78,096 | ' | ' |
Investment in subsidiaries | -1,873,449 | -2,066,962 | ' | ' |
Intercompany advances, net | -2,708,081 | -2,506,281 | ' | ' |
Other Assets | 0 | 0 | ' | ' |
Other Intangibles | 0 | 0 | ' | ' |
Property and Equipment, net | 0 | 0 | ' | ' |
Goodwill | 0 | 0 | ' | ' |
Total Assets | -4,640,817 | -4,651,339 | ' | ' |
Current Liabilities | ' | ' | ' | ' |
Accounts payable | 0 | 0 | ' | ' |
Accrued expenses | -7,240 | -6,030 | ' | ' |
Accrued income taxes | 0 | 0 | ' | ' |
Due to Affiliate, Current | -48,864 | -69,410 | ' | ' |
Short-term debt and current maturities of long-term obligations | 0 | 0 | ' | ' |
Liabilities of Assets Held-for-sale | ' | 0 | ' | ' |
Total Current Liabilities | -56,104 | -75,440 | ' | ' |
Long-Term Debt | 0 | 0 | ' | ' |
Other Long-Term Obligations | 0 | 0 | ' | ' |
Inercompany advances, net | -2,708,081 | -2,506,281 | ' | ' |
Total Shareholders' Equity | -1,876,632 | -2,069,618 | ' | ' |
Total Liabilities and Shareholders' Equity | ($4,640,817) | ($4,651,339) | ' | ' |
Supplemental_Guarantor_Informa4
Supplemental Guarantor Information Consolidating Condensed Statement of Cash Flows (Details) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net Cash Provided (Used) by Operating Activities | ($1,245) | $26,822 |
Investing Activities | ' | ' |
Purchases of property and equipment | -11,086 | -14,775 |
Proceeds from sale of property and equipment | 856 | 97 |
Proceeds from Divestiture of Business, net | 187,552 | 0 |
Other long-term assets | 949 | 409 |
Other | -147 | -219 |
Net Cash Used for Investing Activities | 178,124 | -14,488 |
Financing Activities | ' | ' |
Proceeds from revolving lines of credit and long-term borrowings | 250,124 | 255,703 |
Payments on revolving lines of credit and long-term borrowings | -432,185 | -266,721 |
Payment of Financing Costs | 0 | -1 |
Payment of dividends | -1,187 | -1,183 |
Net Cash Provided (Used) by Financing Activities | -183,248 | -12,202 |
Effect of exchange rate changes on cash | 203 | 226 |
Increase (decrease) in cash and cash equivalents | -6,166 | 358 |
Cash and cash equivalents at beginning of year | 38,791 | 34,924 |
Cash and cash equivalents at end of year | 32,625 | 35,282 |
The Company (Parent) [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net Cash Provided (Used) by Operating Activities | 35,179 | 18,260 |
Investing Activities | ' | ' |
Purchases of property and equipment | -3,234 | -1,353 |
Proceeds from sale of property and equipment | 0 | 18 |
Proceeds from Divestiture of Business, net | 0 | ' |
Other long-term assets | 783 | -214 |
Other | 171,353 | -158 |
Net Cash Used for Investing Activities | 168,902 | -1,707 |
Financing Activities | ' | ' |
Proceeds from revolving lines of credit and long-term borrowings | 226,189 | 252,590 |
Payments on revolving lines of credit and long-term borrowings | -431,709 | -266,182 |
Payment of Financing Costs | ' | -1 |
Payment of dividends | -1,187 | -1,183 |
Net Cash Provided (Used) by Financing Activities | -206,707 | -14,776 |
Effect of exchange rate changes on cash | 0 | 0 |
Increase (decrease) in cash and cash equivalents | -2,626 | 1,777 |
Cash and cash equivalents at beginning of year | 5,774 | 3,642 |
Cash and cash equivalents at end of year | 3,148 | 5,419 |
Combined Guarantor Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net Cash Provided (Used) by Operating Activities | -81,077 | 5,405 |
Investing Activities | ' | ' |
Purchases of property and equipment | -3,611 | -7,854 |
Proceeds from sale of property and equipment | 11 | 14 |
Other long-term assets | 0 | 0 |
Other | -103,417 | -117 |
Net Cash Used for Investing Activities | 80,535 | -7,957 |
Financing Activities | ' | ' |
Proceeds from revolving lines of credit and long-term borrowings | 0 | 3,113 |
Payments on revolving lines of credit and long-term borrowings | -476 | 0 |
Payment of Financing Costs | ' | 0 |
Payment of dividends | 0 | 0 |
Net Cash Provided (Used) by Financing Activities | -476 | 3,113 |
Effect of exchange rate changes on cash | 0 | 0 |
Increase (decrease) in cash and cash equivalents | -1,018 | 561 |
Cash and cash equivalents at beginning of year | 1,018 | 2,104 |
Cash and cash equivalents at end of year | 0 | 2,665 |
Combined Non-Guarantor Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net Cash Provided (Used) by Operating Activities | -20,736 | 7,527 |
Investing Activities | ' | ' |
Purchases of property and equipment | -4,241 | -5,568 |
Proceeds from sale of property and equipment | 845 | 65 |
Proceeds from Divestiture of Business, net | 0 | ' |
Other long-term assets | 166 | 623 |
Other | 0 | 56 |
Net Cash Used for Investing Activities | -3,230 | -4,824 |
Financing Activities | ' | ' |
Proceeds from revolving lines of credit and long-term borrowings | 23,935 | 0 |
Payments on revolving lines of credit and long-term borrowings | 0 | -539 |
Payment of Financing Costs | ' | 0 |
Payment of dividends | -2,694 | -4,370 |
Net Cash Provided (Used) by Financing Activities | 21,241 | -4,909 |
Effect of exchange rate changes on cash | 203 | 226 |
Increase (decrease) in cash and cash equivalents | -2,522 | -1,980 |
Cash and cash equivalents at beginning of year | 31,999 | 29,178 |
Cash and cash equivalents at end of year | 29,477 | 27,198 |
Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Net Cash Provided (Used) by Operating Activities | 65,389 | -4,370 |
Investing Activities | ' | ' |
Purchases of property and equipment | 0 | 0 |
Proceeds from sale of property and equipment | 0 | 0 |
Proceeds from Divestiture of Business, net | 0 | ' |
Other long-term assets | 0 | 0 |
Other | -68,083 | 0 |
Net Cash Used for Investing Activities | -68,083 | 0 |
Financing Activities | ' | ' |
Proceeds from revolving lines of credit and long-term borrowings | 0 | 0 |
Payments on revolving lines of credit and long-term borrowings | 0 | 0 |
Payment of Financing Costs | ' | 0 |
Payment of dividends | 2,694 | 4,370 |
Net Cash Provided (Used) by Financing Activities | 2,694 | 4,370 |
Effect of exchange rate changes on cash | 0 | 0 |
Increase (decrease) in cash and cash equivalents | 0 | 0 |
Cash and cash equivalents at beginning of year | 0 | 0 |
Cash and cash equivalents at end of year | $0 | $0 |